

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: A randomised double-blind placebocontrolled trial of single dose tocilizumab in patients with psychosis

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-067944
Article Type:	Protocol
Date Submitted by the Author:	02-Sep-2022
Complete List of Authors:	Foley, Éimear; University of Bristol, MRC Integrative Epidemiology Unit, Population Health Sciences; Bristol Medical School, Centre for Academic Mental Health, Population Health Sciences Griffiths, Sian Lowri; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Murray, Alexander; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Rogers, Jack; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Corsi-Zuelli, Fabiana; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health; University of Sao Paulo, Department of Neuroscience and Behaviour Hickinbotham, Hannah; University of Cambridge, Department of Psychiatry Kaser, Muzaffer; University of Cambridge, Psychiatry; Cambridgeshire and Peterborough NHS Foundation Trust Murray, Graham K.; University of Cambridge, Psychiatry; Cambridgeshire and Peterborough NHS Foundation Trust Deakin, Bill; The University of Cambridge, Medicine Suckling, John; University of Cambridge, Psychiatry; Cambridgeshire and Peterborough NHS Foundation Trust Barnes, Nicholas ; University of Cambridge, Psychiatry; Cambridgeshire and Peterborough NHS Foundation Trust Barnes, Nicholas ; University of Birmingham, Institute of Clinical Sciences Upthegrove, Rachel; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health; Early Intervention Service, Birmingham Women's and Children's NHS Foundation Trust Khandaker, Golam M.; University of Birstol, MRC Integrative Epidemiology Unit, Population Health Sciences; NIHR Bristol Biomedical Research Centre
Keywords:	Schizophrenia & psychotic disorders < PSYCHIATRY, IMMUNOLOGY, Clinical trials < THERAPEUTICS, Magnetic resonance imaging < RADIOLOGY & IMAGING

1	
2	
3 4	SCHOLAR ONE [™]
5	Manuscripta
6	Manuscripts
7	
8	
9	
10	
11	
12	
13	
14	
15	
16 17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29 30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41 42	
42	
44	
45	
46	
47	
48	
49	
50	
51	
52 53	
55	
55	
56	
57	
58	
59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2					
3 4	1	Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: A			
5 6	2	randomised double-blind placebo-controlled trial of single dose tocilizumab in patients			
7 8 9	3	with psychosis			
9 10 11	4				
12 13	5	Éimear M. Foley ^{a,b} ; Sian Lowri Griffiths ^c ; Alexander Murray ^c ; Jack Rogers ^c ; Fabiana Corsi-			
14 15 16	6	Zuelli ^{c,d,e} ; Hannah Hickinbotham ^f ; Muzaffer Kaser ^{f,g} ; Graham K. Murray ^{f,g} ; Bill Deakin ^h ;			
16 17 18	7	Deepak Jadon ⁱ ; John Suckling ^{f,g} ; Nicholas M. Barnes ^{e;} Rachel Upthegrove ^{c,j,†} ; and Golam M.			
19 20	8	Khandaker ^{a,b,k,l,†,*} ; for the PIMS Collaboration			
21 22	9				
23 24 25	10	^a MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,			
26 27	11	University of Bristol, Bristol, United Kingdom			
28 29	12	^b Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School,			
30 31 32	13	University of Bristol, Bristol, United Kingdom			
33 34	14	^c Institute for Mental Health and Centre for Human Brain Health, University of Birmingham,			
35 36	15	Birmingham, United Kingdom			
37 38 20	^d Department of Neuroscience and Behaviour, Division of Psychiatry, Ribeirão Preto Medical				
39 40 41	17	School, University of São Paulo, São Paulo, Brazil			
42 43	18	^e Institute of Clinical Sciences, College of Medical and Dental Sciences, University of			
44 45	19	Birmingham, United Kingdom			
46 47 48	20	^f Department of Psychiatry, University of Cambridge, United Kingdom			
49 50	21	^g Cambridgeshire and Peterborough NHS Foundation Trust, United Kingdom			
51 52	22	^h Faculty of Biology, Medicine and Health, Division of Neuroscience and Experimental			
53 54 55	23	Psychology, School of Biological Sciences, University of Manchester, Manchester Academic			
56 57	24	Health Science Centre, Manchester, United Kingdom			
58 59 60	25	ⁱ Department of Medicine, University of Cambridge, United Kingdom			

1 2		
2 3 4	26	^j Early Intervention Service, Birmingham Women's and Children's NHS Foundation Trust
5 6	27	^k NIHR Bristol Biomedical Research Centre, Bristol, United Kingdom
7 8 9	28	¹ Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, United Kingdom
9 10 11	29	
12 13	30	[†] Joint senior authors
14 15 16	31	
16 17 18	32	* Corresponding author and address: Prof Golam M. Khandaker, MRC Integrative
19 20	33	Epidemiology Unit, Oakfield House, Oakfield Grove, Clifton, Bristol, BS8 2BN, UK
21 22 23	34	Email: golam.khandaker@bristol.ac.uk
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60		Email: golam.khandaker@bristol.ac.uk

35 ABSTRACT

Introduction: Evidence suggests a potentially causal role of interleukin 6 (IL-6), a pleiotropic cytokine that generally promotes inflammation, in the pathogenesis of psychosis, but no interventional studies elucidating potential mechanisms in patients with psychosis, stratified using inflammatory markers, have been conducted. Tocilizumab is a humanised monoclonal antibody targeting the IL-6 receptor to inhibit IL-6 signalling licensed in the UK for treatment of rheumatoid arthritis. The primary objective of this study is to test whether IL-6 contributes to the pathogenesis of psychosis, and to examine potential mechanisms by which IL-6 affects psychotic symptoms. A secondary objective is to examine characteristics of inflammation-associated psychosis.

Methods and analysis: A proof-of-concept study employing a randomised, parallel-group, double-blind, placebo-controlled design testing the effect of IL-6 inhibition on anhedonia in patients with psychosis. Approximately 60 participants with diagnosis of schizophrenia and related psychotic disorders (ICD-10 codes F20, F22, F25, F28, F29) with evidence of low-grade inflammation (IL-6 >0.7pg/ml) will receive either one intravenous infusion of tocilizumab (4.0mg/kg; max 800mg) or normal saline. Psychiatric measures and blood samples will be collected at baseline, and 7-, 14-, and 28-days post-infusion. Cognitive and neuroimaging data will be collected at baseline and 14 days post-infusion. In addition, approximately 30 patients with psychosis without evidence of inflammation (IL-6 < 0.7 pg/ml) and 30 matched healthy controls will be recruited to complete identical baseline assessments to allow for comparison of the characteristic features of inflammation-associated psychosis. Ethics and dissemination: The study is sponsored by the University of Bristol and has been approved by the Cambridge East Research Ethics Committee (reference: 22/EE/0010; IRAS project ID: 301682). Study findings will be published in peer-review journals. Findings will be also disseminated by scientific presentation and by other means.

1 2		
3 4	60	Trial registration number: ISRCTN 23256704
5 6	61	
7 8 9	62	KEYWORDS: Psychotic Disorders; Negative Symptoms; Interleukin 6; Immunotherapy;
10 11 12 13 14 15 16 17 18 19 20 21 22 32 42 52 62 72 82 93 03 12 23 24 52 62 72 82 93 03 12 23 24 52 62 72 82 93 03 12 23 24 52 62 72 82 93 03 12 23 24 52 52 54 55 55 55 55 56 57 58 960	63	Tocilizumab; Clinical Trial.

Adopting a randomised controlled trial (RCT) design and patient selection based on

elevated level of IL-6 (in addition to other criteria) will help examine the causal role

The use of target specific intervention (anti-IL6R monoclonal antibody tocilizumab)

of IL-6, and the therapeutic potential of targeting IL-6 pathway, in psychosis.

will help assess the clinical relevance of IL-6 and related up- and downstream

64 ARTICLE SUMMARY

•

•

Strengths and limitations of this study

inflammatory cytokines in psychosis.
The use of neuroimaging, cognitive tests, and extensive peripheral blood biomarker exploration before and after tocilizumab treatment to assess potential mechanisms of effect.
One dose of tocilizumab is unlikely to be sufficient to test the efficacy of this drug as potential treatment for psychosis.
Tocilizumab inhibits both anti-inflammatory (classic) and pro-inflammatory (trans) pathways of IL-6 that may have complementary or differential effects relevant to potential therapeutic effects.

BMJ Open

2		
3 4	81	Word count: 3,956
5 6	82	INTRODUCTION
7 8 9	83	Scientific background and study rationale
10 11	84	The neuroimmune hypothesis of schizophrenia proposes that mild peripheral immune
12 13	85	activation gives rise to an inflammatory response in the brain and neurobiological changes
14 15 16	86	associated with psychotic illness [1-4]. Meta-analytic evidence is clear that circulating
17 18	87	concentrations of interleukin 6 (IL-6) and other inflammatory proteins, such as C-reactive
19 20	88	protein (CRP), are increased in patients with psychosis, including treatment naïve first
21 22 23	89	episode psychosis (FEP) [5], compared with controls [6–9]. Prospective cohort studies show
24 25	90	that these indices of mild immune activation precede the onset of symptoms [10,11].
26 27	91	Furthermore, genetic variants known to increase IL-6 concentrations are associated with
28 29 30	92	genetic risk of schizophrenia [12,13]. These Mendelian randomization studies eliminate the
31 32	93	possibility that raised IL-6 concentrations are a consequence of environmental exposures
33 34	94	associated with schizophrenia, such as obesity and smoking and instead suggest that IL-6 has
35 36 27	95	a causal role in psychosis. Extending this approach using the UK Biobank population, we
37 38 39	96	found that genetically-predicted levels of IL-6 were associated with reduced grey matter
40 41	97	primarily in the middle temporal gyrus, a region whose gene expression profile is enriched
42 43	98	for IL-6 pathway proteins and for neuropsychiatric disorder ontologies [14]. Moreover,
44 45 46	99	clinical studies report correlations between IL-6 levels and structural brain changes in
40 47 48	100	individuals with schizophrenia [15], with reduced grey matter volume being exaggerated in
49 50	101	patients with psychosis and elevated inflammatory cytokines [16]. Though this causal
51 52	102	evidence strongly implicates IL-6, only an intervention study in patients can test the causal
53 54 55	103	hypothesis.
56 57	104	The neuroimmune hypothesis generally assumes that microglia, the brain's resident

immune cells, are activated and pathogenic in schizophrenia. This is supported by traditional

BMJ Open

2	
2	
4	
5	
6	
7 8	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20 21	
21 22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
30 37	
37 38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
53 54	
53 54 55	
53 54 55 56	
53 54 55 56 57	
53 54 55 56 57 58	
53 54 55 56 57	

1

106	neuropathological studies and initial in-vivo PET imaging studies [17-19], possibly reflecting
107	impaired cellular control of inflammation or oxidative defence. Inflammatory damage may
108	also account for evidence of oxidative stress from MRS glutathione studies [20]. However,
109	whether microglia are the direct target of IL-6 is unclear and it is not certain that IL-6 can
110	cross the blood-brain barrier and/or increase its permeability to circulating inflammatory
111	cells, cytokines, and chemokines [2,21]. Additionally, it is increasingly uncertain whether
112	microglial inflammation, as traditionally understood, occurs in schizophrenia [22,23]. Recent
113	meta-analyses of PET radioligand binding studies report decreased rather than increased
114	radioligand binding to activated microglia [24,25]. This may account for the unexpected lack
115	of therapeutic benefit of the anti-microglial antibiotic, minocycline, in recent large clinical
116	trials [26,27]. Furthermore, large transcriptomic studies in post-mortem brains report no
117	change or reduction in microglial gene expression but increases in astrocytic expression
118	[23,28–32]. It is increasingly understood that both peripheral immune responses and brain
119	glial function are regulated by specialised T cells (Tregs), a subset of which reside in brain
120	parenchyma [33,34]. A novel proposal is that Treg hypofunction accounts for mild peripheral
121	immune disinhibition and dysregulated astroglial-microglial interaction, such that microglia
122	are driven into a developmental, synapse-pruning phenotype while astroglia disrupt
123	neurotransmitter function [33,34]. Importantly, there are bidirectional interactions between
124	IL-6 and Treg function [34]. Crucially, we will measure IL-6 in addition to cellular and
125	molecular markers of immune function and investigate how they correlate with central
126	markers and clinical state.
127	Previous attempts testing the inflammatory hypothesis in therapeutic clinical trials

Previous attempts testing the inflammatory hypothesis in therapeutic clinical trials have been attempted. However, little evidence of overall efficacy has been found [35]. These trials have generally tested broad spectrum agents, such as non-steroidal anti-inflammatory drugs, with no attempt to stratify patients according to evidence of inflammation. A trial

Page 9 of 38

BMJ Open

using tocilizumab, a humanised monoclonal antibody (mAb) against the IL-6 receptor currently licensed in the UK for treatment of rheumatoid arthritis (RA) and severe coronavirus disease, reported no improvements in any clinical measure in a small sample of 36 patients with established schizophrenia [36]. However, as mentioned previously, no stratification by inflammatory markers or any mechanistic immune measures was applied. Low-grade inflammation is associated with poor response to antipsychotic drugs [37], but immunotherapy is unlikely to be relevant for all patients with psychosis. Meta-analysis suggests that evidence of immune activation, defined by elevated CRP levels, is present in a quarter to one third of patients with schizophrenia [38]. A randomised controlled trial of infliximab, an anti-tumour necrosis factor alpha (TNF- α) mAb, reported that antidepressant response was associated with higher CRP levels at baseline [39], suggesting that patients with evidence of immune activation may be better candidates for immunotherapy trials. As far as we are aware, no previous clinical trial has selected patients with schizophrenia based on evidence of immune activation.

Selection of patients with particular symptom profiles and/or stage of illness may also be a useful strategy that needs to be employed in immunotherapy trials for schizophrenia. A wide variety of symptoms occur in schizophrenia such as hallucinations, delusions, anhedonia, cognitive dysfunction, and affective symptoms and presentation of these symptoms differ from one individual to another. Some symptoms may be more related to inflammation than others. For instance, a recent study from the ALSPAC birth cohort reported that out of 20 positive and negative symptoms, CRP is particularly associated with anhedonia and auditory hallucinations [40]. Anhedonia and amotivation are strongly associated with poor functional outcomes in depression and schizophrenia, and present a formidable barrier to returning to work or building relationships [41,42]. Patients with psychotic disorders also present with cognitive deficits in a range of domains [43]. Available

BMJ Open

antipsychotic medications have a limited effects on poor cognitive functioning in psychosis [44]. Illness stage may also be of relevance. Meta-analytic data has revealed no differences in IL-6 levels between stable, medicated patients with schizophrenia and controls, although compared with controls, IL-6 levels were similarly elevated in patients with FEP and those with acute relapse [7]. A separate meta-analysis found evidence of elevated blood cytokine levels in acutely and chronically ill patients with schizophrenia [6]. Focusing on particular inflammation-related symptoms and/or illness stage may increase the chance of success for immunotherapy trials. **Proposed study** The proposed two-year study is a UK multi-site (Bristol, Birmingham, and Cambridge) proof-of-concept, randomised, parallel-group, double-blind, placebo-controlled trial. Study aims and hypotheses The primary aim of this trial is to examine potential mechanisms by which IL-6 affects anhedonia, psychotic symptoms, and cognition. Our primary hypothesis is that inhibition of IL-6 signalling with a single intravenous infusion of anti-IL6R monoclonal antibody. tocilizumab, in individuals with psychosis and elevated IL-6 at baseline will attenuate symptoms of anhedonia and amotivation in patients with psychosis, relative to placebo. This will provide further evidence for a potential causal role of inflammation in psychosis. Our secondary hypothesis is that reduction in peripheral inflammation after tocilizumab infusion in patients with psychosis and evidence of inflammation will be associated with central measures of oxidative stress and relevant resting state brain function. We will also conduct deep immunophenotyping of peripheral blood mononuclear cell subsets (CD4⁺, CD8⁺, Tregs, natural killer and natural killer-T cells, monocytes, and B cells)

Page 11 of 38

1 2

BMJ Open

3	
4	
5	
6	
7	
/ 0	
ð	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 9 30	
23	
24	
25	
26	
27	
28	
29	
 29 30 31 32 33 34 35 36 37 38 30 	
31	
32	
32	
34	
25	
36	
20	
27 20	
38 39	
40	
41 42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

181 to characterise their absolute number, frequency, and function. Our primary mechanistic 182 outcome is the level of IL-6/STAT3 signalling inhibition within both innate and adaptive 183 immune cells using multi-colour flow cytometry with an established optimised pSTAT3 184 phosflow assay. This will help identify the potential cellular impact of peripheral 185 inflammation in psychosis, which is largely unknown. Functional assessment of IL-6/STAT3 186 signalling in immune cell subsets and their response to exogenous IL-6 stimulation will 187 inform abnormal immune response in psychosis and allow measurement of response to 188 tocilizumab at the cellular level. 189 A secondary objective is to carry out an observational study to examine clinical and 190 biomarker differences and similarities between patients with psychotic disorder with and 191 without evidence of inflammation and healthy controls (HCs). We hypothesise that 192 individuals with psychotic disorder and evidence of inflammation, compared to those without 193 evidence of inflammation and HCs, will have increased symptoms of anhedonia and 194 amotivation, poorer cognitive functioning, and cellular and brain-based measures of immune 195 dysfunction. 196 197 **METHODS** 198 This protocol has been prepared in accordance with the Standard Protocol Items: 199 Recommendations for Interventional Trials (SPIRIT) 2013 statement [45]. Please see 200 supplementary eTable 1 for the SPIRIT checklist. 201 202 Patient and public involvement 203 The study protocol was prepared in collaboration with individuals with lived experience of 204 mental illness who contributed to the development of participant information sheet, consent 205 forms, and data collection procedures.

2	
3 ⊿	
5	
5 6 7	
7 8	
9 10	
10	
11 12	
13	
14 15	
14 15 16 17	
17	
18 19	
20	
21	
22 23	
24	
25 26	
27	
28	
29 30	
31	
32 33	
33 34	
35	
36 37	
38	
39 40	
40 41	
42	
43 44	
45	
46 47	
47 48	
49	
50 51	
52	
53	
54 55	
56	
57 58	
58 59	
60	

1

206 Study	design and	sample
-----------	------------	--------

207 See Figure 1 for an overview of study design. Individuals residing in Bristol, Birmingham, or 208 Cambridge in the United Kingdom will be recruited. Approximately 60 participants with 209 psychosis and evidence of inflammation (i.e., IL-6 \ge 0.7pg/ml) will be randomised to receive 210 either one intravenous infusion of tocilizumab (drug) or normal saline (placebo). For the 211 secondary, observational study, we will compare baseline characteristics of the intervention 212 cohort with approximately 30 participants with psychosis without evidence of inflammation 213 (i.e., IL-6 <0.7pg/ml), and approximately 30 HCs. Participants without evidence of 214 inflammation and controls will not be randomised as they will not receive any intervention. 215 Neuroimaging will only be undertaken by those without MRI contraindications who have 216 given specific informed consent for MRI. Participants not eligible or not consenting for MRI 217 will take part in all other aspects of the study.

219 Intervention

Single intravenous infusion of tocilizumab (4.0mg/kg; max 800mg in total) or normal saline 220 221 given to participants with psychosis and evidence of inflammation. Tocilizumab blocks both 222 IL-6 classic and trans-signalling – the latter being responsible for most of the inflammatory 223 effects of IL-6 – providing broad inhibition of IL-6 signalling and a strong test of a casual 224 role for IL-6 in psychosis [46]. Tocilizumab is the first-in-class, humanized monoclonal 225 antibody against the IL-6R, commercially available and licensed in the UK for treatment of 226 RA. Approved dosage of tocilizumab for treatment of RA is 2, 4, or 8mg/kg; max 800mg in 227 total. In RA, a single tocilizumab infusion has shown to improve clinical and laboratory 228 measures within 48 hours, with most noticeable results in one-to-two weeks [47,48]. The follow-up schedule for our study is in keeping with this observation. 229

י ר	
2	
3	
4	
5	
6	
7	
/	
8	
9	
10	
11	
11	
12	
13	
14	
15	
16	
17	
17	
18	
19	
20	
21	
2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 22 23 24 25 26 27 28 29 30 31 22 33 34 35 37 37 37 37 37 37 37 37 37 37	
23	
24	
25	
26	
27	
27	
28	
29	
30	
31	
32	
22	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

60

230	Eligibility criteria	
-----	----------------------	--

231 We will recruit participants aged 18-40 years. Patient participants must meet International 232 Classification of Diseases 10th Revision (ICD-10) criteria for a diagnosis of schizophrenia and related psychoses (ICD-10 code F20, F22, F25, F28, F29) at the time of eligibility 233 234 assessment, be within three years of first diagnosis of psychotic disorder, be on a stable 235 treatment regime with no recent (within two weeks) initiation, cessation, or change in class of 236 antipsychotic medication, and have a Positive and Negative Syndrome Scale (PANSS) item 237 score ≥ 3 on P1 (delusions), P2 (conceptual disorganisation), P3 (hallucinatory behaviour), or 238 P6 (suspiciousness/persecution). Additionally, patients recruited to the interventional arm 239 will be required to have serum IL-6 levels ≥ 0.7 pg/ml and a Temporal Experience of Pleasure 240 Scale (TEPS) anticipatory pleasure score ≤ 41 (based on item numbers 1, 3, 7, 11, 12, 14, 15, 241 16, 17, and 8) and consummatory pleasure score \leq 36 (based on item numbers 2, 4, 5, 6, 8, 9, 242 10, and 13). Finally, COVID-19 anti-body titre test will be used to determine adequate levels 243 of immune response via the following cut-offs (for poor response): 400IU Roche/700IU 244 Abbot assay. 245 HCs will have no current or lifetime history of psychiatric diagnosis, as determined by 246 the Mini-International Neuropsychiatric Interview (MINI). See Table 1 for complete 247 inclusion and exclusion criteria. HCs will be matched to patient participants at the group level 248 by age and sex. 249 250

Table 1. PIMS Trial inclusion and exclusion criteria.

Additional criteria	- Able and willing to consent to	- Contraindications to MRI.
for neuroimaging (optional)	MRI scanning	
Additional criterion	- No current or lifetime psychiatric	
for healthy controls	diagnosis.	
Additional criteria	- Meet ICD-10 criteria for a	
for all individuals	diagnosis of schizophrenia and	
with psychosis	related psychoses (code F20, F22,	
	F25, F28, F29) at the time of	
	eligibility assessment, as	
	determined by the Mini-	
	International Neuropsychiatric	
	Interview.	
	- Be within three years of first	
	diagnosis of psychotic disorder.	
	- On stable treatment regime with	
	no recent (within 2 weeks) initiation, cessation, or change in	
	class of antipsychotic medication.	
	- No indication or other reason for	
	preclusion into research (e.g.,	
	significant risk of suicidal	
	behaviour or risk to others) as	
	determined by their clinical team.	
	- Positive and Negative Syndrome	
	Scale item score ≥ 3 on P1	
	(delusions), P2 (conceptual	
	disorganisation), P3	
	(hallucinatory behaviour), OR P6	
	(suspiciousness/persecution).	4
Additional criteria	- Serum IL-6 level ≥0.7pg/ml at	
for intervention	eligibility and baseline	
group	assessment.	
	- Temporal Experience of Pleasure	
	Scale anticipatory pleasure score \leq 41 (based upon item numbers 1,	
	3, 7, 11, 12, 14, 15, 16, 17, and 8)	
	and consummatory pleasure score	
	\leq 36 (based upon item numbers 2,	
	4, 5, 6, 8, 9, 10, and 13).	
	- Evidence of COVID-19	
	immunity required prior to	
	infusion, confirmed before	
	randomisation using evidence of	
	vaccination and antibody titre	
	test.	
Additional criterion	- Serum IL-6 level <0.7pg/ml at	
for patients with	eligibility and baseline	
psychosis without	assessment.	

254 Study outcomes

The primary outcome is anhedonia, defined as anticipatory and consummatory pleasure scores, assessed by the TEPS [49] at approximately day 14 post-infusion. The primary mechanistic outcome is the level of IL-6/STAT3 signalling inhibition post-tocilizumab infusion in both innate and adaptive immune cells using multi-colour flow cytometry and an established optimised pSTAT3 phosflow assay. We will also collect data on several tertiary/exploratory measures including positive and negative symptoms of psychosis, depressive symptoms, fatigue, quality of life and subjective wellbeing, cognitive function, peripheral blood inflammatory markers, cortisol, cell expression, including DNA and RNA sequencing, functionality, and neuroimaging measures, including functional resting state MRI and MRS outcomes (Table 2).

9 265

Table 2. PIMS trial study measures

Domain	Tool	• Source	Validated Tool	Time of assessment
	Screening questionnaire	Self-report		Screening
	Medical History Questionnaire	Self- report/General practice		Eligibility
Sociodemographic/lifestyle	Substance Use Questionnaire	Self-report		Eligibility
	Physical Measurements Form	Self-report		Baseline
	Sociodemographic Questionnaire	Self-report		Baseline
	The Temporal Experience of Pleasure Scale	Self-report	\checkmark	Eligibility, baseline, follow-ups
Psychiatric	The Positive and Negative Syndrome Scale	Interviewer assessed	\checkmark	Eligibility, baseline, follow-ups
-	The Mini-International Neuropsychiatric Interview	Interviewer assessed	\checkmark	Eligibility
	Psychiatric History Questionnaire	Self-report		Baseline

1 2 3 4 5 6 7	
8 9 10 11 12 13 14 15	
16 17 18 19 20 21 22 23	
24 25 26 27 28 29 30 31	
32 33 34 35 36 37 38 39	
40 41 42 43 44 45 46	
47 48 49 50 51 52 53 54 55 56	
55 56 57 58 59 60	

	The Scale for the Assessment of Negative Symptoms	Self-report	\checkmark	Baseline, follow-ups
	The Calgary Depression Scale for Schizophrenia	Interviewer assessed	\checkmark	Baseline, follow-ups
	Multi-dimensional Fatigue Inventory	Self-report	\checkmark	Baseline, follow-ups
	European Quality of Life-5 Dimensions Three-Level Version	Self-report	\checkmark	Baseline, follow-ups
	Visual Analogue Scale for Subjective Wellbeing	Self-report	\checkmark	Baseline, follow-ups
	National Adult Reading Test for estimated premorbid IQ	Interviewer assessed	\checkmark	Baseline, follow-up 2
	CANTAB Reaction Time test	Computer task	\checkmark	Baseline, follow-up 2
	Symbol Coding Test	Paper task	\checkmark	Baseline, follow-up 2
Cognitive	CANTAB Rapid Visual Information Processing test	Computer task	\checkmark	Baseline, follow-up 2
	CANTAB Paired Associates Learning test	Computer task	\checkmark	Baseline, follow-up 2
	CANTAB One Touch Stockings of Cambridge test	Computer task	\checkmark	Baseline, follow-up 2
Biologic	Inflammatory markers, cardiometabolic markers, IDO activation, white cell phenotyping	Laboratory tests		Baseline, follow-ups
Genetic	Gene expression/genotyping	Blood (RNA, DNA)		Baseline, follow-ups
	MRI Screening Questionnaire			Baseline, follow-up 2
Neuroimaging	Structural MRI, 1H- MRS measure of glutathione in the prefrontal cortex area, resting state fMRI			Baseline, follow-up 2

268 Sample size and statistical power

We will recruit approximately 60 patients with psychosis. However, currently there are no trials of immunotherapies for anhedonia in schizophrenia making accurate power calculation difficult. This study is a proof-of-concept experiment designed to test whether inhibition of IL-6 signalling leads to changes in psychotic symptoms. It could also inform likely statistical power for future trials testing efficacy of the drug as a treatment of schizophrenia, which is not the intention of this study

BMJ Open

276 Randomisation and blinding

An external agency independent of the study team will arrange random allocation to tocilizumab or normal saline group 1:1, ensuring two groups are comparable regarding anhedonia severity and sex. Randomisation will be stratified by site. Randomising agency will provide the randomisation code to the relevant hospital pharmacy who will dispense tocilizumab or normal saline according to the randomisation schedule. Dispensing pharmacies will keep a log of products dispensed. Infusions will be prepared and administered at clinical research facilities (CRFs). Infusion packs will be prepared by trained staff not part of the core study team, ensuring blinding of treatment allocation. Infusion packs containing drug or placebo will be visually indistinguishable from each other, ensuring that both participants and study team remain blind regarding treatment allocation.

- 288 Statistical analysis

For randomised participants, an intention-to-treat approach will be taken for data analysis by
 including all randomised participants in statistical analyses, regardless of the treatment they
 received (if any). We will compare outcome measures between treatment and placebo groups
 controlling for baseline scores. This mechanistic experiment will focus on overall pattern of

Page 19 of 38

1

BMJ Open

2 3	293	results and their effect sizes rather than <i>P</i> -values for individual tests of statistical significance.
4 5 6	294	The secondary mechanistic and observational analysis will compare psychotic symptoms,
7 8	295	cognitive function, blood, neuroimaging, and other biomarkers between and across study
9 10 11	296	groups using appropriate statistical tests.
12 13 14	297	
15 16 17	299	STUDY PROCEDURE
18 19	300	An overview of study procedures is presented in Figure 1 and all study measures are detailed
20 21 22	301	in Table 2. Recruitment will take place in Bristol, Birmingham, and Cambridge and
22 23 24	302	assessments at University and NHS research facilities.
25 26	303	
27 28	304	Participant identification
29 30 31 32 33 34 35 36 37	305	Potential participants with psychosis will be identified by NHS Psychosis Early Intervention
	306	(EI) teams. HCs will be recruited through advertisement methods in Birmingham and
	307	Cambridge. Potential participants will complete a screening questionnaire to confirm their
	308	eligibility to participate. If deemed eligible, participants will be invited to an appointment to
38 39 40	309	complete a full eligibility assessment.
41 42	310	Eligibility assessment
43 44	311	Eligibility assessment
45 46 47 48 49 50 51	312	Assessments will be carried out to establish eligibility and to obtain informed consent.
	313	Patients will complete the MINI to confirm ICD-10 diagnosis of schizophrenia and related
	314	psychoses, the PANSS to confirm the presence of positive symptoms of psychosis, and the
52 53 54	315	TEPS to confirm eligibility based on anticipatory and consummatory pleasure sum scores. A
55 56	316	blood sample will be collected from patients for serum IL-6 measurement. An MRI screening
57 58	317	questionnaire will be administered to those willing to give informed consent for
59 60	318	neuroimaging.

BMJ Open

2 3 4	
5 6	-
7 8	,
9 10 11	-
12 13	,
8 9 10 11 12 13 14 15 16 17	,
16 17	,
 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 	,
20 21 22	,
22 23 24	,
25 26	-
27 28	•
29 30	-
31 32	•
33 34 35	-
36 37 38	-
38 39	
40 41	-
42 43	
44 45 46	
40 47 48	
49 50	-
51 52	-
53 54	
55 56 57	
57 58 59	,
60	

319 **Baseline assessment**

320 All participants (60 inflamed psychosis, 30 non-inflamed psychosis, and 30 HCs) will attend 321 a baseline assessment comprising psychiatric measures, cognitive tasks, blood sampling, and 322 neuroimaging (optional). This will be the final study contact for patients without evidence of 323 inflammation and HCs. Patients with evidence of inflammation will undergo further tests to 324 establish safety/eligibility to receive tocilizumab, including a chest X-ray and blood tests to 325 exclude pregnancy and certain infections, such as TB, HIV, and COVID-19. Eligible 326 participants will be randomised and invited for infusion.

327

1 2

328 Intervention

Intravenous infusion of tocilizumab or normal saline will be given continuously over one 329 330 hour at CRFs in Bristol, Birmingham, and Cambridge by trained clinical staff under the supervision of a designated study doctor. Participants will remain under clinical observation 331 332 for a further 1-hour period after the end of infusion.

333

334 **Follow-up assessments**

Follow-up assessments will take place approximately 7-, 14-, and 28-days post-infusion, and 335 will collect similar data to the baseline assessment. Cognitive tasks and neuroimaging 336 337 (optional) will be administered only on day 14. Around 42 days post-infusion, participants 338 will be contacted by phone to provide a final debrief; at which point they will exit the study. 339

- 340 **RISK MANAGEMENT**
 - 341 **Psychosis-related risks**

All patients will be under the care of a specialist NHS psychosis EI service. Participation will 342 343 not involve any treatment modifications or significant delays in receiving treatment. If a

Page 21 of 38

1

BMJ Open

2 3 4 5 6	344	patient becomes distressed during an assessment, or does not wish to continue for any reason,
	345	the researcher will stop the assessment. Participants may withdraw at any time without giving
7 8	346	a reason. If there is any concern for the participant's safety, the research team will liaise with
9 10	347	participant's GP and/or mental health team as needed.
11 12 13 14 15 16 17	348	
	349	Procedure-related risks
	350	Venepuncture
18 19 20	351	Blood taking is associated with mild discomfort and other side effects are rare. Efforts will be
21 22	352	made to minimise discomfort. Blood taking will be performed by a nurse, doctor, or research
23 24	353	team member trained in venepuncture.
25 26 27	354	
28 29 30 31 32 33 34	355	Chest X-ray
	356	This study will use a typical effective radiation dose of 0.014 mSv; equivalent to 2.5 days of
	357	average natural background radiation in the UK. The risk of developing cancer as a
35 36	358	consequence of participating in this study is 0.0001%. Only non-pregnant, adult participants
37 38 39	359	will be included.
40 41	360	
42 43 44 45 46	361	Neuroimaging
	362	Discomfort during MRI will be minimised by using mirrors to allow participants to view
40 47 48	363	outside of the machine, providing ear plugs and a panic button, and allowing participants to
49 50 51 52 53 54 55	364	communicate with the researcher and scan operator throughout. Mild transient vertigo may be
	365	experienced when being moved into the MRI machine. Risk of dislodgement or malfunction
	366	of medical implants or metallic foreign objects will be minimised by screening participants to
56 57	367	ensure no metal is present on or within the body.
58 59 60	368	

Some participants will show evidence of inflammation in the blood (IL- $6 \ge 0.7$ pg/ml). This is

not necessarily a cause for concern. In people with FEP, ~50% have serum IL-6 levels

>0.7pg/ml. Reasons for this in the absence of an acute infection or chronic inflammatory

illness could include obesity, smoking, alcohol use, and lack of exercise, so knowledge of

'inflammation status' may prompt participants to adopt a healthier lifestyle. If serum IL-6

explanation, such as infection or chronic inflammatory illness, we will inform the

participant's GP and the participant will be excluded from the study.

Safety considerations for infusion and monitoring of adverse reaction

level is high (i.e., IL-6 \geq 0.7pg/ml) along with elevated CRP (>20mg/L) without any apparent

Staff will follow local safety procedures when lone working. No other risks are anticipated.

Participants will be selected based on strict inclusion and exclusion criteria. Additionally, we

will carry out tests for TB, HIV, VZV antibody, and Hepatitis B and C because, though

participants of childbearing age will be given a pregnancy test, which must be negative.

Participants who are sexually active will be asked to use at least one form of effective

contraception for six weeks post-infusion. Male participants will also be asked not to donate

unlikely after a single dose, tocilizumab could make these infections worse. Female

2	
3	369
4 5	
6	370
7 8	371
9 10	372
11 12	
13	373
14 15	374
16 17 18	375
18 19 20	376
21	377
22 23	3//
24 25	378
26 27	379
28 29	380
30 31	381
32 33	202
34	382
35 36	383
37 38	384
39 40	385
41 42	386
43 44	387
45 46	
47 48	388
49 50	389
51 52	390
53 54	391
55 56	392
57 58	
59 60	393
00	

1

IL-6 levels

Risk to research staff

Before infusion

sperm samples for six weeks post-infusion.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

4
5
6
7
/
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
34 35
35
35 36
35 36 37
35 36 37 38
35 36 37 38 39
35 36 37 38 39 40
35 36 37 38 39
35 36 37 38 39 40
35 36 37 38 39 40 41 42
35 36 37 38 39 40 41 42 43
35 36 37 38 39 40 41 42 43 44
35 36 37 38 39 40 41 42 43 44 45
35 36 37 38 39 40 41 42 43 44 45 46
35 36 37 38 39 40 41 42 43 44 45 46 47
 35 36 37 38 39 40 41 42 43 44 45 46 47 48
 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50
 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51
 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52
 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53
 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54
 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55
 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56
35 36 37 38 39 40 41 42 43 44 45 46 47 48 50 51 52 53 54 55 56
35 36 37 38 39 40 41 42 43 44 45 46 47 48 90 51 52 53 54 55 56 57 58
 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56

394 During infusion

395 Infusions will be given under supervision of a designated study doctor. Participants will be 396 monitored for possible side effects, which will be managed in line with use of tocilizumab for 397 treating patients with RA.

398

399 After infusion

400 Participants will remain under observation for one-hour post-infusion. Participants will be 401 advised to seek help if they feel unwell after leaving the assessment centre and will be given 402 an information sheet containing a telephone number their health professionals can call. If necessary, we will unblind the participant and inform their health professional whether they 403 404 received tocilizumab or normal saline. Adverse reactions will be recorded at each follow-up 405 visit. Additional, safety blood tests will be done at second follow-up (e.g., WBC count, liver elie 406 function, lipids).

407

408 ETHICS AND DISSEMINATION

The study will be conducted in accordance with the REC, Health Research Authority (HRA), 409 410 and local Research and Development (R&D) department approvals and guidelines (REC 411 reference: 22/EE/0010). The study team will prepare protocol amendments as required and 412 ethics approval will be sought before implementing any changes to the approved protocol. 413 The ISRCTN Trial Registry and the Research Governance Office will be informed of any 414 amendments to the protocol.

415

416 Consent

417 Informed consent will be obtained prior to eligibility assessments for participation in the 418 study. This will include consent to randomise, for contact with their GP to inform them about

participation, access GP/psychiatric records to verify medical history to establish eligibility,
and to inform the participant's GP any results/outcomes as necessary. Consent for additional
tests to establish safety for tocilizumab infusion and for storing biological samples will also
be obtained.

424 Study management

The study is sponsored by the University of Bristol. The sponsor, the Chief Investigator
(GMK), and the co-Lead (RU) will have overall responsibility for the study. A named
principal investigator will take clinical responsibility for study activities at each site. The
study does not require the formal arrangement of a steering committee because, according to
the HRA, it is not a Clinical Trial of an Investigational Medicinal Product. However, to
enhance monitoring of the study, a study management group will be established, comprising
academic and clinical experts in psychiatry, rheumatology, neuroscience, and immunology.

433 Data management and retention of samples

All potential participants will be assigned a unique study-specific participant ID number. All data will be subject to good practice as laid down in the Data Protection Act. Each study stage is tracked so that participant's (de-identified) status within the study is known, and assessment and other appointment dates are forecasted. This information is held on a secure, password-protected database. Anonymised data from assessments will be uploaded to a secure, password-protected database using secure web-based data entry systems. Minimal personal data (age, sex) will be indexed by each participant's unique ID number. Blood samples collected in this study may be stored for up to 10 years after the completion for additional research. Stored samples will be coded throughout the sample storage and analysis

BMJ Open

2 3 4	443	process and will not be labelled with personal identifiers. Participants may withdraw their
5 6	444	consent for their samples to be stored for future research.
7 8 9	445	
10 11	446	Dissemination plan
12 13	447	Study results will be published in peer-review journals and will conform to the guidelines of
14 15 16	448	the International Committee of Medical Journal Editors. Findings will be disseminated at
10 17 18	449	conferences, departmental talks, and via social and traditional media.
19 20	450	
21 22	451	AUTHORS CONTRIBUTIONS
23 24 25	452	ÉMF wrote first draft of the PIMS trial protocol and of this manuscript. SLG, MK, GKM,
26 27	453	BD, DJ, JS, and NMB contributed to study design and protocol development and revised
28 29	454	manuscript drafts. RU contributed to study design and study protocol, and revised manuscript
30 31 32	455	drafts. GMK devised study design and trial protocol, and revised drafts. ÉMF and SLG
33 34	456	developed study materials and liaised with REC and HRA regarding approvals. AM, JR,
35 36	457	FCZ, and HH contributed to the revision of the manuscript and validation of operating
37 38 30	458	procedures and mechanistic protocols. RU and GMK co-lead the MRC grant that funds the
39 40 41	459	PIMS trial and provide overall supervision and oversight for the project.
42 43	460	
44 45	461	FUNDING STATEMENT
46 47 48	462	The PIMS trial is funded by a Medical Research Council (MRC) grant to RU and GMK;
49 50	463	Grant Ref: MR/S037675/1. ÉMF is supported by an MRC Integrative Epidemiology Unit
51 52	464	PhD Studentship. AM is supported by funding from the MRC for doctoral training
53 54 55	465	(MR/2434208). FCZ receives a PhD Fellowship from the São Paulo Research Foundation
56 57	466	(2019/13229-2 and 2021/07448-3). HH is supported by the PIMS Trial MRC grant
58 59 60	467	(MR/S037675/1). DJ is supported by the Cambridge Arthritis Research Endeavour and the

2.

3 4	
5	
6	
7 8	
o 9	
10	
11	
12 13	
14	
15	
16	
17 18	
19	
20	
21	
22 23	
24	
25	
26	
27 28	
29	
30	
31	
32 33	
34	
35	
36	
37 38	
39	
40	
41 42	
42 43	
44	
45	
46 47	
47 48	
49	
50	
51 52	
52	
54	
55	
56 57	
57 58	
59	
60	

468	National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre
469	(BRC-1215-20014). NMB acknowledges funding support from the MRC (MR/R006008/1
470	and MR/N019016/1), Ministry of Defence (702931454), Diabetes UK (20/0006296), NIHR
471	(14/WM/0093), and Innovate UK (84361). RU has grants from MRC, NIHR: Health
472	Technology Assessment, European Commission - Research: The Seventh Framework
473	Programme, and personal fees from Sunovion, outside the submitted work. GMK
474	acknowledges funding support from the Wellcome Trust (Grant No. 201486/Z/16/Z). The
475	funders had no role in the design of this study.
476	
477	COMPETING INTERESTS STATEMENT
478	ÉMF, SLG, AM, JR, FCZ, HH, MK, GKM, BD, DJ, JS, RU, and GMK have no conflicts of
479	interest to report. NMB holds shares and is a Director of Celentyx Ltd.
480	

2			
3 4	481	RE	EFERENCES
5 6 7 8	482 483 484	1	Khandaker GM, Cousins L, Deakin J, <i>et al.</i> Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. <i>Lancet Psychiatry</i> 2015; 2 :258–70. doi:10.1016/S2215-0366(14)00122-9
9 10 11 12 13	485 486 487	2	Khandaker GM, Dantzer R. Is there a role for immune-to-brain communication in schizophrenia? <i>Psychopharmacology</i> 2016; 233 :1559–73. doi:10.1007/s00213-015-3975-1
14 15 16	488 489	3	Khandaker GM, Dantzer R, Jones PB. Immunopsychiatry: important facts. <i>Psychol Med</i> 2017; 47 :2229–37. doi:10.1017/S0033291717000745
17 18 19 20 21	490 491 492	4	Upthegrove R, Khandaker G. Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia. <i>Current topics in behavioral neurosciences</i> 2020; 44 :49– 66. doi:10.1007/7854_2018_88
22 23 24 25	493 494 495	5	Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. <i>Schizophr Res</i> 2014; 155 :101–8. doi:10.1016/j.schres.2014.03.005
26 27 28 29 30	496 497 498	6	Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. <i>Mol Psychiatry</i> 2016; 21 :1696–709. doi:10.1038/mp.2016.3
31 32 33 34	499 500 501	7	Miller BJ, Buckley P, Seabolt W, <i>et al.</i> Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. <i>Biological psychiatry</i> 2011; 70 :663–71. doi:10.1016/j.biopsych.2011.04.013
35 36 37 38 39	502 503 504	8	Potvin S, Stip E, Sepehry AA, <i>et al.</i> Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. <i>Biol Psychiatry</i> 2008; 63 :801–8. doi:10.1016/j.biopsych.2007.09.024
40 41 42 43 44	505 506 507 508	9	Wang AK, Miller BJ. Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression. <i>Schizophr Bull</i> 2018;44:75–83. doi:10.1093/schbul/sbx035
45 46 47 48 49	509 510 511	10	Khandaker GM, Zimbron J, Dalman C, <i>et al.</i> Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. <i>Schizophr Res</i> 2012; 139 :161–8. doi:10.1016/j.schres.2012.05.023
50 51 52 53	512 513 514	11	Khandaker GM, Zimbron J, Lewis G, <i>et al.</i> Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. <i>Psychol Med</i> 2013; 43 :239–57. doi:10.1017/S0033291712000736
54 55 56 57	515 516 517	12	Khandaker GM, Zammit S, Burgess S, <i>et al.</i> Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort. <i>Brain Behav Immun</i> 2018; 69 :264–72. doi:10.1016/j.bbi.2017.11.020
58 59 60	518 519	13	Perry BI, Upthegrove R, Kappelmann N, <i>et al.</i> Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional

1 2			
2 3 4 5	520 521		two-sample mendelian randomization study. <i>Brain, Behavior, and Immunity</i> 2021; 97 :176–85. doi:10.1016/j.bbi.2021.07.009
6 7 8 9	522 523 524	14	Williams JA, Burgess S, Suckling J, <i>et al.</i> Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders: A Mendelian Randomization Study. <i>JAMA Psychiatry</i> 2022; 79 :498. doi:10.1001/jamapsychiatry.2022.0407
10 11 12 13 14	525 526 527	15	Kose M, Pariante CM, Dazzan P, <i>et al.</i> The Role of Peripheral Inflammation in Clinical Outcome and Brain Imaging Abnormalities in Psychosis: A Systematic Review. <i>Front Psychiatry</i> 2021; 12 :612471. doi:10.3389/fpsyt.2021.612471
15 16 17 18	528 529 530	16	Lesh TA, Careaga M, Rose DR, <i>et al.</i> Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms. <i>Journal of Neuroinflammation</i> 2018; 15 :165. doi:10.1186/s12974-018-1197-2
19 20 21 22 23	531 532 533	17	Trépanier MO, Hopperton KE, Mizrahi R, <i>et al.</i> Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. <i>Mol Psychiatry</i> 2016; 21 :1009–26. doi:10.1038/mp.2016.90
24 25 26 27	534 535 536	18	van Kesteren CFMG, Gremmels H, de Witte LD, <i>et al.</i> Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. <i>Transl Psychiatry</i> 2017;7:e1075–e1075. doi:10.1038/tp.2017.4
28 29 30 31 32	537 538 539	19	Marques TR, Ashok AH, Pillinger T, <i>et al.</i> Neuroinflammation in schizophrenia: meta- analysis of in vivo microglial imaging studies. <i>Psychological Medicine</i> 2019; 49 :2186–96. doi:10.1017/S0033291718003057
33 34 35 36 37	540 541 542 543	20	Murray AJ, Rogers JC, Katshu MZUH, <i>et al.</i> Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders. <i>Frontiers in Psychiatry</i> 2021; 12 .https://www.frontiersin.org/articles/10.3389/fpsyt.2021.703452 (accessed 9 Aug 2022).
38 39 40 41	544 545	21	Upthegrove R. The immune system and schizophrenia: An update for clinicians. <i>Advances in Psychiatric Treatment</i> 2014; 20 :83–91. doi:10.1192/apt.bp.113.011452
42 43 44 45 46	546 547 548 549	22	Conen S, Gregory CJ, Hinz R, <i>et al.</i> Neuroinflammation as measured by positron emission tomography in patients with recent onset and established schizophrenia: implications for immune pathogenesis. <i>Mol Psychiatry</i> 2021; 26 :5398–406. doi:10.1038/s41380-020-0829-y
47 48 49 50 51	550 551 552	23	van Mierlo HC, Schot A, Boks MPM, <i>et al.</i> The association between schizophrenia and the immune system: Review of the evidence from unbiased 'omic-studies.' <i>Schizophrenia Research</i> 2020; 217 :114–23. doi:10.1016/j.schres.2019.05.028
52 53 54 55 56	553 554 555 556	24	Plavén-Sigray P, Matheson GJ, Collste K, <i>et al.</i> Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta- analysis Using Individual Participant Data. <i>Biological Psychiatry</i> 2018; 84 :433–42. doi:10.1016/j.biopsych.2018.02.1171
57 58 59 60	557 558 559	25	Plavén-Sigray P, Matheson GJ, Coughlin JM, <i>et al.</i> Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences. <i>Biol Psychiatry</i> 2021; 89 :e5–8. doi:10.1016/j.biopsych.2020.05.028

2			
3	560	26	Deakin B, Suckling J, Barnes TRE, et al. The benefit of minocycline on negative
4 5	561		symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a
6	562		randomised, double-blind, placebo-controlled trial. The Lancet Psychiatry 2018;5:885-
7	563		94. doi:10.1016/S2215-0366(18)30345-6
8 9	564	27	Weiser M, Levi L, Burshtein S, et al. The effect of minocycline on symptoms in
10	565		schizophrenia: Results from a randomized controlled trial. Schizophrenia Research
11	566		2019; 206 :325–32. doi:10.1016/j.schres.2018.10.023
12 13		• •	
14	567	28	Ramaker RC, Bowling KM, Lasseigne BN, <i>et al.</i> Post-mortem molecular profiling of
15	568		three psychiatric disorders. <i>Genome Medicine</i> 2017; 9 :72. doi:10.1186/s13073-017-0458-
16	569		5
17 18	570	29	González-Peñas J, Costas J, Villamayor MJG, et al. Enrichment of rare genetic variants
19	571	_>	in astrocyte gene enriched co-expression modules altered in postmortem brain samples of
20	572		schizophrenia. Neurobiology of Disease 2019;121:305–14.
21	573		doi:10.1016/j.nbd.2018.10.013
22 23		• •	
24	574	30	Gandal MJ, Zhang P, Hadjimichael E, <i>et al.</i> Transcriptome-wide isoform-level
25	575		dysregulation in ASD, schizophrenia, and bipolar disorder. <i>Science</i> 2018; 362 :eaat8127.
26	576		doi:10.1126/science.aat8127
27 28	577	31	Gandal MJ, Haney JR, Parikshak NN, et al. Shared molecular neuropathology across
20	578	51	major psychiatric disorders parallels polygenic overlap. <i>Science</i> 2018; 359 :693–7.
30	579		doi:10.1126/science.aad6469
31			
32 33	580	32	Toker L, Mancarci BO, Tripathy S, et al. Transcriptomic Evidence for Alterations in
34	581		Astrocytes and Parvalbumin Interneurons in Subjects With Bipolar Disorder and
35	582		Schizophrenia. <i>Biological Psychiatry</i> 2018; 84 :787–96.
36	583		doi:10.1016/j.biopsych.2018.07.010
37 38	584	33	Corsi-Zuelli F, Deakin B. Impaired regulatory T cell control of astroglial overdrive and
39	585	55	microglial pruning in schizophrenia. Neuroscience & Biobehavioral Reviews
40	586		2021; 125 :637–53. doi:10.1016/j.neubiorev.2021.03.004
41			
42 43	587	34	Corsi-Zuelli F, Deakin B, de Lima MHF, et al. T regulatory cells as a potential
44	588		therapeutic target in psychosis? Current challenges and future perspectives. <i>Brain</i> ,
45	589		Behavior, & Immunity - Health 2021;17:100330. doi:10.1016/j.bbih.2021.100330
46 47	590	35	Jeppesen R, Christensen RHB, Pedersen EMJ, et al. Efficacy and safety of anti-
47 48	591	55	inflammatory agents in treatment of psychotic disorders – A comprehensive systematic
49	592		review and meta-analysis. <i>Brain, Behavior, and Immunity</i> 2020; 90 :364–80.
50	593		doi:10.1016/j.bbi.2020.08.028
51 52			
52	594	36	Girgis RR, Ciarleglio A, Choo T, <i>et al.</i> A Randomized, Double-Blind, Placebo-
54	595 506		Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For
55	596 507		Residual Symptoms in Schizophrenia. <i>Neuropsychopharmacology : official publication</i>
56 57	597 598		of the American College of Neuropsychopharmacology 2018;43:1317–23. doi:10.1038/npp.2017.258
58	570		uoi.10.1050/npp.2017.250
59			
60			


1 2			
3 4 5 6	599 600 601	37	Mondelli V, Ciufolini S, Belvederi Murri M, <i>et al.</i> Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis. <i>Schizophrenia bulletin</i> 2015; 41 :1162–70. doi:10.1093/schbul/sbv028
7 8 9 10 11	602 603 604	38	Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia: a review and meta-analysis. <i>Clinical schizophrenia & related psychoses</i> 2014;7:223–30. doi:10.3371/CSRP.MICU.020813
12 13 14 15 16	605 606 607 608	39	Raison CL, Rutherford RE, Woolwine BJ, <i>et al.</i> A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. <i>JAMA Psychiatry</i> 2013; 70 :31–41. doi:10.1001/2013.jamapsychiatry.4
17 18 19 20 21 22	609 610 611 612	40	Khandaker GM, Stochl J, Zammit S, <i>et al.</i> Association between circulating levels of C-reactive protein and positive and negative symptoms of psychosis in adolescents in a general population birth cohort. <i>J Psychiatr Res</i> 2021; 143 :534–42. doi:10.1016/j.jpsychires.2020.11.028
23 24 25 26 27 28	613 614 615 616	41	Edwards CJ, Cella M, Tarrier N, <i>et al.</i> Investigating the empirical support for therapeutic targets proposed by the temporal experience of pleasure model in schizophrenia: A systematic review. <i>Schizophrenia research</i> 2015; 168 :120–44. doi:10.1016/j.schres.2015.08.013
29 30 31 32 33	617 618 619 620	42	Lalousis PA, Schmaal L, Wood SJ, <i>et al.</i> Neurobiologically Based Stratification of Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. <i>Biological Psychiatry</i> 2022;:S0006322322011568. doi:10.1016/j.biopsych.2022.03.021
34 35 36 37 38	621 622 623	43	Fioravanti M, Carlone O, Vitale B, <i>et al.</i> A Meta-Analysis of Cognitive Deficits in Adults with a Diagnosis of Schizophrenia. <i>Neuropsychol Rev</i> 2005; 15 :73–95. doi:10.1007/s11065-005-6254-9
39 40 41 42	624 625 626	44	Keefe RSE, Bilder RM, Davis SM, <i>et al.</i> Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> 2007; 64 :633–47. doi:10.1001/archpsyc.64.6.633
43 44 45	627 628	45	Chan A-W, Tetzlaff JM, Altman DG, <i>et al.</i> SPIRIT 2013 Statement: defining standard protocol items for clinical trials. <i>Rev Panam Salud Publica</i> 2015; 38 :506–14.
46 47 48 49	629 630	46	Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. <i>Nature reviews Rheumatology</i> 2014; 10 :720–7. doi:10.1038/nrrheum.2014.127
50 51 52 53 54	631 632 633 634	47	Choy EHS, Isenberg DA, Garrood T, <i>et al.</i> Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. <i>Arthritis and rheumatism</i> 2002; 46 :3143–50. doi:10.1002/art.10623
55 56 57 58 59 60	635 636 637 638 639	48	Woo P, Wilkinson N, Prieur A-M, <i>et al.</i> Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. <i>Arthritis research & therapy</i> 2005;7:R1281-8. doi:10.1186/ar1826


1 2 3 4 5 6	640 641 642	 49 Gard DE, Gard MG, Kring AM, <i>et al.</i> Anticipatory and consummatory components of the experience of pleasure: A scale development study. <i>Journal of Research in Personality</i> 2006;40:1086–102. doi:10.1016/j.jrp.2005.11.001
8	643	
6 7	642	experience of pressure. A scale development study. John Au of Research in Personality 2006;40:1086–102. doi:10.1016/j.jrp.2005.11.001
58 59 60		
50		

645 FIGURE LEGEND

646 Figure 1. Overview of study design

to beet teries only





240x165mm (144 x 144 DPI)



Foley et al. Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: A randomised double-blind placebo-controlled trial of single dose tocilizumab in patients with psychosis.

eTable1: SPIRIT 2013 Checklist - Recommended items to address in a clinical trial protocol and related documents*

Section/item	ltem No	Description	Addressed on page number
Administrative infe	ormation		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
Protocol version	2b 3	All items from the World Health Organization Trial Registration Data Set	4 (ISRCTN 23256704)
Funding	4	Sources and types of financial, material, and other support	24 - 25
Roles and	5a	Names, affiliations, and roles of protocol contributors	1, 24
responsibilities	5b	Name and contact information for the trial sponsor	23
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	23-25

 BMJ Open

	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	23 - 25
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	6-9
	6b	Explanation for choice of comparators	6-9
Objectives	7	Specific objectives or hypotheses	9-10
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	9
Methods: Participa	ints, inte	erventions, and outcomes	
Study setting	9	Description of study settings (e.g., community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	9, 11
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	12, Table 1
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	11, 19, 21-22, Figure 1
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	22
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	-
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	12, Table 1
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Dutcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	9-10, Figure 1, Table 2
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	18-19, Figure 1
ample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	17
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	18
lethods: Assignme	nt of i	nterventions (for controlled trials)	
llocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	17
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	17
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	17
linding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	17
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	22
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Methods: Data colle	ction,	management, and analysis	
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	10-15, 18-19, Table 2
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	17-18
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	23-24
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	17-18
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	17-18
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	-
Methods: Monitorin	g		
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	23
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	-
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	20-22

Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	-
Ethics and dissemin	ation		
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	22
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	22
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	22-23
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	22-23
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	23-24
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	25
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	23
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	22
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	24
	31b	Authorship eligibility guidelines and any intended use of professional writers	24
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	-
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Available in full protocol
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	23-24

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "<u>Attribution-NonCommercial-NoDerivs 3.0 Unported</u>" license.

peer review only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: A randomised double-blind placebocontrolled trial of single dose tocilizumab in patients with psychosis

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-067944.R1
Article Type:	Protocol
Date Submitted by the Author:	28-Nov-2022
Complete List of Authors:	Foley, Éimear; University of Bristol, MRC Integrative Epidemiology Unit, Population Health Sciences; Bristol Medical School, Centre for Academic Mental Health, Population Health Sciences Griffiths, Sian Lowri; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Murray, Alexander; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Rogers, Jack; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Corsi-Zuelli, Fabiana; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health; University of Sao Paulo, Department of Neuroscience and Behaviour Hickinbotham, Hannah; University of Cambridge, Department of Psychiatry Warwick, Ella; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Wilson, Martin; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Wilson, Martin; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Warwick, Ella; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Warwick, Sill; University of Cambridge, Psychiatry; Cambridgeshire and Peterborough NHS Foundation Trust Murray, Graham K.; University of Cambridge, Psychiatry; Cambridgeshire and Peterborough NHS Foundation Trust Deakin, Bill; The University of Cambridge, Medicine Suckling, John; University of Cambridge, Psychiatry; Cambridgeshire and Peterborough NHS Foundation Trust Barnes, Nicholas ; University of Birmingham, Institute of Clinical Sciences Upthegrove, Rachel; University of Birmingham, Institute of Clinical Sciences Upthegrove, Rachel; University of Birmingham, Institute of Clinical Sciences Upthegrove, Rachel; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health; Early Intervention Service, Birmingham Women's and Children's NHS Foundation Trust Khandaker, Golam M.; University of Birstol, MRC Integrative Epidemiology Unit, Po
Primary Subject Heading :	Mental health

Secondary Subject Heading:	Immunology (including allergy)
Keywords:	Schizophrenia & psychotic disorders < PSYCHIATRY, IMMUNOLOGY, Clinical trials < THERAPEUTICS, Magnetic resonance imaging < RADIOLOGY & IMAGING
	SCHOLARONE [™] Manuscripts
For peer review	only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2		
3 4	1	Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: A
5 6	2	randomised double-blind placebo-controlled trial of single dose tocilizumab in patients
7 8 9	3	with psychosis
9 10 11	4	
12 13	5	Éimear M. Foley ^{a,b} ; Sian Lowri Griffiths ^c ; Alexander Murray ^c ; Jack Rogers ^c ; Fabiana Corsi-
14 15	6	Zuelli ^{c,d,e} ; Hannah Hickinbotham ^f ; Ella Warwick ^c ; Martin Wilson ^c ; Muzaffer Kaser ^{f,g} ;
16 17 18	7	Graham K. Murray ^{f,g} ; Bill Deakin ^h ; Deepak Jadon ⁱ ; John Suckling ^{f,g} ; Nicholas M. Barnes ^{e;}
19 20	8	Rachel Upthegrove ^{c,j,†} ; and Golam M. Khandaker ^{a,b,k,l,†,*} ; for the PIMS Collaboration
21 22	9	
23 24 25	10	^a MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,
25 26 27	11	University of Bristol, Bristol, United Kingdom
28 29	12	^b Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School,
30 31 32	13	University of Bristol, Bristol, United Kingdom
33 34	14	^c Institute for Mental Health and Centre for Human Brain Health, University of Birmingham,
35 36	15	Birmingham, United Kingdom
37 38 20	16	^d Department of Neuroscience and Behaviour, Division of Psychiatry, Ribeirão Preto Medical
39 40 41	17	School, University of São Paulo, São Paulo, Brazil
42 43	18	^e Institute of Clinical Sciences, College of Medical and Dental Sciences, University of
44 45	19	Birmingham, United Kingdom
46 47 48	20	^f Department of Psychiatry, University of Cambridge, United Kingdom
49 50	21	^g Cambridgeshire and Peterborough NHS Foundation Trust, United Kingdom
51 52	22	^h Faculty of Biology, Medicine and Health, Division of Neuroscience and Experimental
53 54 55	23	Psychology, School of Biological Sciences, University of Manchester, Manchester Academic
56 57	24	Health Science Centre, Manchester, United Kingdom
58 59 60	25	ⁱ Department of Medicine, University of Cambridge, United Kingdom

1 2		
3 4	26	^j Early Intervention Service, Birmingham Women's and Children's NHS Foundation Trust
5 6	27	^k NIHR Bristol Biomedical Research Centre, Bristol, United Kingdom
7 8 0	28	¹ Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, United Kingdom
9 10 11	29	
12 13	30	[†] Joint senior authors
14 15 16	31	
17 18	32	* Corresponding author and address: Prof Golam M. Khandaker, MRC Integrative
19 20	33	Epidemiology Unit, Oakfield House, Oakfield Grove, Clifton, Bristol, BS8 2BN, UK
21 22 23	34	Email: golam.khandaker@bristol.ac.uk
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 50 51 52 53 54 55 57 58 59 60		Email: golam.khandaker@bristol.ac.uk

35 ABSTRACT

Introduction: Evidence suggests a potentially causal role of interleukin 6 (IL-6), a pleiotropic cytokine that generally promotes inflammation, in the pathogenesis of psychosis, but no interventional studies elucidating potential mechanisms in patients with psychosis, stratified using inflammatory markers, have been conducted. Tocilizumab is a humanised monoclonal antibody targeting the IL-6 receptor to inhibit IL-6 signalling licensed in the UK for treatment of rheumatoid arthritis. The primary objective of this study is to test whether IL-6 contributes to the pathogenesis of psychosis, and to examine potential mechanisms by which IL-6 affects psychotic symptoms. A secondary objective is to examine characteristics of inflammation-associated psychosis.

Methods and analysis: A proof-of-concept study employing a randomised, parallel-group, double-blind, placebo-controlled design testing the effect of IL-6 inhibition on anhedonia in patients with psychosis. Approximately 60 participants with diagnosis of schizophrenia and related psychotic disorders (ICD-10 codes F20, F22, F25, F28, F29) with evidence of low-grade inflammation (IL-6 >0.7pg/ml) will receive either one intravenous infusion of tocilizumab (4.0mg/kg; max 800mg) or normal saline. Psychiatric measures and blood samples will be collected at baseline, and 7-, 14-, and 28-days post-infusion. Cognitive and neuroimaging data will be collected at baseline and 14 days post-infusion. In addition, approximately 30 patients with psychosis without evidence of inflammation (IL-6 < 0.7 pg/ml) and 30 matched healthy controls will be recruited to complete identical baseline assessments to allow for comparison of the characteristic features of inflammation-associated psychosis. Ethics and dissemination: The study is sponsored by the University of Bristol and has been approved by the Cambridge East Research Ethics Committee (reference: 22/EE/0010; IRAS project ID: 301682). Study findings will be published in peer-review journals. Findings will be also disseminated by scientific presentation and by other means.

1 2		
3 4	60	Trial registration number: ISRCTN 23256704
5 6	61	
7 8 9	62	KEYWORDS: Psychotic Disorders; Negative Symptoms; Interleukin 6; Immunotherapy;
$\begin{array}{c} 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 9\\ 20\\ 21\\ 22\\ 3\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 45\\ 36\\ 37\\ 38\\ 9\\ 40\\ 41\\ 43\\ 44\\ 56\\ 57\\ 58\\ 56\\ 57\\ 58\\ 9\\ 60\\ \end{array}$	63	Tocilizumab; Clinical Trial.

64 ARTICLE SUMMARY

- Strengths and limitations of this study
 Adopting a randomised controlled trial (RCT) design and patient selection based on elevated level of IL-6 (in addition to other criteria) will help examine the causal role
- 68 of IL-6, and the therapeutic potential of targeting IL-6 pathway, in psychosis.
- The use of target specific intervention (anti-IL6R monoclonal antibody tocilizumab)
 will help assess the clinical relevance of IL-6 and related up- and downstream
 inflammatory cytokines in psychosis.
 - The use of neuroimaging, cognitive tests, and extensive peripheral blood biomarker exploration before and after tocilizumab treatment to assess potential mechanisms of effect.
 - One dose of tocilizumab is unlikely to be sufficient to test the efficacy of this drug as potential treatment for psychosis.
 - Tocilizumab inhibits both anti-inflammatory (classic) and pro-inflammatory (trans) pathways of IL-6 that may have complementary or differential effects relevant to potential therapeutic effects.

BMJ Open

	81	Word count: 4,245
	82	INTRODUCTION
	83	Scientific background and study rationale
0 1	84	The neuroimmune hypothesis of schizophrenia proposes that mild peripheral immune
2 3	85	activation gives rise to an inflammatory response in the brain and neurobiological changes
1 2 3 4 5 6 7 8 9 0	86	associated with psychotic illness [1-4]. Meta-analytic evidence is clear that circulating
0 7 8	87	concentrations of interleukin 6 (IL-6) and other inflammatory proteins, such as C-reactive
	88	protein (CRP), are increased in patients with psychosis, including treatment naïve first
1 2 3 4 5 6 7 8 9	89	episode psychosis (FEP) [5], compared with controls [6–9]. Prospective cohort studies show
3 4 5	90	that these indices of mild immune activation precede the onset of symptoms [10,11].
6 7	91	Furthermore, genetic variants known to increase IL-6 concentrations are associated with
	92	genetic risk of schizophrenia [12,13]. These Mendelian randomization studies eliminate the
0 1 2	93	possibility that raised IL-6 concentrations are a consequence of environmental exposures
1 2 3 4 5 6 7	94	associated with schizophrenia, such as obesity and smoking and instead suggest that IL-6 has
5 6	95	a causal role in psychosis. Extending this approach using the UK Biobank population, we
7 8 9	96	found that genetically-predicted levels of IL-6 were associated with reduced grey matter
9 0 1	97	primarily in the middle temporal gyrus, a region whose gene expression profile is enriched
2 3	98	for IL-6 pathway proteins and for neuropsychiatric disorder ontologies [14]. Moreover,
2 3 4 5 6	99	clinical studies report correlations between IL-6 levels and structural brain changes in
6 7 8	100	individuals with schizophrenia [15], with reduced grey matter volume being exaggerated in
9 0	101	patients with psychosis and elevated inflammatory cytokines [16]. Though this causal
1 2	102	evidence strongly implicates IL-6, only an intervention study in patients can test the causal
3 4 5	103	hypothesis.
5 6 7	104	The neuroimmune hypothesis generally assumes that microglia, the brain's resident
^		

105 immune cells, are activated and pathogenic in schizophrenia. This is supported by traditional

2
3
-
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
40 47
48
49
50
51
52
53
55 54
55
56
57
58
59
60
00

1

106	neuropathological studies and initial in-vivo PET imaging studies [17-19], possibly reflecting
107	impaired cellular control of inflammation or oxidative defence. Inflammatory damage may
108	also account for evidence of oxidative stress from MRS glutathione studies [20]. However,
109	whether microglia are the direct target of IL-6 is unclear and it is not certain that IL-6 can
110	cross the blood-brain barrier and/or increase its permeability to circulating inflammatory
111	cells, cytokines, and chemokines [2,21]. Additionally, it is increasingly uncertain whether
112	microglial inflammation, as traditionally understood, occurs in schizophrenia [22,23]. Recent
113	meta-analyses of PET radioligand binding studies report decreased rather than increased
114	radioligand binding to activated microglia [24,25]. This may account for the unexpected lack
115	of therapeutic benefit of the anti-microglial antibiotic, minocycline, in recent large clinical
116	trials [26,27]. Furthermore, large transcriptomic studies in post-mortem brains report no
117	change or reduction in microglial gene expression but increases in astrocytic expression
118	[23,28–32]. It is increasingly understood that both peripheral immune responses and brain
119	glial function are regulated by specialised T cells (Tregs), a subset of which reside in brain
120	parenchyma [33,34]. A novel proposal is that Treg hypofunction accounts for mild peripheral
121	immune disinhibition and dysregulated astroglial-microglial interaction, such that microglia
122	are driven into a developmental, synapse-pruning phenotype while astroglia disrupt
123	neurotransmitter function [33,34]. Importantly, there are bidirectional interactions between
124	IL-6 and Treg function [34]. Crucially, we will measure IL-6 in addition to cellular and
125	molecular markers of immune function and investigate how they correlate with central
126	markers and clinical state.
127	Previous attempts testing the inflammatory hypothesis in therapeutic clinical trials

Previous attempts testing the inflammatory hypothesis in therapeutic clinical trials have been attempted. However, little evidence of overall efficacy has been found [35]. These trials have generally tested broad spectrum agents, such as non-steroidal anti-inflammatory drugs, with no attempt to stratify patients according to evidence of inflammation. A trial

Page 9 of 47

BMJ Open

using tocilizumab, a humanised monoclonal antibody (mAb) against the IL-6 receptor currently licensed in the UK for treatment of rheumatoid arthritis (RA) and severe coronavirus disease, reported no improvements in any clinical measure in a small sample of 36 patients with established schizophrenia [36]. However, as mentioned previously, no stratification by inflammatory markers or any mechanistic immune measures was applied. Low-grade inflammation is associated with poor response to antipsychotic drugs [37], but immunotherapy is unlikely to be relevant for all patients with psychosis. Meta-analysis suggests that evidence of immune activation, defined by elevated CRP levels, is present in a quarter to one third of patients with schizophrenia [38]. A randomised controlled trial of infliximab, an anti-tumour necrosis factor alpha (TNF- α) mAb, reported that antidepressant response was associated with higher CRP levels at baseline [39], suggesting that patients with evidence of immune activation may be better candidates for immunotherapy trials. As far as we are aware, no previous clinical trial has selected patients with schizophrenia based on evidence of immune activation. Selection of patients with particular symptom profiles and/or stage of illness may also

be a useful strategy that needs to be employed in immunotherapy trials for schizophrenia. A wide variety of symptoms occur in schizophrenia such as hallucinations, delusions, anhedonia, cognitive dysfunction, and affective symptoms and presentation of these symptoms differ from one individual to another. Some symptoms may be more related to inflammation than others. For instance, meta-analytic data suggests that elevated proinflammatory cytokines are associated with negative psychotic symptomatology [40]. Moreover, a recent study from the ALSPAC birth cohort reported that out of 20 positive and negative symptoms, CRP is particularly associated with anhedonia and auditory hallucinations [41]. Lastly, results from work we have completed to date as part of the MRC-funded larger PIMS collaboration (MR/S037675/1), suggest that anhedonia may be a

2	
3	
4	
5	
6 7	
8	
9 10	
11	
12	
13	
14 15	
16	
16 17	
18	
19	
20	
21 22	
22	
24	
25	
26	
27	
28	
29 30	
31	
32	
33	
34	
35	
36 37	
38	
39	
40	
41	
42	
43 44	
45	
46	
47	
48	
49 50	
50 51	
52	
53	
54	
55	
56	
57 58	
58 59	
60	
-	

156	promising target in early phases of established psychotic disorder. Anhedonia and
157	amotivation are strongly associated with poor functional outcomes in depression and
158	schizophrenia, and present a formidable barrier to returning to work or building relationships
159	[42,43]. Patients with psychotic disorders also present with cognitive deficits in a range of
160	domains [44]. Available antipsychotic medications have a limited effects on poor cognitive
161	functioning in psychosis [45]. Illness stage may also be of relevance. Meta-analytic data has
162	revealed no differences in IL-6 levels between stable, medicated patients with schizophrenia
163	and controls, although compared with controls, IL-6 levels were similarly elevated in patients
164	with FEP and those with acute relapse [7]. A separate meta-analysis found evidence of
165	elevated blood cytokine levels in acutely and chronically ill patients with schizophrenia [6].
166	Focusing on particular inflammation-related symptoms, such as anhedonia, and/or illness
167	stage may increase the chance of success for immunotherapy trials.
168	
168 169	Proposed study
	Proposed study The proposed two-year study is a UK multi-site (Bristol, Birmingham, and Cambridge)
169	
169 170	The proposed two-year study is a UK multi-site (Bristol, Birmingham, and Cambridge)
169 170 171	The proposed two-year study is a UK multi-site (Bristol, Birmingham, and Cambridge)
169 170 171 172	The proposed two-year study is a UK multi-site (Bristol, Birmingham, and Cambridge) proof-of-concept, randomised, parallel-group, double-blind, placebo-controlled trial.
 169 170 171 172 173 	The proposed two-year study is a UK multi-site (Bristol, Birmingham, and Cambridge) proof-of-concept, randomised, parallel-group, double-blind, placebo-controlled trial. <i>Study aims and hypotheses</i>
 169 170 171 172 173 174 	The proposed two-year study is a UK multi-site (Bristol, Birmingham, and Cambridge) proof-of-concept, randomised, parallel-group, double-blind, placebo-controlled trial. <i>Study aims and hypotheses</i> The primary aim of this trial is to examine potential mechanisms by which IL-6 affects
 169 170 171 172 173 174 175 	The proposed two-year study is a UK multi-site (Bristol, Birmingham, and Cambridge) proof-of-concept, randomised, parallel-group, double-blind, placebo-controlled trial. <i>Study aims and hypotheses</i> The primary aim of this trial is to examine potential mechanisms by which IL-6 affects anhedonia, psychotic symptoms, and cognition. Our primary hypothesis is that inhibition of
 169 170 171 172 173 174 175 176 	The proposed two-year study is a UK multi-site (Bristol, Birmingham, and Cambridge) proof-of-concept, randomised, parallel-group, double-blind, placebo-controlled trial. <i>Study aims and hypotheses</i> The primary aim of this trial is to examine potential mechanisms by which IL-6 affects anhedonia, psychotic symptoms, and cognition. Our primary hypothesis is that inhibition of IL-6 signalling with a single intravenous infusion of anti-IL6R monoclonal antibody,
 169 170 171 172 173 174 175 176 177 	The proposed two-year study is a UK multi-site (Bristol, Birmingham, and Cambridge) proof-of-concept, randomised, parallel-group, double-blind, placebo-controlled trial. <i>Study aims and hypotheses</i> The primary aim of this trial is to examine potential mechanisms by which IL-6 affects anhedonia, psychotic symptoms, and cognition. Our primary hypothesis is that inhibition of IL-6 signalling with a single intravenous infusion of anti-IL6R monoclonal antibody, tocilizumab, in individuals with psychosis and elevated IL-6 at baseline will attenuate

Page 11 of 47

BMJ Open

1		
2		
3 4	181	in patients with psychosis and evidence of inflammation will be associated with central
5 6 7	182	measures of oxidative stress and relevant resting state brain function.
7 8 9	183	We will also conduct deep immunophenotyping of peripheral blood mononuclear cell
10 11	184	subsets (CD4 ⁺ , CD8 ⁺ , Tregs, natural killer and natural killer-T cells, monocytes, and B cells)
12 13	185	to characterise their absolute number, frequency, and function. Our primary mechanistic
14 15	186	outcome is the level of IL-6/STAT3 signalling inhibition within both innate and adaptive
16 17 18	187	immune cells using multi-colour flow cytometry with an established optimised pSTAT3
19 20	188	phosflow assay. This will help identify the potential cellular impact of peripheral
21 22	189	inflammation in psychosis, which is largely unknown. Functional assessment of IL-6/STAT3
23 24 25	190	signalling in immune cell subsets and their response to exogenous IL-6 stimulation will
26 27	191	inform abnormal immune response in psychosis and allow measurement of response to
28 29	192	tocilizumab at the cellular level.
30 31 32	193	A secondary objective is to carry out an observational study to examine clinical and
32 33 34	194	biomarker differences and similarities between patients with psychotic disorder with and
35 36	195	without evidence of inflammation and healthy controls (HCs). We hypothesise that
37 38	196	individuals with psychotic disorder and evidence of inflammation, compared to those without
39 40 41	197	evidence of inflammation and HCs, will have increased symptoms of anhedonia and
42 43	198	amotivation, poorer cognitive functioning, and cellular and brain-based measures of immune
44 45	199	dysfunction.
46 47	200	
48 49		
50 51	201	METHODS
52 53 54	202	This protocol has been prepared in accordance with the Standard Protocol Items:
55 56	203	Recommendations for Interventional Trials (SPIRIT) 2013 statement [46]. Please see
57 58	204	supplementary eTable 1 for the SPIRIT checklist. The planned start date for the PIMS trial
59 60	205	was 1st November 2021, however, this was delayed due to the COVID-19 pandemic. We

4	206
5 6	207
7 8 9	208
9 10 11	209
12 13	210
14 15 16	211
16 17 18	212
19 20	213
21 22	214
23 24 25	215
26 27	216
28 29 20	217
30 31 32	218
33 34	219
35 36 27	220
37 38 39	221
40 41	222
42 43	223
44 45 46	224
47 48	225
49 50	226
51 52 53	227
54 55	228
56 57	229
58 59 60	230

206 began recruiting at our site in Birmingham in November 2022, and we soon expect 207 recruitment to begin at our Bristol and Cambridge sites. The planned end date is 31st May 208 2024.

1 2 З

> 210 Patient and public involvement

211 The study protocol was prepared in collaboration with individuals with lived experience of 212 mental illness who contributed to the development of participant information sheet, consent 213 forms (Appendix I, II, and III), and data collection procedures.

Study design and sample 215

See Figure 1 for an overview of study design. Individuals residing in Bristol, Birmingham, or 216 Cambridge in the United Kingdom will be recruited. Approximately 60 participants with 217 psychosis and evidence of inflammation (i.e., IL-6 ≥ 0.7 pg/ml) will be randomised to receive 218 either one intravenous infusion of tocilizumab (drug) or normal saline (placebo). For the 219 220 secondary, observational study, we will compare baseline characteristics of the intervention 221 cohort with approximately 30 participants with psychosis without evidence of inflammation 222 (i.e., IL-6 <0.7pg/ml), and approximately 30 HCs. Participants without evidence of 223 inflammation and controls will not be randomised as they will not receive any intervention. 224 Neuroimaging will only be undertaken by those without MRI contraindications who have 225 given specific informed consent for MRI. Participants not eligible or not consenting for MRI 226 will take part in all other aspects of the study.

Intervention 228

Single intravenous infusion of tocilizumab (4.0mg/kg; max 800mg in total) or normal saline 229 given to participants with psychosis and evidence of inflammation. Tocilizumab blocks both 230

IL-6 classic and trans-signalling – the latter being responsible for most of the inflammatory effects of IL-6 – providing broad inhibition of IL-6 signalling and a strong test of a casual role for IL-6 in psychosis [47]. Tocilizumab is the first-in-class, humanized monoclonal antibody against the IL-6R, commercially available and licensed in the UK for treatment of RA. Approved dosage of tocilizumab for treatment of RA is 2, 4, or 8mg/kg; max 800mg in total. In RA, a single tocilizumab infusion has shown to improve clinical and laboratory measures within 48 hours, with most noticeable results in one-to-two weeks [48,49]. The follow-up schedule for our study is in keeping with this observation.

Eligibility criteria

We will recruit participants aged 18-40 years. Patient participants must meet International Classification of Diseases 10th Revision (ICD-10) criteria for a diagnosis of schizophrenia and related psychoses (ICD-10 code F20, F22, F25, F28, F29) at the time of eligibility assessment, be within three years of first diagnosis of psychotic disorder, be on a stable treatment regime with no recent (within two weeks) initiation, cessation, or change in class of antipsychotic medication, and have a Positive and Negative Syndrome Scale (PANSS) item score ≥ 3 on P1 (delusions), P2 (conceptual disorganisation), P3 (hallucinatory behaviour), or P6 (suspiciousness/persecution). Additionally, patients recruited to the interventional arm will be required to have serum IL-6 levels ≥ 0.7 pg/ml and a Temporal Experience of Pleasure Scale (TEPS) anticipatory pleasure score ≤ 41 (based on item numbers 1, 3, 7, 11, 12, 14, 15, 16, 17, and 8) and consummatory pleasure score \leq 36 (based on item numbers 2, 4, 5, 6, 8, 9, 10, and 13). The threshold of serum IL-6 \geq 0.7pg/mL as evidence of inflammation for this particular trial was chosen based on observations from the Personalised Prognostic Tools for Early Psychosis Management (PRONIA) cohort [https://www.pronia.eu]. In 192 first-episode psychosis patients included in the PRONIA study, the median value of serum IL-6 was

3	
4	
5	
6 7	
, 8	
9	
10	
11	
12	
13	
14	
15 16	
17	
18	
19	
20	
21	
22	
23	
24 25	
26	
27	
28	
29	
30	
31	
32 33	
33 34	
35	
36	
37	
38	
39	
40	
41 42	
42	
44	
45	
46	
47	
48	
49 50	
50 51	
52	
53	
54	
55	
56	
57	
58 59	
59 60	
50	

256 0.49pg/mL (25th percentile 0.22pg/mL; 75th percentile 1.11pg/mL), and the mean was

257 0.79 pg/mL (SD ± 0.84). Based on these observations, we chose the cut-off of 0.7 pg/mL for

258 patient selection in current trial. Finally, COVID-19 anti-body titre test will be used to

259 determine adequate levels of immune response via the following cut-offs (for poor response):

260 400IU Roche/700IU Abbot assay.

HCs will have no current or lifetime history of psychiatric diagnosis, as determined by

the Mini-International Neuropsychiatric Interview (MINI). See Table 1 for complete

263 inclusion and exclusion criteria. HCs will be matched to patient participants at the group level

by age and sex.

265

261

1 2 3

266 **Table 1. PIMS Trial inclusion and exclusion criteria.**

Group	Inclusion criteria	Exclusion criteria
All participants	 Provide informed consent. Understand written and spoken English. Able and willing to consent to blood sampling. Willing to abstain from strenuous exercise for 72 hours prior to assessment. 	 Pregnancy (confirmed by urine pregnancy test) or breast feeding. Body mass index >35. Current or lifetime diagnosis of antisocial personality disorder, autism or other neurodevelopmental disorder, major traumatic brain injury. Currently active diagnosed eating disorder likely to compromise ability to take part. History of alcohol or substance use disorde (abuse/dependence) within six months prior to eligibility assessment (nicotine and caffeine dependence are not exclusionary). Current use of medication likely to compromise interpretation of immunologica data. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other opportunistic infections. Current infection with VZV, TB, Hepatitis B, Hepatitis C, or HIV confirmed by blood test. Chest X-ray will also be performed to assess for TB. Any major episode of infection requiring hospitalisation or treatment with IV antibiotics within 4 weeks of eligibility assessment.

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	Additional criteria for neuroimaging	- Able and willing to consent to MRI scanning	 Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active infectious disease, including current or prior malignancy. Diverticulitis, inflammatory bowel disease, or uncontrolled gastric/duodenal ulcer. Concomitant auto-immune or auto-inflammatory rheumatological disease. Concomitant treatment with any biologic drugs. Current and active ischemic heart disease. Uncontrolled hypertension defined as systolic blood pressure > 170 or diastolic blood pressure > 110. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies. No history of chicken pox infection or no history of varicella zoster immunity. Contraindications to MRI.
28	(optional) Additional criterion	- No current or lifetime psychiatric	
30	for healthy controls	diagnosis.	
29	Additional criteria for all individuals with psychosis	 Meet ICD-10 criteria for a diagnosis of schizophrenia and related psychoses (code F20, F22, F25, F28, F29) at the time of eligibility assessment, as determined by the Mini-International Neuropsychiatric Interview. Be within three years of first diagnosis of psychotic disorder. On stable treatment regime with no recent (within 2 weeks) initiation, cessation, or change in class of antipsychotic medication. No indication or other reason for preclusion into research (e.g., significant risk of suicidal behaviour or risk to others) as determined by their clinical team. Positive and Negative Syndrome Scale item score ≥3 on P1 (delusions), P2 (conceptual disorganisation), P3 (hallucinatory behaviour), OR P6 (suspiciousness/persecution). 	

Additional criteria	- Serum IL-6 level ≥0.7pg/ml at	
for intervention	eligibility and baseline	
group	assessment.	
	- Temporal Experience of Pleasure	
	Scale anticipatory pleasure score	
	\leq 41 (based upon item numbers 1,	
	3, 7, 11, 12, 14, 15, 16, 17, and 8)	
	and consummatory pleasure score	
	\leq 36 (based upon item numbers 2,	
	4, 5, 6, 8, 9, 10, and 13).	
	- Evidence of COVID-19	
	immunity required prior to	
	infusion, confirmed before	
	randomisation using evidence of	
	vaccination and antibody titre	
	test.	
Additional criterion	- Serum IL-6 level <0.7pg/ml at	
for patients with	eligibility and baseline	
psychosis without	assessment.	
inflammation	\sim	

270 Study outcomes

The primary outcome is anhedonia, defined as anticipatory and consummatory pleasure scores, assessed by the TEPS [50] at approximately day 14 post-infusion. The primary mechanistic outcome is the level of IL-6/STAT3 signalling inhibition post-tocilizumab infusion in both innate and adaptive immune cells using multi-colour flow cytometry and an established optimised pSTAT3 phosflow assay. We will also collect data on several tertiary/exploratory measures including positive and negative symptoms of psychosis, depressive symptoms, fatigue, quality of life and subjective wellbeing, cognitive function (psychomotor speed, attention and memory, and executive function), peripheral blood inflammatory markers, cortisol, cell expression, including DNA and RNA sequencing, functionality, and neuroimaging measures, including functional resting state MRI and MRS outcomes (Table 2). Where possible, blood samples will be collected during working hours

and time of sampling will be recorded. However, a specified time window will not be given

to ease burden on patients and to maximise participation.

Table 2. PIMS trial study measures

Domain	Tool	Source	Validated Tool	Time of assessment
	Screening questionnaire	Self-report		Screening
	Medical History Questionnaire	Self- report/General practice		Eligibility
Sociodemographic/lifestyle	Substance Use Questionnaire	Self-report		Eligibility
	Physical Measurements Form	Self-report		Baseline
	Sociodemographic Questionnaire	Self-report		Baseline
	The Temporal Experience of Pleasure Scale	Self-report	\checkmark	Eligibility, baseline, follow-ups
	The Positive and Negative Syndrome Scale	Interviewer assessed	\checkmark	Eligibility, baseline, follow-ups
	The Mini-International Neuropsychiatric Interview	Interviewer assessed	\checkmark	Eligibility
	Psychiatric History Questionnaire	Self-report		Baseline
Psychiatric	The Scale for the Assessment of Negative Symptoms	Self-report	\checkmark	Baseline, follow-ups
	The Calgary Depression Scale for Schizophrenia	Interviewer assessed	\checkmark	Baseline, follow-ups
	Multi-dimensional Fatigue Inventory	Self-report	\checkmark	Baseline, follow-ups
	European Quality of Life-5 Dimensions Three-Level Version	Self-report	\checkmark	Baseline, follow-ups
	Visual Analogue Scale for Subjective Wellbeing	Self-report	\checkmark	Baseline, follow-ups
Cognitive	National Adult Reading Test for estimated premorbid IQ	Interviewer assessed	\checkmark	Baseline, follow-up 2

	CANTAB Reaction Time test	Computer task	\checkmark	Baseline, follow-up
	Symbol Coding Test	Paper task	\checkmark	Baseline, follow-up
	CANTAB Rapid Visual Information Processing test	Computer task	\checkmark	Baseline, follow-up
	CANTAB Paired Associates Learning test	Computer task	\checkmark	Baseline, follow-up
	CANTAB One Touch Stockings of Cambridge test	Computer task	\checkmark	Baseline, follow-up
Biologic	Inflammatory markers, cardiometabolic markers, IDO activation, white cell phenotyping	Laboratory tests		Baseline, follow-ups
Genetic	Gene expression/genotyping	Blood (RNA, DNA)		Baseline, follow-ups
	MRI Screening Questionnaire			Baseline, follow-up
Neuroimaging	Structural MRI, 1H- MRS measure of glutathione in the prefrontal cortex area, resting state fMRI	•		Baseline, follow-up

288 Sample size and statistical power

We will recruit approximately 60 patients with psychosis. However, currently there are no trials of immunotherapies for anhedonia in schizophrenia making accurate power calculation difficult. This study is a proof-of-concept experiment designed to test whether inhibition of IL-6 signalling leads to changes in psychotic symptoms. It could also inform likely statistical power for future trials testing efficacy of the drug as a treatment of schizophrenia, which is not the intention of this study. The exact statistical tests and techniques that will be applied to the data will depend on the objective of specific analysis and data characteristics (e.g.,

1 2		
2 3 4	296	variable type, distribution). These details will be specified in analysis plans and registered
5 6	297	online before participants are unblinded and any data analysis is performed.
7 8	298	
9 10 11	299	Randomisation and blinding
12 13	300	An external agency independent of the study team will arrange random allocation to
14 15	301	tocilizumab or normal saline group 1:1, ensuring two groups are comparable regarding
16 17	302	anhedonia severity and sex. Randomisation will be stratified by site. Randomising agency
18 19 20	303	will provide the randomisation code to the relevant hospital pharmacy who will dispense
20 21 22	304	tocilizumab or normal saline according to the randomisation schedule. Dispensing
23 24	305	pharmacies will keep a log of products dispensed. Infusions will be prepared and
25 26	306	administered at clinical research facilities (CRFs). Infusion packs will be prepared by trained
27 28 29	307	staff not part of the core study team, ensuring blinding of treatment allocation. Infusion packs
30 31 32 33 34 35	308	containing drug or placebo will be visually indistinguishable from each other, ensuring that
	309	both participants and study team remain blind regarding treatment allocation.
	310	
36 37		Statistical analysis
38 39	311	Statistical analysis
40 41	312	For randomised participants, an intention-to-treat approach will be taken for data analysis by
42 43	313	including all randomised participants in statistical analyses, regardless of the treatment they
44 45 46	314	received (if any). We will compare outcome measures between treatment and placebo groups
47 48	315	controlling for baseline scores. This mechanistic experiment will focus on overall pattern of
49 50	316	results and their effect sizes rather than P-values for individual tests of statistical significance.
51 52	317	The secondary mechanistic and observational analysis will compare psychotic symptoms,
53 54 55	318	cognitive function, blood, neuroimaging, and other biomarkers between and across study
56 57	319	groups using appropriate statistical tests.
58 59	320	
60		

322 STUDY PROCEDURE

An overview of study procedures is presented in Figure 1 and all study measures are detailed
in Table 2. Recruitment will take place in Bristol, Birmingham, and Cambridge and
assessments at University and NHS research facilities.

327 Participant identification

Potential participants with psychosis will be identified by NHS Psychosis Early Intervention
(EI) teams. HCs will be recruited through advertisement methods in Birmingham and
Cambridge. Potential participants will complete a screening questionnaire to confirm their
eligibility to participate. If deemed eligible, participants will be invited to an appointment to
complete a full eligibility assessment.

334 Eligibility assessment

Assessments will be carried out to establish eligibility and to obtain informed consent.
Patients will complete the MINI to confirm ICD-10 diagnosis of schizophrenia and related
psychoses, the PANSS to confirm the presence of positive symptoms of psychosis, and the
TEPS to confirm eligibility based on anticipatory and consummatory pleasure sum scores. A
blood sample will be collected from patients for serum IL-6 measurement. An MRI screening
questionnaire will be administered to those willing to give informed consent for
neuroimaging.

Baseline assessment

All participants (60 inflamed psychosis, 30 non-inflamed psychosis, and 30 HCs) will attend
 a baseline assessment comprising psychiatric measures, cognitive tasks, blood sampling, and
 neuroimaging (optional). This will be the final study contact for patients without evidence of

Page 21 of 47

1

BMJ Open

2 3	2.47	
4	347	inflammation and HCs. Patients with evidence of inflammation will undergo further tests to
5 6 7	348	establish safety/eligibility to receive tocilizumab, including a chest X-ray and blood tests to
7 8 9	349	exclude pregnancy and certain infections, such as TB, HIV, and COVID-19. Eligible
10 11	350	participants will be randomised and invited for infusion.
12 13	351	
14 15	352	Intervention
16 17 18 19 20 21 22	353	Intravenous infusion of tocilizumab or normal saline will be given continuously over one
	354	hour at CRFs in Bristol, Birmingham, and Cambridge by trained clinical staff under the
	355	supervision of a designated study doctor. Participants will remain under clinical observation
23 24	356	for a further 1-hour period after the end of infusion.
25 26 27	357	
27 28 29	358	Follow-up assessments
30 31 32 33 34 35 36	359	Follow-up assessments will take place approximately 7-, 14-, and 28-days post-infusion, and
	360	will collect similar data to the baseline assessment. Cognitive tasks and neuroimaging
	361	(optional) will be administered only on day 14. Around 42 days post-infusion, participants
37 38	362	will be contacted by phone to provide a final debrief; at which point they will exit the study.
39 40	363	
41 42	364	RISK MANAGEMENT Psychosis-related risks
43 44	365	Psychosis-related risks
45 46	200	
47 48	366	All patients will be under the care of a specialist NHS psychosis EI service. Participation will
49 50	367	not involve any treatment modifications or significant delays in receiving treatment. If a
51 52	368	patient becomes distressed during an assessment, or does not wish to continue for any reason,
53 54 55	369	the researcher will stop the assessment. Participants may withdraw at any time without giving
56 57	370	a reason. If there is any concern for the participant's safety, the research team will liaise with
58 59 60	371	participant's GP and/or mental health team as needed.

2

1		
2 3 4	372	
5 6	373	Procedure-related risks
7 8 9 10 11 12 13 14	374	Venepuncture
	375	Blood taking is associated with mild discomfort and other side effects are rare. Efforts will be
	376	made to minimise discomfort. Blood taking will be performed by a nurse, doctor, or research
14 15	377	team member trained in venepuncture.
16 17 18	378	
19 20	379	Chest X-ray
21 22	380	This study will use a typical effective radiation dose of 0.014 mSv; equivalent to 2.5 days of
23 24 25	381	average natural background radiation in the UK. The risk of developing cancer as a
25 26 27	382	consequence of participating in this study is 0.0001%. Only non-pregnant, adult participants
28 29	383	will be included.
30 31	384	
32 33 34	385	Neuroimaging
35 36	386	Discomfort during MRI will be minimised by using mirrors to allow participants to view
37 38	387	outside of the machine, providing ear plugs and a panic button, and allowing participants to
39 40 41	388	communicate with the researcher and scan operator throughout. Mild transient vertigo may be
42 43	389	experienced when being moved into the MRI machine. Risk of dislodgement or malfunction
44 45	390	of medical implants or metallic foreign objects will be minimised by screening participants to
46 47 48	391	ensure no metal is present on or within the body.
48 49 50	392	
51 52	393	IL-6 levels
53 54	394	Some participants will show evidence of inflammation in the blood (IL-6 \ge 0.7pg/ml). This is
55 56 57	395	not necessarily a cause for concern. In people with FEP, \sim 50% have serum IL-6 levels
58 59	396	>0.7pg/ml. Reasons for this in the absence of an acute infection or chronic inflammatory
60		

Page 23 of 47

1 2

BMJ Open

2 3 4	397	illness could include obesity, smoking, alcohol use, and lack of exercise, so knowledge of
5 6	398	'inflammation status' may prompt participants to adopt a healthier lifestyle. If serum IL-6
7 8 9	399	level is high (i.e., IL-6 \ge 0.7pg/ml) along with elevated CRP (>20mg/L) without any apparent
9 10 11	400	explanation, such as infection or chronic inflammatory illness, we will inform the
12 13	401	participant's GP and the participant will be excluded from the study.
14 15 16 17 18 19 20	402	
	403	Risk to research staff
	404	Staff will follow local safety procedures when lone working. No other risks are anticipated.
21 22	405	
23 24 25	406	Safety considerations for infusion and monitoring of adverse reaction
26 27	407	Before infusion
28 29	408	Participants will be selected based on strict inclusion and exclusion criteria. Additionally, we
30 31 32	409	will carry out tests for TB, HIV, VZV antibody, and Hepatitis B and C because, though
33 34	410	unlikely after a single dose, tocilizumab could make these infections worse. Female
35 36 37 38 39 40 41	411	participants of childbearing age will be given a pregnancy test, which must be negative.
	412	Participants who are sexually active will be asked to use at least one form of effective
	413	contraception for six weeks post-infusion. Male participants will also be asked not to donate
42 43	414	sperm samples for six weeks post-infusion.
44 45	415	
46 47 48	416	During infusion
49 50	417	Infusions will be given under supervision of a designated study doctor. Participants will be
51 52	418	monitored for possible side effects, which will be managed in line with use of tocilizumab for
53 54 55	419	treating patients with RA.
56 57	420	
58 59	421	After infusion
60		
		-

Participants will remain under observation for one-hour post-infusion. Participants will be advised to seek help if they feel unwell after leaving the assessment centre and will be given an information sheet containing a telephone number their health professionals can call. If necessary, we will unblind the participant and inform their health professional whether they received tocilizumab or normal saline. Adverse reactions will be recorded at each follow-up visit. Additional, safety blood tests will be done at second follow-up (e.g., WBC count, liver function, lipids).

430 ETHICS AND DISSEMINATION

The study will be conducted in accordance with the REC, Health Research Authority (HRA),
and local Research and Development (R&D) department approvals and guidelines (REC
reference: 22/EE/0010). The study team will prepare protocol amendments as required and
ethics approval will be sought before implementing any changes to the approved protocol.
The ISRCTN Trial Registry and the Research Governance Office will be informed of any
amendments to the protocol.

438 Consent

Informed consent will be obtained prior to eligibility assessments for participation in the
study (Appendix I, II, and II). This will include consent to randomise, for contact with their
GP to inform them about participation, access GP/psychiatric records to verify medical
history to establish eligibility, and to inform the participant's GP any results/outcomes as
necessary. Consent for additional tests to establish safety for tocilizumab infusion and for
storing biological samples will also be obtained.

Study management

Page 25 of 47

BMJ Open

The study is sponsored by the University of Bristol. The sponsor, the Chief Investigator (GMK), and the co-Lead (RU) will have overall responsibility for the study. A named principal investigator will take clinical responsibility for study activities at each site. The study does not require the formal arrangement of a steering committee because, according to the HRA, it is not a Clinical Trial of an Investigational Medicinal Product. However, to enhance monitoring of the study, a study management group will be established, comprising academic and clinical experts in psychiatry, rheumatology, neuroscience, and immunology.

455 Data management and retention of samples

All potential participants will be assigned a unique study-specific participant ID number. All data will be subject to good practice as laid down in the Data Protection Act. Each study stage is tracked so that participant's (de-identified) status within the study is known, and assessment and other appointment dates are forecasted. This information is held on a secure, password-protected database. Anonymised data from assessments will be uploaded to a secure, password-protected database using secure web-based data entry systems. Minimal personal data (age, sex) will be indexed by each participant's unique ID number. Blood samples collected in this study may be stored for up to 10 years after the completion for additional research. Stored samples will be coded throughout the sample storage and analysis process and will not be labelled with personal identifiers. Participants may withdraw their consent for their samples to be stored for future research.

Dissemination plan

469 Study results will be published in peer-review journals and will conform to the guidelines of 470 the International Committee of Medical Journal Editors. Findings will be disseminated at 471 conferences, departmental talks, and via social and traditional media.

1 ว		
2 3 4	472	
5 6	473	AUTHORS CONTRIBUTIONS
7 8 9	474	ÉMF wrote first draft of the PIMS trial protocol and of this manuscript. SLG, MK, GKM,
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	475	BD, DJ, JS, and NMB contributed to study design and protocol development and revised
	476	manuscript drafts. RU contributed to study design and study protocol, and revised manuscript
	477	drafts. GMK devised study design and trial protocol, and revised drafts. ÉMF and SLG
	478	developed study materials and liaised with REC and HRA regarding approvals. AM, JR,
	479	FCZ, HH, EW, and MW contributed to the revision of the manuscript and validation of
	480	operating procedures and mechanistic protocols. RU and GMK co-lead the MRC grant that
	481	funds the PIMS trial and provide overall supervision and oversight for the project.
25 26 27	482	
28 29 30 31 32 33 34 35 36 37 38 39 40 41	483	FUNDING STATEMENT
	484	The PIMS trial is funded by a Medical Research Council (MRC) grant to RU and GMK;
	485	Grant Ref: MR/S037675/1. ÉMF is supported by an MRC Integrative Epidemiology Unit
	486	PhD Studentship. AM is supported by funding from the MRC for doctoral training
	487	(MR/2434208). FCZ receives a PhD Fellowship from the São Paulo Research Foundation
	488	(2019/13229-2 and 2021/07448-3). HH is supported by the PIMS Trial MRC grant
41 42 43	489	(MR/S037675/1). DJ is supported by the Cambridge Arthritis Research Endeavour and the
44 45	490	National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre
46 47	491	(BRC-1215-20014). NMB acknowledges funding support from the MRC (MR/R006008/1
48 49 50	492	and MR/N019016/1), Ministry of Defence (702931454), Diabetes UK (20/0006296), NIHR
51 52	493	(14/WM/0093), and Innovate UK (84361). RU has grants from MRC, NIHR: Health
53 54	494	Technology Assessment, European Commission - Research: The Seventh Framework
55 56 57 58 59	495	Programme, and personal fees from Sunovion, outside the submitted work. GMK
60		

1 2		
3 4 5 6 7 8 9 10 11	496	acknowledges funding support from the Wellcome Trust (Grant No. 201486/Z/16/Z). The
	497	funders had no role in the design of this study.
	498	
	499	COMPETING INTERESTS STATEMENT
12 13	500	ÉMF, SLG, AM, JR, FCZ, HH, EW, MW, MK, GKM, BD, DJ, JS, RU, and GMK have no
14 15	501	conflicts of interest to report. NMB holds shares and is a Director of Celentyx Ltd.
$\begin{array}{c} 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\\ 60\\ \end{array}$	502	

2 3 4	503	REFERENCES		
$\begin{array}{c} 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 32\\ 4\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 9\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 56\\ 57\\ 56\\ 57\\ 56\\ 57\\ 56\\ 56\\ 57\\ 56\\ 56\\ 57\\ 56\\ 56\\ 57\\ 56\\ 56\\ 57\\ 56\\ 56\\ 57\\ 56\\ 56\\ 57\\ 56\\ 56\\ 57\\ 56\\ 56\\ 56\\ 56\\ 56\\ 56\\ 56\\ 56\\ 56\\ 56$	504 505 506	1	Khandaker GM, Cousins L, Deakin J, <i>et al.</i> Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. <i>Lancet Psychiatry</i> 2015; 2 :258–70. doi:10.1016/S2215-0366(14)00122-9	
	507 508 509	2	Khandaker GM, Dantzer R. Is there a role for immune-to-brain communication in schizophrenia? <i>Psychopharmacology</i> 2016; 233 :1559–73. doi:10.1007/s00213-015-3975-1	
	510 511	3	Khandaker GM, Dantzer R, Jones PB. Immunopsychiatry: important facts. <i>Psychol Med</i> 2017; 47 :2229–37. doi:10.1017/S0033291717000745	
	512 513 514	4	Upthegrove R, Khandaker G. Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia. <i>Current topics in behavioral neurosciences</i> 2020; 44 :49–66. doi:10.1007/7854_2018_88	
	515 516 517	5	Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. <i>Schizophr Res</i> 2014; 155 :101–8. doi:10.1016/j.schres.2014.03.005	
	518 519 520	6	Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. <i>Mol Psychiatry</i> 2016; 21 :1696–709. doi:10.1038/mp.2016.3	
	521 522 523	7	Miller BJ, Buckley P, Seabolt W, <i>et al.</i> Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. <i>Biological psychiatry</i> 2011; 70 :663–71. doi:10.1016/j.biopsych.2011.04.013	
	524 525 526	8	Potvin S, Stip E, Sepehry AA, <i>et al.</i> Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. <i>Biol Psychiatry</i> 2008; 63 :801–8. doi:10.1016/j.biopsych.2007.09.024	
	527 528 529 530	9	Wang AK, Miller BJ. Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression. <i>Schizophr Bull</i> 2018; 44 :75–83. doi:10.1093/schbul/sbx035	
	531 532 533	10	Khandaker GM, Zimbron J, Dalman C, <i>et al.</i> Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. <i>Schizophr Res</i> 2012; 139 :161–8. doi:10.1016/j.schres.2012.05.023	
	534 535 536	11	Khandaker GM, Zimbron J, Lewis G, <i>et al.</i> Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. <i>Psychol Med</i> 2013; 43 :239–57. doi:10.1017/S0033291712000736	
	537 538 539	12	Khandaker GM, Zammit S, Burgess S, <i>et al.</i> Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort. <i>Brain Behav Immun</i> 2018; 69 :264–72. doi:10.1016/j.bbi.2017.11.020	
58 59 60	540 541	13	Perry BI, Upthegrove R, Kappelmann N, <i>et al.</i> Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional	

2			
3	542		two-sample mendelian randomization study. Brain, Behavior, and Immunity
4 5	543		2021; 97 :176–85. doi:10.1016/j.bbi.2021.07.009
6	544	14	Williams JA, Burgess S, Suckling J, et al. Inflammation and Brain Structure in
7 8	545	14	Schizophrenia and Other Neuropsychiatric Disorders: A Mendelian Randomization
8 9	546		Study. <i>JAMA Psychiatry</i> 2022; 79 :498. doi:10.1001/jamapsychiatry.2022.0407
10	510		Study. 571/11 1 Sychiatry 2022, 19: 196. doi:10.1001/juinupSychiatry.2022.0107
11	547	15	Kose M, Pariante CM, Dazzan P, et al. The Role of Peripheral Inflammation in Clinical
12	548		Outcome and Brain Imaging Abnormalities in Psychosis: A Systematic Review. Front
13 14	549		Psychiatry 2021;12:612471. doi:10.3389/fpsyt.2021.612471
15		1.0	
16	550	16	Lesh TA, Careaga M, Rose DR, <i>et al.</i> Cytokine alterations in first-episode schizophrenia
17	551		and bipolar disorder: relationships to brain structure and symptoms. <i>Journal of</i>
18 19	552		Neuroinflammation 2018;15:165. doi:10.1186/s12974-018-1197-2
20	553	17	Trépanier MO, Hopperton KE, Mizrahi R, et al. Postmortem evidence of cerebral
21	554		inflammation in schizophrenia: a systematic review. <i>Mol Psychiatry</i> 2016; 21 :1009–26.
22	555		doi:10.1038/mp.2016.90
23			
24 25	556	18	van Kesteren CFMG, Gremmels H, de Witte LD, et al. Immune involvement in the
26	557		pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. Transl
27	558		Psychiatry 2017;7:e1075-e1075. doi:10.1038/tp.2017.4
28		10	
29	559	19	Marques TR, Ashok AH, Pillinger T, et al. Neuroinflammation in schizophrenia: meta-
30 31	560		analysis of in vivo microglial imaging studies. <i>Psychological Medicine</i> 2019; 49 :2186–96.
32	561		doi:10.1017/S0033291718003057
33	562	20	Murray AJ, Rogers JC, Katshu MZUH, et al. Oxidative Stress and the Pathophysiology
34	563	20	and Symptom Profile of Schizophrenia Spectrum Disorders. <i>Frontiers in Psychiatry</i>
35	564		2021; 12 .https://www.frontiersin.org/articles/10.3389/fpsyt.2021.703452 (accessed 9 Aug
36 37	565		2022).
38	000		
39	566	21	Upthegrove R. The immune system and schizophrenia: An update for clinicians.
40	567		Advances in Psychiatric Treatment 2014;20:83–91. doi:10.1192/apt.bp.113.011452
41	-	~~	
42 43	568	22	Conen S, Gregory CJ, Hinz R, et al. Neuroinflammation as measured by positron
44	569		emission tomography in patients with recent onset and established schizophrenia:
45	570		implications for immune pathogenesis. <i>Mol Psychiatry</i> 2021; 26 :5398–406.
46	571		doi:10.1038/s41380-020-0829-y
47 49	572	23	van Mierlo HC, Schot A, Boks MPM, et al. The association between schizophrenia and
48 49	573	25	the immune system: Review of the evidence from unbiased 'omic-studies.' <i>Schizophrenia</i>
50	574		<i>Research</i> 2020; 217 :114–23. doi:10.1016/j.schres.2019.05.028
51	011		
52	575	24	Plavén-Sigray P, Matheson GJ, Collste K, et al. Positron Emission Tomography Studies
53 54	576		of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-
54 55	577		analysis Using Individual Participant Data. Biological Psychiatry 2018;84:433-42.
56	578		doi:10.1016/j.biopsych.2018.02.1171
57	-------------	~ -	
58	579	25	Plavén-Sigray P, Matheson GJ, Coughlin JM, <i>et al.</i> Meta-analysis of the Glial Marker
59 60	580		TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control
00	581		Differences. <i>Biol Psychiatry</i> 2021; 89 :e5–8. doi:10.1016/j.biopsych.2020.05.028

1			
2 3 4 5 6 7 8 9 10 11 2 13 14 15 16 7 8 9 0 11 2 2 3 2 4 5 26 27 8 9 0 31 2 33 4 5 6 7 8 9 0 11 2 12 23 4 5 26 27 8 9 0 31 2 33 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 3 4 5 6 7 8 9 0 11 2 2 3 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 1 2 2 3 3 4 5 6 7 8 9 0 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 5 6 7 8 9 0 1 2 2 3 4 5 5 6 7 8 9 0 1 2 2 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 5 5 7 8 9 0 1 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	582 583 584 585	26	Deakin B, Suckling J, Barnes TRE, <i>et al.</i> The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. <i>The Lancet Psychiatry</i> 2018; 5 :885–94. doi:10.1016/S2215-0366(18)30345-6
	586 587 588	27	Weiser M, Levi L, Burshtein S, <i>et al.</i> The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. <i>Schizophrenia Research</i> 2019; 206 :325–32. doi:10.1016/j.schres.2018.10.023
	589 590 591	28	Ramaker RC, Bowling KM, Lasseigne BN, <i>et al.</i> Post-mortem molecular profiling of three psychiatric disorders. <i>Genome Medicine</i> 2017; 9 :72. doi:10.1186/s13073-017-0458-5
	592 593 594 595	29	González-Peñas J, Costas J, Villamayor MJG, <i>et al.</i> Enrichment of rare genetic variants in astrocyte gene enriched co-expression modules altered in postmortem brain samples of schizophrenia. <i>Neurobiology of Disease</i> 2019; 121 :305–14. doi:10.1016/j.nbd.2018.10.013
	596 597 598	30	Gandal MJ, Zhang P, Hadjimichael E, <i>et al.</i> Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. <i>Science</i> 2018; 362 :eaat8127. doi:10.1126/science.aat8127
	599 600 601	31	Gandal MJ, Haney JR, Parikshak NN, <i>et al.</i> Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. <i>Science</i> 2018; 359 :693–7. doi:10.1126/science.aad6469
	602 603 604 605	32	Toker L, Mancarci BO, Tripathy S, <i>et al.</i> Transcriptomic Evidence for Alterations in Astrocytes and Parvalbumin Interneurons in Subjects With Bipolar Disorder and Schizophrenia. <i>Biological Psychiatry</i> 2018; 84 :787–96. doi:10.1016/j.biopsych.2018.07.010
	606 607 608	33	Corsi-Zuelli F, Deakin B. Impaired regulatory T cell control of astroglial overdrive and microglial pruning in schizophrenia. <i>Neuroscience & Biobehavioral Reviews</i> 2021; 125 :637–53. doi:10.1016/j.neubiorev.2021.03.004
	609 610 611	34	Corsi-Zuelli F, Deakin B, de Lima MHF, <i>et al.</i> T regulatory cells as a potential therapeutic target in psychosis? Current challenges and future perspectives. <i>Brain, Behavior, & Immunity - Health</i> 2021; 17 :100330. doi:10.1016/j.bbih.2021.100330
	612 613 614 615	35	Jeppesen R, Christensen RHB, Pedersen EMJ, <i>et al.</i> Efficacy and safety of anti- inflammatory agents in treatment of psychotic disorders – A comprehensive systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> 2020; 90 :364–80. doi:10.1016/j.bbi.2020.08.028
	616 617 618 619 620	36	Girgis RR, Ciarleglio A, Choo T, <i>et al.</i> A Randomized, Double-Blind, Placebo- Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia. <i>Neuropsychopharmacology : official publication</i> <i>of the American College of Neuropsychopharmacology</i> 2018; 43 :1317–23. doi:10.1038/npp.2017.258

2			
3 4 5 6	621 622 623	37	Mondelli V, Ciufolini S, Belvederi Murri M, <i>et al.</i> Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis. <i>Schizophrenia bulletin</i> 2015; 41 :1162–70. doi:10.1093/schbul/sbv028
7		• •	
8	624	38	Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia: a
9	625		review and meta-analysis. <i>Clinical schizophrenia & related psychoses</i> 2014;7:223–30.
10	626		doi:10.3371/CSRP.MICU.020813
11 12	()7	20	
13	627	39	Raison CL, Rutherford RE, Woolwine BJ, <i>et al.</i> A randomized controlled trial of the
14	628		tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of
15	629		baseline inflammatory biomarkers. JAMA Psychiatry 2013;70:31–41.
16	630		doi:10.1001/2013.jamapsychiatry.4
17	621	40	Dupleavy C. Elsworthy DI. Unthegrave D. et al. Inflammation in first enjoyde neuchosis:
18 10	631	40	Dunleavy C, Elsworthy RJ, Upthegrove R, <i>et al.</i> Inflammation in first-episode psychosis:
19 20	632		The contribution of inflammatory biomarkers to the emergence of negative symptoms, a
20	633		systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> 2022; 146 :6–20.
22	634		doi:10.1111/acps.13416
23	635	<i>1</i> 1	Khandaker GM, Stochl J, Zammit S, et al. Association between circulating levels of C-
24	636	41	reactive protein and positive and negative symptoms of psychosis in adolescents in a
25	637		general population birth cohort. <i>J Psychiatr Res</i> 2021; 143 :534–42.
26	638		doi:10.1016/j.jpsychires.2020.11.028
27 28	038		doi.10.1010/J.jpsychites.2020.11.028
28 29	639	42	Edwards CJ, Cella M, Tarrier N, <i>et al.</i> Investigating the empirical support for therapeutic
30	640	74	targets proposed by the temporal experience of pleasure model in schizophrenia: A
31	641		systematic review. <i>Schizophrenia research</i> 2015; 168 :120–44.
32	642		doi:10.1016/j.schres.2015.08.013
33	042		doi.10.1010/j.semes.2013.00.015
34 35	643	43	Lalousis PA, Schmaal L, Wood SJ, et al. Neurobiologically Based Stratification of
35 36	644		Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic
37	645		Phenotypes. Biological Psychiatry 2022;:S0006322322011568.
38	646		doi:10.1016/j.biopsych.2022.03.021
39			
40	647	44	Fioravanti M, Carlone O, Vitale B, et al. A Meta-Analysis of Cognitive Deficits in Adults
41	648		with a Diagnosis of Schizophrenia. Neuropsychol Rev 2005;15:73–95.
42 43	649		doi:10.1007/s11065-005-6254-9
43 44			
45	650	45	Keefe RSE, Bilder RM, Davis SM, et al. Neurocognitive Effects of Antipsychotic
46	651		Medications in Patients With Chronic Schizophrenia in the CATIE Trial. Archives of
47	652		General Psychiatry 2007;64:633-47. doi:10.1001/archpsyc.64.6.633
48			
49 50	653	46	Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: defining standard
50 51	654		protocol items for clinical trials. Rev Panam Salud Publica 2015;38:506–14.
52	(55	47	
53	655	4/	Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic
54	656		disease. <i>Nature reviews Rheumatology</i> 2014; 10 :720–7. doi:10.1038/nrrheum.2014.127
55	657	18	Choy EHS, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6
56	658	40	activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis:
57 58	659		a randomized, double-blind, placebo-controlled, dose-escalation trial. <i>Arthritis and</i>
58 59	660		<i>rheumatism</i> 2002; 46 :3143–50. doi:10.1002/art.10623
60	000		i neumuusin 2002, 40.5145-50. u01.10.1002/a11.10025

49 Woo P, Wilkinson N, Prieur A-M, *et al.* Open label phase II trial of single, ascending
doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis:
proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and
demonstration of prolonged clinical improvement. *Arthritis research & therapy*2005;7:R1281-8. doi:10.1186/ar1826


666 50 Gard DE, Gard MG, Kring AM, *et al.* Anticipatory and consummatory components of the 667 experience of pleasure: A scale development study. *Journal of Research in Personality* 668 2006;40:1086–102. doi:10.1016/j.jrp.2005.11.001


to occurrent on the second

- 15 669
- 17 670

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2		
2 3 4	671	FIGURE LEGEND
5 6	672	Figure 1. Overview of study design
7 8		
9 10		
11 12		
13 14		
15		
16 17		
18 19		
20 21		
22 23		
24 25		
26 27		
28 29		
30 31		
32 33		
34 35		
36 37		
38 39		
40 41		
42 43		
44 45		
45 46 47		
48		
49 50		
51 52		
53 54		
55 56		
57 58		
59 60		





240x165mm (144 x 144 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Supplementary Material

Foley et al. Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: A randomised double-blind placebo-controlled trial of single dose tocilizumab in patients with psychosis.

Table of Contents

eTable1: SPIRIT 2013 Checklist - Recommended items to address in a clinical trial protocol and related documents*



Standard Protocol Items: Recommendations for Interventional Trials

Section/item	ltem No	Description	Addressed on page number
Administrative inf	ormatior		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
	2b	All items from the World Health Organization Trial Registration Data Set	4 (ISRCTN 23256704)
Protocol version	3	Date and version identifier	-
Funding	4	Sources and types of financial, material, and other support	24 - 25
Roles and	5a	Names, affiliations, and roles of protocol contributors	1, 24
responsibilities	5b	Name and contact information for the trial sponsor	23
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	23-25

BMJ Open

	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	23 - 25
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	6-9
	6b	Explanation for choice of comparators	6-9
Objectives	7	Specific objectives or hypotheses	9-10
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	9
Methods: Participa	ants, inte	erventions, and outcomes	
Study setting	9	Description of study settings (e.g., community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	9, 11
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	12, Table 1
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	11, 19, 21-22, Figure 1
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	22
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	-
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	12, Table 1
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	9-10, Figure 1, Table 2
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	18-19, Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	17
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	18
Methods: Assignme	nt of ir	nterventions (for controlled trials)	
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	17
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	17
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	17
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	17
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	22

Page 39 of 47

BMJ Open

Methods: Data colle	ection,	management, and analysis	
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	10-15, 18-19, Table 2
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	17-18
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	23-24
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	17-18
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	17-18
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	-
Methods: Monitorin	g		
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	23
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	-
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	20-22

Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	-
Ethics and dissemin	ation		
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	22
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	22
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	22-23
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	22-23
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	23-24
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	25
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	23
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	22
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	24
	31b	Authorship eligibility guidelines and any intended use of professional writers	24
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	-
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendix I, II and III
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	23-24

"It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Appendix I – Consent Form for Screening: All Participants

Informed Consent Form for Screening

REC No. 22/EE/0010, Date: 08.02.2022, Version: 1.2

Psychosis Immune Mechanism Stratified Medicine Trial: The PIMS Trial

PARTICIPANT ID: _____

Thank you for considering taking part in the PIMS Trial. The research team must explain the eligibility assessment of the study to you before you agree to take part. If you have any questions arising from the Participant Information Sheet or from the explanation already given to you, please ask a member of the research team before you decide to participate. You will be given a copy of this Informed Consent Form to keep for future reference.

Please read the statements below and insert your initial in the box next to each statement if you agree with them:

Statement	Initial	Here
1. I have read and understood the information sheet version XX,		
DD.MM.YYYY and have had the opportunity to ask questions.		
2. I understand that my participation is voluntary and I am free to withdraw at any time without giving a reason, without my current or future medical care or legal rights being affected.		
3. I agree to provide blood samples for eligibility screening. I understand my blood samples will be analysed to test for evidence of immune activation. The purposes and possible risks of donating these samples have been explained to me. I understand that donated samples will be considered a gift but I will have the right to withdraw permission for analysis.		
4. I agree that my GP can be told that I am participating in the eligibility assessment of the PIMS Trial, and can be informed if any unexpected results are found pertaining specifically to my health.		
5. I consent for my GP/Psychiatrist to share information from my medical record in order to confirm my eligibility to take part in this study. The study team may access my GP/Psychiatrist records if necessary.		
Optional (Not agreeing to these will not exclude you from this study). Please tick Yes / No (as appropriate)	Yes	No
6. I agree that the samples can be stored after completion of the screening analysis, for use in future, ethically approved, non-genetic studies, even if I am deemed non-eligible to partake in the PIMS study.		
7. I agree that data and samples can be stored after completion of the PIMS Trial for use in future, ethically approved, genetic studies. This includes the main stocks of any genetic material collected, such as DNA and RNA.		

If you want to participate in the screening session of the PIMS Trial, please sign your name below:

Participant Signature

Participant Full Name _____

1 2	
3	
4	
5	Date//
6	
7 8	
9	
10	
11	
12	The researcher who has explained this study to you also needs to sign this form:
13	
14	
15	Staff Signature
16	
17	Staff Full Name
18 19	Staff Full Name
20	Date//
20	
22	Date//
23	
24	Thank you for your help.
25	Thank you for your help.
26	By completing and returning this form, you are giving us your consent that the personal
27	information you provide will be treated as strictly confidential and handled in accordance with
28	the provisions of the UK Data Protection Act 2018.
29	
30 31	*When completed: 1 for participant; and 1 for researcher site file.
32	
33	
34	
35	
36	
37	
38	
39	
40 41	
41 42	
43	
44	
45	
46	
47	
48	
49	
50 51	
52	
52	
54	
55	
56	
57	
58	
59	
60	

Appendix II – Informed Consent Form for Study Participation: Patients

Informed Consent Form for Study Participation

REC No. 22/EE/0010, Date: 24.08.2022, Version: 1.5

Psychosis Immune Mechanism Stratified Medicine Trial: The PIMS Trial

PARTICIPANT ID: _____

Thank you for taking part in the PIMS Trial eligibility assessment. Based on this assessment, you are eligible to take part in the PIMS Trial. Before you agree to take part, the research team must explain the study to you. If you have any questions arising from the Participant Information Sheet or from the explanation already given to you, please ask a member of the research team before you decide to participate. You will be given a copy of this Informed Consent Form to keep for future reference.

Please read the statements below and insert your initial in the box next to each statement if you agree with them:

Statement	Initial Here
1. I have read and understood the information sheet version XX	
dated DD.MM.YYYY and have had the opportunity to ask questions.	
2. I agree to take part in the PIMS Trial. I understand that my participation is	
voluntary and I am free to withdraw at any time without giving a reason,	
without my current or future medical care or legal rights being affected.	
3. I understand that confidentiality and anonymity will be maintained and it will	
not be possible to identify me in any publications.	
4. I agree to partake in interviews, complete questionnaires, and cognitive	
tests as part of this study. I understand what will happen during the study	
assessments.	
5. I agree to provide blood samples. The purposes and possible risks of	
donating these samples have been explained to me. I understand that	
donated samples will be considered a gift but I will have the right to withdraw	
permission for analysis.	
6. I understand that blood samples collected from me will be used to measure	
non-genetic factors such as biochemical changes in the blood.	
7. I agree that the samples and information I provide can be stored, used and	
shared between PIMS Trial sites and with collaborators/contractors for the	
purpose of the study.	
8. I understand that blood samples collected will be stored at PIMS Trial	
centres.	
9. I understand that any of my samples (labelled with an anonymous ID only),	
or any information obtained from them, including the sequence of my genetic	
material, may be sent to specialist research laboratories in the UK and abroad	
for analyses and the results returned to PIMS Trial centres. Researchers at	
these laboratories have no access to personal information about study	
participants.	
10. I agree, if necessary, to provide blood/urine samples to test for pregnancy,	
COVID-19 immunity, Hepatitis B, Hepatitis C, HIV, VZV and Tuberculosis, and	
to undergo a chest X ray.	
11. I agree to being randomised into the tocilizumab or placebo group if	
deemed eligible to take part.	

1	
2	
3 ⊿	
4	
5	
7	
/ 0	
0	
10	
11	
12	
13	
14	
15	
16	
17	
18	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	
20	
21	
22	
23	
24	
25 24	
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37	
ע∠ 28	
20	
30	
31	
32	
33	
34	
35	
36	
38	
39	
40	
41	
42 43	
43 44	
44 45	
45 46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59 60	

13. I agree that my GP can be told that I am participating in this study, and about any findings that require further attention.		
14. I understand that information related to my participation in this study may be accessed by responsible individuals from the sponsors of this study for quality control purposes. I give permission for these individuals to have access to this data.		
15. I understand that relevant sections of my medical notes and data collected during the study, may be looked at by individuals from research team, from regulatory authorities or from the NHS Trust, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records.		
Optional (Not agreeing to these will not exclude you from this study). Please tick Yes / No (as appropriate)	Yes	Nc
16. I agree to undergo brain scans as part of the PIMS Trial.		
17. I agree to be contacted in future by researchers to participate in follow up studies to this project, or in future studies of a similar nature.		
18. I understand that researchers may use the blood samples for genetic analysis.		
19. I agree that the samples can be stored after completion of the PIMS Trial for use in future, ethically approved, non-genetic studies.		
20. I agree that the information I give can be stored after completion of the PIMS Trial for use in future, ethically approved, non-genetic studies.		
21. I agree that data and samples can be stored after completion of the PIMS		

If you want to participate in the PIMS Trial, plea ur name below: 07

Participant Signature	Participa	nt Signature	
-----------------------	-----------	--------------	--

Participant Full Name _____

Date ___/ ___/

Research staff who has explained this study to you also needs to sign this form:

Staff Signature	
-----------------	--

Staff Full Name	

Date ___/ ___/

Thank you for your help.

By completing and returning this form, you are giving us your consent that the personal information you provide will be treated as strictly confidential and handled in accordance with the provisions of the UK Data Protection Act 2018.

*When completed: 1 for participant; and 1 for researcher site file.

to been terien only

Appendix III – Informed Consent Form for Study Participation: Healthy Controls

Healthy Controls Informed Consent Form for Study Participation REC No. 22/EE/0010, Date: 17.02.2022, Version: 1

Psychosis Immune Mechanism Stratified Medicine Trial: The PIMS Trial

PARTICIPANT ID: _____

Thank you for taking part in the PIMS Trial eligibility assessment. Based on this assessment, you are eligible to take part in the PIMS Trial. Before you agree to take part, the research team must explain the study to you. If you have any questions arising from the Participant Information Sheet or from the explanation already given to you, please ask a member of the research team before you decide to participate. You will be given a copy of this Informed Consent Form to keep for future reference.

Please read the statements below and insert your initial in the box next to each statement if you agree with them:

Statement	Initial	Her
1. I have read and understood the information sheet version XX		
dated DD.MM.YYYY and have had the opportunity to ask questions.		
2. I agree to take part in the PIMS Trial. I understand that my participation is		
voluntary, and I am free to withdraw at any time without giving a reason,		
without my current or future medical care or legal rights being affected.		
3. I understand that confidentiality and anonymity will be maintained, and it wil	I	
not be possible to identify me in any publications.		
4. I agree to partake in interviews, complete questionnaires, and cognitive		
tests as part of this study. I understand what will happen during the study		
assessments.		
5. I agree to provide blood samples. The purposes and possible risks of		
donating these samples have been explained to me. I understand that		
donated samples will be considered a gift, but I will have the right to withdraw		
permission for analysis.		
6. I understand that my blood samples collected will be stored at PIMS Trial		
centres.		
7. I understand that blood samples collected from me will be used to measure		
non-genetic factors such as biochemical changes in the blood.		
8. I understand that any of my samples (labelled with an anonymous ID only),		
or any information obtained from them, including the sequence of my genetic		
material, may be sent to specialist research laboratories in the UK and abroad		
for analyses and the results returned to PIMS Trial centres. Researchers at		
these laboratories have no access to personal information about study		
participants.		
9. I agree that the samples and information I provide can be stored, used and		
shared between PIMS Trial sites and with collaborators/contractors for the		
purpose of the study.		
10. I understand that information related to my participation in this study may		
be accessed by responsible individuals from the sponsors of this study for		
quality control purposes. I give permission for these individuals to have access	5	
to this data.		
Optional (Not agreeing to these will not exclude you from this study).	Yes	No
Please tick Yes / No (as appropriate)		

12. I agree to be contacted in future by researchers to participate in follow up studies to this project, or in future studies of a similar nature.	
 I understand that researchers may use the blood samples for genetic analysis. 	
14. I agree that the samples can be stored after completion of the PIMS Trial or use in future, ethically approved, non-genetic studies.	
15. I agree that the information I give can be stored after completion of the PIMS Trial for use in future, ethically approved, non-genetic studies.	
16. I agree that data and samples can be stored after completion of the PIMS Frial for use in future, ethically approved, genetic studies. This includes the main stocks of any genetic material collected, such as DNA and RNA.	
f you want to participate in the PIMS Trial, please sign your name below	:

Participant Full Name

Date ___/ ___/ ____/

Research staff who has explained this study to you also needs to sign this form:

Staff Signature _____

Staff Full Name

Date ___/ ___/ ____

Thank you for your help.

By completing and returning this form, you are giving us your consent that the personal information you provide will be treated as strictly confidential and handled in accordance with the provisions of the UK Data Protection Act 2018.

*When completed: 1 for participant; and 1 for researcher site file.

BMJ Open

Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: A randomised double-blind placebocontrolled trial of single dose tocilizumab in patients with psychosis

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-067944.R2
Article Type:	Protocol
Date Submitted by the Author:	25-Jan-2023
Complete List of Authors:	Foley, Éimear; University of Bristol, MRC Integrative Epidemiology Unit, Population Health Sciences; Bristol Medical School, Centre for Academic Mental Health, Population Health Sciences Griffiths, Sian Lowri; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Murray, Alexander; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Rogers, Jack; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Corsi-Zuelli, Fabiana; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health; University of Sao Paulo, Department of Neuroscience and Behaviour Hickinbotham, Hannah; University of Cambridge, Department of Psychiatry Warwick, Ella; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Wilson, Martin; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Wilson, Martin; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health Wilson, Martin; University of Cambridge, Psychiatry; Cambridgeshire and Peterborough NHS Foundation Trust Murray, Graham K.; University of Cambridge, Psychiatry; Cambridgeshire and Peterborough NHS Foundation Trust Deakin, Bill; The University of Cambridge, Medicine Suckling, John; University of Cambridge, Psychiatry; Cambridgeshire and Peterborough NHS Foundation Trust Barnes, Nicholas ; University of Cambridge, Psychiatry; Cambridgeshire and Peterborough NHS Foundation Trust Barnes, Nicholas ; University of Birmingham, Institute of Clinical Sciences Upthegrove, Rachel; University of Birmingham, Institute of Clinical Sciences Upthegrove, Rachel; University of Birmingham, Institute for Mental Health and Centre for Human Brain Health; Early Intervention Service, Birmingham Women's and Children's NHS Foundation Trust Khandaker, Golam M.; University of Birstol, MRC Integrative Epidemiology Unit, Population Health Sciences; NIHR Bristol Biomedical Research Centre
Primary Subject Heading :	Mental health

Secondary Subject Heading:	Immunology (including allergy)
Keywords:	Schizophrenia & psychotic disorders < PSYCHIATRY, IMMUNOLOGY, Clinical trials < THERAPEUTICS, Magnetic resonance imaging < RADIOLOGY & IMAGING
	SCHOLARONE [™] Manuscripts
For peer review	only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2		
3 4	1	Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: A
5 6	2	randomised double-blind placebo-controlled trial of single dose tocilizumab in patients
7 8 9	3	with psychosis
9 10 11	4	
12 13	5	Éimear M. Foley ^{a,b} ; Sian Lowri Griffiths ^c ; Alexander Murray ^c ; Jack Rogers ^c ; Fabiana Corsi-
14 15	6	Zuelli ^{c,d,e} ; Hannah Hickinbotham ^f ; Ella Warwick ^c ; Martin Wilson ^c ; Muzaffer Kaser ^{f,g} ;
16 17 18	7	Graham K. Murray ^{f,g} ; Bill Deakin ^h ; Deepak Jadon ⁱ ; John Suckling ^{f,g} ; Nicholas M. Barnes ^{e;}
19 20	8	Rachel Upthegrove ^{c,j,†} ; and Golam M. Khandaker ^{a,b,k,l,†,*} ; for the PIMS Collaboration
21 22	9	
23 24 25	10	^a MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,
25 26 27	11	University of Bristol, Bristol, United Kingdom
28 29	12	^b Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School,
30 31 32	13	University of Bristol, Bristol, United Kingdom
33 34	14	^c Institute for Mental Health and Centre for Human Brain Health, University of Birmingham,
35 36	15	Birmingham, United Kingdom
37 38 20	16	^d Department of Neuroscience and Behaviour, Division of Psychiatry, Ribeirão Preto Medical
39 40 41	17	School, University of São Paulo, São Paulo, Brazil
42 43	18	^e Institute of Clinical Sciences, College of Medical and Dental Sciences, University of
44 45	19	Birmingham, United Kingdom
46 47 48	20	^f Department of Psychiatry, University of Cambridge, United Kingdom
49 50	21	^g Cambridgeshire and Peterborough NHS Foundation Trust, United Kingdom
51 52	22	^h Faculty of Biology, Medicine and Health, Division of Neuroscience and Experimental
53 54 55	23	Psychology, School of Biological Sciences, University of Manchester, Manchester Academic
56 57	24	Health Science Centre, Manchester, United Kingdom
58 59 60	25	ⁱ Department of Medicine, University of Cambridge, United Kingdom

1 2		
3 4	26	^j Early Intervention Service, Birmingham Women's and Children's NHS Foundation Trust
5 6	27	^k NIHR Bristol Biomedical Research Centre, Bristol, United Kingdom
7 8 9	28	¹ Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, United Kingdom
10 11	29	
12 13	30	[†] Joint senior authors
14 15 16	31	
17 18	32	* Corresponding author and address: Prof Golam M. Khandaker, MRC Integrative
19 20	33	Epidemiology Unit, Oakfield House, Oakfield Grove, Clifton, Bristol, BS8 2BN, UK
21 22 23	34	Email: golam.khandaker@bristol.ac.uk
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 50 51 52 53 54 55 57 58 59 60		Email: golam.khandaker@bristol.ac.uk

35 ABSTRACT

Introduction: Evidence suggests a potentially causal role of interleukin 6 (IL-6), a pleiotropic cytokine that generally promotes inflammation, in the pathogenesis of psychosis. However, no interventional studies in patients with psychosis, stratified using inflammatory markers, have been conducted to assess the therapeutic potential of targeting IL-6 in psychosis and to elucidate potential mechanism of effect. Tocilizumab is a humanised monoclonal antibody targeting the IL-6 receptor to inhibit IL-6 signalling licensed in the UK for treatment of rheumatoid arthritis. The primary objective of this study is to test whether IL-6 contributes to the pathogenesis of first episode psychosis, and to examine potential mechanisms by which IL-6 affects psychotic symptoms. A secondary objective is to examine characteristics of inflammation-associated psychosis. **Methods and analysis:** A proof-of-concept study employing a randomised, parallel-group, double-blind, placebo-controlled design testing the effect of IL-6 inhibition on anhedonia in patients with psychosis. Approximately 60 participants with diagnosis of schizophrenia and related psychotic disorders (ICD-10 codes F20, F22, F25, F28, F29) with evidence of lowgrade inflammation (IL-6 \geq 0.7pg/ml) will receive either one intravenous infusion of tocilizumab (4.0mg/kg; max 800mg) or normal saline. Psychiatric measures and blood samples will be collected at baseline, and 7-, 14-, and 28-days post-infusion. Cognitive and neuroimaging data will be collected at baseline and 14 days post-infusion. In addition, approximately 30 patients with psychosis without evidence of inflammation (IL-6 <0.7pg/ml) and 30 matched healthy controls will be recruited to complete identical baseline assessments to allow for comparison of the characteristic features of inflammation-associated psychosis. Ethics and dissemination: The study is sponsored by the University of Bristol and has been approved by the Cambridge East Research Ethics Committee (reference: 22/EE/0010; IRAS

1 2		
2 3 4	59	project ID: 301682). Study findings will be published in peer-review journals. Findings will
5 6	60	also be disseminated by scientific presentation and other means.
7 8 9	61	Trial registration number: ISRCTN 23256704
) 10 11	62	
12 13	63	KEYWORDS: Psychotic Disorders; Negative Symptoms; Interleukin 6; Immunotherapy;
14 15 16	64	Tocilizumab; Clinical Trial.
$\begin{array}{c} 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 57\\ 58\\ 56\\ 57\\ 58\\ 59\\ 60\\ \end{array}$		Tocilizumab; Clinical Trial.

65 ARTICLE SUMMARY

- 66 Strengths and limitations of this study
 67 Adopting a randomised controlled trial (RC
 - Adopting a randomised controlled trial (RCT) design and patient selection based on elevated level of IL-6 (in addition to other criteria) will help examine the causal role of IL-6, and the therapeutic potential of targeting IL-6 pathway, in psychosis.
- The use of target specific intervention (anti-IL6R monoclonal antibody tocilizumab)
 will help assess the clinical relevance of IL-6 and related up and downstream
 inflammatory cytokines in psychosis.
 - The use of neuroimaging, cognitive tests, and extensive peripheral blood biomarker exploration before and after tocilizumab treatment to assess potential mechanisms of effect.
 - One dose of tocilizumab is unlikely to be sufficient to test the efficacy of this drug as potential treatment for psychosis, which is not the intention of this study.
 - Tocilizumab inhibits both IL-6 classical and trans signalling, and consequently the trial will not be able to distinguish between the effects of modulating these two signalling pathways specifically in psychosis.

Word count: 4,336

 BMJ Open

ŀ	62	Word Count. 4 ,550
5	83	INTRODUCTION
7 3 3	84	Scientific background and study rationale
, 0 1	85	The neuroimmune hypothesis of schizophrenia proposes that mild peripheral immune
2 3	86	activation gives rise to an inflammatory response in the brain and neurobiological changes
4 5 6	87	associated with psychotic illness [1-4]. Meta-analytic evidence is clear that circulating
7 8	88	concentrations of interleukin 6 (IL-6) and other inflammatory proteins, such as C-reactive
9 20	89	protein (CRP), are increased in patients with psychosis, including treatment naïve first
21 22 23 24 25 26 27 28	90	episode psychosis (FEP) [5], compared with controls [6–9]. Prospective cohort studies show
25 24 25	91	that these indices of mild immune activation precede the onset of symptoms [10,11].
26 27	92	Furthermore, genetic variants known to increase IL-6 concentrations are associated with
29	93	genetic risk of schizophrenia [12,13]. These Mendelian randomization studies eliminate the
80 81 82	94	possibility that raised IL-6 concentrations are a consequence of environmental exposures
81 82 83 84 85 86	95	associated with schizophrenia, such as obesity and smoking and instead suggest that IL-6 has
	96	a causal role in psychosis. Extending this approach using the UK Biobank population, we
87 88 89	97	found that genetically-predicted levels of IL-6 were associated with reduced grey matter
, y 10 11	98	primarily in the middle temporal gyrus, a region whose gene expression profile is enriched
2 3 4 5	99	for IL-6 pathway proteins and for neuropsychiatric disorder ontologies [14]. Moreover,
4 5 6	100	clinical studies report correlations between IL-6 levels and structural brain changes in
17 18	101	individuals with schizophrenia [15], with reduced grey matter volume being exaggerated in
19 50	102	patients with psychosis and elevated inflammatory cytokines [16]. Though this causal
51 52	103	evidence strongly implicates IL-6, only an intervention study in patients can test the causal
53 54 55	104	hypothesis.
56 57	105	The neuroimmune hypothesis generally assumes that microglia, the brain's resident

immune cells, are activated and pathogenic in schizophrenia. This is supported by traditional

2
3
1
4 5
6
7
8
9
10
11
12
13
13 14
15
16
17
18
19
20
21
22
23
24
25
26
26 27
28
29
30
31
32
32 33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
47 48
49 50
50
51
52
53
54
55
56
57
58
59
60

1

107	neuropathological studies and initial in-vivo PET imaging studies [17-19], possibly reflecting
108	impaired cellular control of inflammation or oxidative defence. Inflammatory damage may
109	also account for evidence of oxidative stress from MRS glutathione studies [20]. However,
110	whether microglia are the direct target of IL-6 is unclear and it is not certain that IL-6 can
111	cross the blood-brain barrier and/or increase its permeability to circulating inflammatory
112	cells, cytokines, and chemokines [2,21]. Additionally, it is increasingly uncertain whether
113	microglial inflammation, as traditionally understood, occurs in schizophrenia [22,23]. Recent
114	meta-analyses of PET radioligand binding studies report decreased rather than increased
115	radioligand binding to activated microglia [24,25]. This may account for the unexpected lack
116	of therapeutic benefit of the anti-microglial antibiotic, minocycline, in recent large clinical
117	trials [26,27]. Furthermore, large transcriptomic studies in post-mortem brains report no
118	change or reduction in microglial gene expression but increases in astrocytic expression
119	[23,28–32]. It is increasingly understood that both peripheral immune responses and brain
120	glial function are regulated by specialised T cells (Tregs), a subset of which reside in brain
121	parenchyma [33,34]. A novel proposal is that Treg hypofunction accounts for mild peripheral
122	immune disinhibition and dysregulated astroglial-microglial interaction, such that microglia
123	are driven into a developmental, synapse-pruning phenotype while astroglia disrupt
124	neurotransmitter function [33,34]. Importantly, there are bidirectional interactions between
125	IL-6 and Treg function [34]. Crucially, we will measure IL-6 in addition to cellular and
126	molecular markers of immune function and investigate how they correlate with central
127	markers and clinical state.
128	Previous attempts testing the inflammatory hypothesis in the apeutic clinical trials

Previous attempts testing the inflammatory hypothesis in therapeutic clinical trials have been attempted. However, little evidence of overall efficacy has been found [35]. These trials have generally tested broad spectrum agents, such as non-steroidal anti-inflammatory drugs, with no attempt to stratify patients according to evidence of inflammation. A trial

Page 9 of 47

BMJ Open

132	using tocilizumab, a humanised monoclonal antibody (mAb) against the IL-6 receptor		
133	currently licensed in the UK for treatment of rheumatoid arthritis (RA) and severe		
134	coronavirus disease, reported no improvements in any clinical measure in a small sample of		
135	36 patients with established schizophrenia [36]. However, as mentioned previously, no		
136	stratification by inflammatory markers or any mechanistic immune measures was applied.		
137	Low-grade inflammation is associated with poor response to antipsychotic drugs [37], but		
138	immunotherapy is unlikely to be relevant for all patients with psychosis. Meta-analysis		
139	suggests that evidence of immune activation, defined by elevated CRP levels, is present in a		
140	quarter to one third of patients with schizophrenia [38]. A randomised controlled trial of		
141	infliximab, an anti-tumour necrosis factor alpha (TNF- α) mAb, reported that antidepressant		
142	response was associated with higher CRP levels at baseline [39], suggesting that patients with		
143	evidence of immune activation may be better candidates for immunotherapy trials. As far as		
144	we are aware, no previous clinical trial has selected patients with schizophrenia based on		
145	evidence of immune activation.		
146	Selection of patients with particular symptom profiles and/or stage of illness may also		
147	be a useful strategy that needs to be employed in immunotherapy trials for schizophrenia. A		

wide variety of symptoms occur in schizophrenia such as hallucinations, delusions,

anhedonia, cognitive dysfunction, and affective symptoms and presentation of these

inflammation than others. For instance, meta-analytic data suggests that elevated

negative symptoms, CRP is particularly associated with anhedonia and auditory

funded larger PIMS collaboration (MR/S037675/1), suggest that anhedonia may be a

symptoms differ from one individual to another. Some symptoms may be more related to

proinflammatory cytokines are associated with negative psychotic symptomatology [40].

Moreover, a recent study from the ALSPAC birth cohort reported that out of 20 positive and

hallucinations [41]. Lastly, results from work we have completed to date as part of the MRC-

1 2	
2	
4	
5	
6	
7	
8	
9	
10	
11 12	
12	
14	
15	
16	
17	
18	
19	
20	
22	
23	
24	
25	
26	
27	
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	
30	
31	
32	
33 34	
34 35 36 37	
36	
37	
38	
39	
40 41	
42	
43	
44	
45	
46 47	
48	
49	
50	
51	
52 53	
55 54	
55	
56	
57	
58	
59 60	
00	

1

157	promising target in early phases of established psychotic disorder. Anhedonia and
158	amotivation are strongly associated with poor functional outcomes in depression and
159	schizophrenia, and present a formidable barrier to returning to work or building relationships
160	[42,43]. Patients with psychotic disorders also present with cognitive deficits in a range of
161	domains [44]. Available antipsychotic medications have a limited effects on poor cognitive
162	functioning in psychosis [45]. Illness stage may also be of relevance. Meta-analytic data has
163	revealed no differences in IL-6 levels between stable, medicated patients with schizophrenia
164	and controls, although compared with controls, IL-6 levels were similarly elevated in patients
165	with FEP and those with acute relapse [7]. A separate meta-analysis found evidence of
166	elevated blood cytokine levels in acutely and chronically ill patients with schizophrenia [6].
167	Focusing on particular inflammation-related symptoms, such as anhedonia, and/or illness
168	stage may increase the chance of success for immunotherapy trials.
169	
169 170	Proposed study
	Proposed study The proposed study is a UK multi-site (Birmingham, Bristol, and Cambridge) proof-of-
170	
170 171	The proposed study is a UK multi-site (Birmingham, Bristol, and Cambridge) proof-of-
170 171 172	The proposed study is a UK multi-site (Birmingham, Bristol, and Cambridge) proof-of-
 170 171 172 173 	The proposed study is a UK multi-site (Birmingham, Bristol, and Cambridge) proof-of- concept, randomised, parallel-group, double-blind, placebo-controlled trial.
 170 171 172 173 174 	The proposed study is a UK multi-site (Birmingham, Bristol, and Cambridge) proof-of- concept, randomised, parallel-group, double-blind, placebo-controlled trial. <i>Study aims and hypotheses</i>
 170 171 172 173 174 175 	The proposed study is a UK multi-site (Birmingham, Bristol, and Cambridge) proof-of- concept, randomised, parallel-group, double-blind, placebo-controlled trial. <i>Study aims and hypotheses</i> The primary aim of this trial is to examine potential mechanisms by which IL-6 affects
 170 171 172 173 174 175 176 	The proposed study is a UK multi-site (Birmingham, Bristol, and Cambridge) proof-of- concept, randomised, parallel-group, double-blind, placebo-controlled trial. <i>Study aims and hypotheses</i> The primary aim of this trial is to examine potential mechanisms by which IL-6 affects anhedonia, psychotic symptoms, and cognition. Our primary hypothesis is that inhibition of
 170 171 172 173 174 175 176 177 	The proposed study is a UK multi-site (Birmingham, Bristol, and Cambridge) proof-of- concept, randomised, parallel-group, double-blind, placebo-controlled trial. <i>Study aims and hypotheses</i> The primary aim of this trial is to examine potential mechanisms by which IL-6 affects anhedonia, psychotic symptoms, and cognition. Our primary hypothesis is that inhibition of IL-6 signalling with a single intravenous infusion of anti-IL6R monoclonal antibody,
 170 171 172 173 174 175 176 177 178 	The proposed study is a UK multi-site (Birmingham, Bristol, and Cambridge) proof-of- concept, randomised, parallel-group, double-blind, placebo-controlled trial. <i>Study aims and hypotheses</i> The primary aim of this trial is to examine potential mechanisms by which IL-6 affects anhedonia, psychotic symptoms, and cognition. Our primary hypothesis is that inhibition of IL-6 signalling with a single intravenous infusion of anti-IL6R monoclonal antibody, tocilizumab, in individuals with psychosis and elevated IL-6 at baseline will attenuate

181 secondary hypothesis is that reduction in peripheral inflammation after tocilizumab infusion

Page 11 of 47

1

BMJ Open

2		
3 4	182	in patients with psychosis and evidence of inflammation will be associated with central
5 6	183	measures of oxidative stress and relevant resting state brain function.
7 8 9	184	We will also conduct deep immunophenotyping of peripheral blood mononuclear cell
10 11	185	subsets (CD4 ⁺ , CD8 ⁺ , Tregs, natural killer and natural killer-T cells, monocytes, and B cells)
12 13	186	to characterise their absolute number, frequency, and function. The level of IL-6/STAT3
14 15 16	187	signalling inhibition within both innate and adaptive immune cells will also be examined
17 18	188	using multi-colour flow cytometry with an established optimised pSTAT3 phosflow assay.
19 20	189	This will help identify the potential cellular impact of peripheral inflammation in psychosis,
21 22 22	190	which is largely unknown. Functional assessment of IL-6/STAT3 signalling in immune cell
23 24 25	191	subsets and their response to exogenous IL-6 stimulation will inform abnormal immune
26 27	192	response in psychosis and allow measurement of response to tocilizumab at the cellular level.
28 29	193	A secondary objective is to carry out an observational study to examine clinical and
30 31 32	194	biomarker differences and similarities between patients with psychotic disorder with and
33 34	195	without evidence of inflammation and healthy controls (HCs). We hypothesise that
35 36	196	individuals with psychotic disorder and evidence of inflammation, compared to those without
37 38 39	197	evidence of inflammation and HCs, will have increased symptoms of anhedonia and
40 41	198	amotivation, poorer cognitive functioning, and cellular and brain-based measures of immune
42 43	199	dysfunction.
44 45	200	
46 47 48	201	METHODS
49 50	201	This protocol has been prepared in accordance with the Standard Protocol Items:
51 52		
53 54	203	Recommendations for Interventional Trials (SPIRIT) 2013 statement [46]. Please see
55 56	204	supplementary eTable 1 for the SPIRIT checklist. The planned start date for the PIMS trial
57 58	205	was 1st November 2021, however, this was delayed due to the COVID-19 pandemic. We
59 60	206	began recruiting at our site in Birmingham in November 2022, and we soon expect

2 3 4	207	recruitment to begin at our Bristol and Cambridge sites. The planned end date is 31st May			
4 5 6	208	2024.			
7 8	209				
9 10 11	210	Patient and public involvement			
12 13	211	The study protocol was prepared in collaboration with individuals with lived experience of			
14 15 16	212	mental illness who contributed to the development of participant information sheet, consent			
16 17 18	213	forms (Appendix I, II, and III), and data collection procedures.			
19 20	214				
21 22	215	Study design and sample			
23 24 25	216	See Figure 1 for an overview of study design. Individuals residing in Birmingham, Bristol, or			
26 27	217	Cambridge in the United Kingdom will be recruited. Approximately 60 participants with first			
28 29	218	episode psychosis and evidence of inflammation (i.e., IL-6 \geq 0.7pg/ml) will be randomised to			
30 31 32	219	receive either one intravenous infusion of tocilizumab (drug) or normal saline (placebo). For			
33 34	220	the secondary, observational study, we will compare baseline characteristics of the			
35 36	221	intervention cohort with approximately 30 participants with psychosis without evidence of			
37 38 30	222	inflammation (i.e., IL-6 <0.7pg/ml), and approximately 30 HCs across Birmingham and			
39 40 41	223	Cambridge. Participants without evidence of inflammation and controls will not be			
42 43	224	randomised as they will not receive any intervention. Neuroimaging will only be undertaken			
44 45	225	by those without MRI contraindications who have given specific informed consent for MRI.			
46 47 48	226	Participants not eligible or not consenting for MRI will take part in all other aspects of the			
49 50	227	study.			
51 52	228				
53 54 55	229	Intervention			
56 57	230	Single intravenous infusion of tocilizumab (4.0mg/kg; max 800mg in total) or normal saline			
58 59 60	231	given to participants with psychosis and evidence of inflammation. Tocilizumab blocks both			

IL-6 classic and trans-signalling – the latter being responsible for most of the inflammatory effects of IL-6 – providing broad inhibition of IL-6 signalling and a strong test of a casual role for IL-6 in psychosis [47]. Tocilizumab is the first-in-class, humanized monoclonal antibody against the IL-6R, commercially available and licensed in the UK for treatment of RA. Approved dosage of tocilizumab for treatment of RA is 2, 4, or 8mg/kg; max 800mg in total. In RA, a single tocilizumab infusion has shown to improve clinical and laboratory measures within 48 hours, with most noticeable results in one-to-two weeks [48,49]. The follow-up schedule for our study is in keeping with this observation.

Eligibility criteria

We will recruit participants aged 18-40 years. Patient participants must meet International Classification of Diseases 10th Revision (ICD-10) criteria for a diagnosis of schizophrenia and related psychoses (ICD-10 code F20, F22, F25, F28, F29) at the time of eligibility assessment, be within three years of first diagnosis of psychotic disorder, be on a stable treatment regime with no recent (within two weeks) initiation, cessation, or change in class of antipsychotic medication, and have a Positive and Negative Syndrome Scale (PANSS) item score ≥ 3 on P1 (delusions), P2 (conceptual disorganisation), P3 (hallucinatory behaviour), or P6 (suspiciousness/persecution). Additionally, patients recruited to the interventional arm will be required to have serum IL-6 levels ≥ 0.7 pg/ml and a Temporal Experience of Pleasure Scale (TEPS) anticipatory pleasure score ≤ 41 (based on item numbers 1, 3, 7, 11, 12, 14, 15, 16, 17, and 8) and consummatory pleasure score \leq 36 (based on item numbers 2, 4, 5, 6, 8, 9, 10, and 13). The threshold of serum IL-6 \geq 0.7pg/mL as evidence of inflammation for this particular trial was chosen based on observations from the Personalised Prognostic Tools for Early Psychosis Management (PRONIA) cohort [https://www.pronia.eu]. In 192 first-episode psychosis patients included in the PRONIA study, the median value of serum IL-6 was

3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13 14	
15 16	
17	
17	
10	
20	
20	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57 58	
58 59	
59 60	
00	

257 0.49pg/mL (25th percentile 0.22pg/mL; 75th percentile 1.11pg/mL), and the mean was

258 0.79 pg/mL (SD ± 0.84). Based on these observations, we chose the cut-off of 0.7 pg/mL for

259 patient selection in current trial. Finally, COVID-19 anti-body titre test will be used to

260 determine adequate levels of immune response via the following cut-offs (for poor response):

261 400IU Roche/700IU Abbot assay.

HCs will have no current or lifetime history of psychiatric diagnosis, as determined by

263 the Mini-International Neuropsychiatric Interview (MINI). See Table 1 for complete

264 inclusion and exclusion criteria. HCs will be matched to patient participants at the group level

by age and sex.

266

262

1 2 3

267 Table 1. PIMS Trial inclusion and exclusion criteria.

Group	Inclusion criteria	Exclusion criteria
All participants	 Provide informed consent. Understand written and spoken English. Able and willing to consent to blood sampling. Willing to abstain from strenuous exercise for 72 hours prior to assessment. 	 Pregnancy (confirmed by urine pregnancy test) or breast feeding. Body mass index >35. Current or lifetime diagnosis of antisocial personality disorder, autism or other neurodevelopmental disorder, major traumatic brain injury. Currently active diagnosed eating disorder likely to compromise ability to take part. History of alcohol or substance use disorde (abuse/dependence) within six months prio to eligibility assessment (nicotine and caffeine dependence are not exclusionary). Current use of medication likely to compromise interpretation of immunologic data. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other opportunistic infections. Current infection with VZV, TB, Hepatitis B, Hepatitis C, or HIV confirmed by blood test. Chest X-ray will also be performed to assess for TB. Any major episode of infection requiring hospitalisation or treatment with IV antibiotics within 4 weeks of eligibility assessment.

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	Additional criteria for neuroimaging	- Able and willing to consent to MRI scanning	 Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active infectious disease, including current or prior malignancy. Diverticulitis, inflammatory bowel disease, or uncontrolled gastric/duodenal ulcer. Concomitant auto-immune or auto-inflammatory rheumatological disease. Concomitant treatment with any biologic drugs. Current and active ischemic heart disease. Uncontrolled hypertension defined as systolic blood pressure > 170 or diastolic blood pressure > 110. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies. No history of chicken pox infection or no history of varicella zoster immunity. Contraindications to MRI.
28 29	(optional) Additional criterion	- No current or lifetime psychiatric	
30	for healthy controls	diagnosis.	
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 	Additional criteria for all individuals with psychosis	 Meet ICD-10 criteria for a diagnosis of schizophrenia and related psychoses (code F20, F22, F25, F28, F29) at the time of eligibility assessment, as determined by the Mini-International Neuropsychiatric Interview. Be within three years of first diagnosis of psychotic disorder. On stable treatment regime with no recent (within 2 weeks) initiation, cessation, or change in class of antipsychotic medication. No indication or other reason for preclusion into research (e.g., significant risk of suicidal behaviour or risk to others) as determined by their clinical team. Positive and Negative Syndrome Scale item score ≥3 on P1 (delusions), P2 (conceptual disorganisation), P3 (hallucinatory behaviour), OR P6 (suspiciousness/persecution). 	

Additional criteria	- Serum IL-6 level ≥0.7pg/ml at	
for intervention	eligibility and baseline	
group	assessment.	
	- Temporal Experience of Pleasure	
	Scale anticipatory pleasure score	
	\leq 41 (based upon item numbers 1,	
	3, 7, 11, 12, 14, 15, 16, 17, and 8)	
	and consummatory pleasure score	
	\leq 36 (based upon item numbers 2,	
	4, 5, 6, 8, 9, 10, and 13).	
	- Evidence of COVID-19	
	immunity required prior to	
	infusion, confirmed before	
	randomisation using evidence of	
	vaccination and antibody titre	
	test.	
Additional criterion	- Serum IL-6 level <0.7pg/ml at	
for patients with	eligibility and baseline	
psychosis without	assessment.	
inflammation	\sim	

271 Study outcomes

The primary outcome is anhedonia, defined as anticipatory and consummatory pleasure scores, assessed by the TEPS [50] at approximately day 14 post-infusion. We will also collect data on several secondary/exploratory measures including 1) clinical outcomes, namely positive and negative symptoms of psychosis, depressive symptoms, fatigue, general quality of life and subjective wellbeing, 2) cognitive function (psychomotor speed, attention, memory, and executive function), 3) neuroimaging outcomes based on comparisons of brain structure, function, and oxidative stress levels using MRI and MRS outcomes, 4) blood biomarker outcomes, namely peripheral blood inflammatory markers, biochemical assays, including cortisol and cardiometabolic markers, and peripheral blood cellular immunophenotyping, and 5) genetic outcomes including DNA and RNA sequencing and epigenetic mechanism assessment with methylation assays(see Table 2 for more details). Where possible, blood samples will be collected during working hours and time of

284 sampling will be recorded. However, a specified time window will not be given to ease

285 burden on patients and to maximise participation.

286287 Table 2. PIMS trial study measures

Domain	Tool	Source	Validated Tool	Time of assessment
Sociodemographic/lifestyle	Screening questionnaire	Self-report		Screening
	Medical History Questionnaire	Self- report/General practice		Eligibility
	Substance Use Questionnaire	Self-report		Eligibility
	Physical Measurements Form	Self-report		Baseline
	Sociodemographic Questionnaire	Self-report		Baseline
Psychiatric	The Temporal Experience of Pleasure Scale	Self-report	\checkmark	Eligibility, baseline, follow-ups
	The Positive and Negative Syndrome Scale	Interviewer assessed	\checkmark	Eligibility, baseline, follow-ups
	The Mini- International Neuropsychiatric Interview	Interviewer assessed	\checkmark	Eligibility
	Psychiatric History Questionnaire	Self-report		Baseline
	The Scale for the Assessment of Negative Symptoms	Self-report	~	Baseline, follow-ups
	The Calgary Depression Scale for Schizophrenia	Interviewer assessed	\checkmark	Baseline, follow-ups
	Multi-dimensional Fatigue Inventory	Self-report	\checkmark	Baseline, follow-ups
	European Quality of Life-5 Dimensions Three-Level Version	Self-report	\checkmark	Baseline, follow-ups
	Visual Analogue Scale for Subjective Wellbeing	Self-report	\checkmark	Baseline, follow-ups
Cognitive	National Adult Reading Test for	Interviewer assessed	\checkmark	Baseline, follow-up 2

2
3
4
5
6
_
/
8
9
10
11
12
13
14
15
16
17
18
19 20
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
44 45
46
47
48
49
50
51
52
53
54
55
56
50 57
58
59

60

1

	estimated premorbid IQ			
	CANTAB Reaction Time test	Computer task	\checkmark	Baseline, follow-up 2
	Symbol Coding Test	Paper task	\checkmark	Baseline, follow-up 2
	CANTAB Rapid Visual Information Processing test	Computer task	\checkmark	Baseline, follow-up 2
	CANTAB Paired Associates Learning test	Computer task	\checkmark	Baseline, follow-up 2
	CANTAB One Touch Stockings of Cambridge test	Computer task	\checkmark	Baseline, follow-up 2
Biologic	Inflammatory markers, cardiometabolic markers, IDO activation, white cell phenotyping	Laboratory tests		Baseline, follow-ups
Genetic	RNA and DNA sequencing, methylation assay	Blood (RNA, DNA)		Baseline, follow-ups
	MRI Screening Questionnaire			Baseline, follow-up 2
Neuroimaging	Structural MRI, 1H- MRS measure of glutathione in the prefrontal cortex area, resting state fMRI	er O		Baseline, follow-up 2

290 Sample size and statistical power

We will recruit approximately 60 patients with psychosis. However, currently there are no trials of immunotherapies for anhedonia in schizophrenia making accurate power calculation difficult. This study is a proof-of-concept experiment designed to test whether inhibition of IL-6 signalling leads to changes in psychotic symptoms. It could also inform likely statistical power for future trials testing efficacy of the drug as a treatment of schizophrenia, which is not the intention of this study. The exact statistical tests and techniques that will be applied to Page 19 of 47

1

BMJ Open

2 3	297	1
4 5 6	298	,
6 7 8	299	(
8 9 10		
11	300	
12 13	301]
14 15 16	302	
16 17 18	303	1
19 20	304	á
21 22	305	ľ
23 24	306	1
25 26 27	307]
27 28 29	308	ć
30 31	309	ŝ
32 33	310	(
34 35		
36 37	311	1
37 38 39	312	
40 41	313	
42 43	314]
44 45	315	j
46 47	316	1
48 49	317	(
50 51		
52 53	318	1
55 54 55	319	,
56 57	320	(
58 59	321	2
60		

the data will depend on the objective of specific analysis and data characteristics (e.g.,
variable type, distribution). These details will be specified in analysis plans and registered
online before participants are unblinded and any data analysis is performed. **Randomisation and blinding**

An external agency independent of the study team will arrange random allocation to tocilizumab or normal saline group 1:1, ensuring two groups are comparable regarding anhedonia severity and sex. Randomisation will be stratified by site. Randomising agency will provide the randomisation code to the relevant hospital pharmacy who will dispense tocilizumab or normal saline according to the randomisation schedule. Dispensing pharmacies will keep a log of products dispensed. Infusions will be prepared and administered at clinical research facilities (CRFs). Infusion packs will be prepared by trained staff not part of the core study team, ensuring blinding of treatment allocation. Infusion packs containing drug or placebo will be visually indistinguishable from each other, ensuring that both participants and study team remain blind regarding treatment allocation.

313 Statistical analysis

For randomised participants, an intention-to-treat approach will be taken for data analysis by including all randomised participants in statistical analyses, regardless of the treatment they received (if any). We will compare outcome measures between treatment and placebo groups controlling for baseline scores. This mechanistic experiment will focus on overall pattern of results and their effect sizes rather than *P*-values for individual tests of statistical significance. The secondary mechanistic and observational analysis will compare psychotic symptoms, cognitive function, blood, neuroimaging, and other biomarkers between and across study groups using appropriate statistical tests.

1 2 3 4 5	322	
6 7 8 9 10 11 12 13 14	324	STUDY PROCEDURE
	325	An overview of study procedures is presented in Figure 1 and all study measures are detailed
	326	in Table 2. Recruitment will take place in Birmingham, Bristol, and Cambridge and
	327	assessments at University and NHS research facilities.
15 16 17	328	
18 19	329	Participant identification
20 21	330	Potential participants with psychosis will be identified by NHS Psychosis Early Intervention
22 23 24	331	(EI) teams. HCs will be recruited through advertisement methods in Birmingham and
24 25 26	332	Cambridge. Potential participants will complete a screening questionnaire to confirm their
27 28 29 30 31 32 33 34 35	333	eligibility to participate. If deemed eligible, participants will be invited to an appointment to
	334	complete a full eligibility assessment.
	335	
	336	Eligibility assessment
36 37	337	Assessments will be carried out to establish eligibility and to obtain informed consent.
38 39 40	338	Patients will complete the MINI to confirm ICD-10 diagnosis of schizophrenia and related
41 42	339	psychoses, the PANSS to confirm the presence of positive symptoms of psychosis, and the
43 44	340	TEPS to confirm eligibility based on anticipatory and consummatory pleasure sum scores. A
45 46 47	341	blood sample will be collected from patients for serum IL-6 measurement. An MRI screening
48 49	342	questionnaire will be administered to those willing to give informed consent for
50 51	343	neuroimaging.
52 53	344	
54 55 56	345	Baseline assessment
57 58	346	All participants (60 inflamed psychosis, 30 non-inflamed psychosis, and 30 HCs) will attend
59 60	347	a baseline assessment comprising psychiatric measures, cognitive tasks, blood sampling, and

Page 21 of 47

1 2 BMJ Open

3 4	348	neuroimaging (optional). This will be the final study contact for patients without evidence of
5 6 7	349	inflammation and HCs. Patients with evidence of inflammation will undergo further tests to
, 8 9	350	establish safety/eligibility to receive tocilizumab, including a chest X-ray and blood tests to
10 11	351	exclude pregnancy and certain infections, such as TB, HIV, and COVID-19. Eligible
12 13 14	352	participants will be randomised and invited for infusion.
14 15 16	353	
17 18	354	Intervention
19 20 21	355	Intravenous infusion of tocilizumab or normal saline will be given continuously over one
22 22 23	356	hour at CRFs in Birmingham, Bristol, and Cambridge by trained clinical staff under the
24 25	357	supervision of a designated study doctor. Participants will remain under clinical observation
26 27 28	358	for a further 1-hour period after the end of infusion.
29 30	359	
31 32	360	Follow-up assessments
33 34 35	361	Follow-up assessments will take place approximately 7-, 14-, and 28-days post-infusion, and
36 37	362	will collect similar data to the baseline assessment. Cognitive tasks and neuroimaging
38 39	363	(optional) will be administered only on day 14. Around 42 days post-infusion, participants
40 41 42	364	will be contacted by phone to provide a final debrief; at which point they will exit the study.
42 43 44	365	
45 46	366	RISK MANAGEMENT
47 48 49	367	Psychosis-related risks
49 50 51	368	All patients will be under the care of a specialist NHS psychosis EI service. Participation will
52 53	369	not involve any treatment modifications or significant delays in receiving treatment. If a
54 55	370	patient becomes distressed during an assessment, or does not wish to continue for any reason,
56 57 58 59 60	371	the researcher will stop the assessment. Participants may withdraw at any time without giving

2 3 4 5 6 7 8 9 10 11 12 13 14 15	372	a reason. If there is any concern for the participant's safety, the research team will liaise with
	373	participant's GP and/or mental health team as needed.
	374	
	375	Procedure-related risks
	376	Venepuncture
	377	Blood taking is associated with mild discomfort and other side effects are rare. Efforts will be
16 17 18	378	made to minimise discomfort. Blood taking will be performed by a nurse, doctor, or research
19 20	379	team member trained in venepuncture.
21 22	380	
23 24 25	381	Chest X-ray
25 26 27	382	This study will use a typical effective radiation dose of 0.014 mSv; equivalent to 2.5 days of
28 29	383	average natural background radiation in the UK. The risk of developing cancer as a
30 31	384	consequence of participating in this study is 0.0001%. Only non-pregnant, adult participants
32 33 34	385	will be included.
34 35 36	386	
37 38	387	Neuroimaging
39 40	388	Discomfort during MRI will be minimised by using mirrors to allow participants to view
41 42 43	389	outside of the machine, providing ear plugs and a panic button, and allowing participants to
44 45	390	communicate with the researcher and scan operator throughout. Mild transient vertigo may be
46 47	391	experienced when being moved into the MRI machine. Risk of dislodgement or malfunction
48 49 50 51 52 53 54 55 56 57 58 59 60	392	of medical implants or metallic foreign objects will be minimised by screening participants to
	393	ensure no metal is present on or within the body.
	394	
	395	IL-6 levels

1	
~	
2	
4	
2 3 4 5 6 7 8 9 10 11 23 4 5 6 7 8 9 10 11 23 14 15 16 17 18 9 20 21 22 24 25 26 27 28 9 30 132 33 34	
0	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
23	
24	
25	
20	
27	
28	
29	
30	
31	
32	
33	
34	
35	
33 34 35 36 37	
37	
38	
39	
40	
41	
41	
42 43	
43 44	
44 45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50 59	
60	
00	

396	We expect some 30-50% of patient participants to have evidence of inflammation in the
397	blood (IL-6 \geq 0.7pg/ml). This is not a cause for concern. Reasons for elevated IL-6 in the
398	absence of an acute infection or chronic inflammatory illness could include obesity, smoking,
399	alcohol use, and lack of exercise, so knowledge of 'inflammation status' may prompt
400	participants to adopt a healthier lifestyle. If serum IL-6 level is high (i.e., IL-6 ≥0.7pg/ml)
401	along with elevated CRP (>20mg/L) without any apparent explanation, such as infection or
402	chronic inflammatory illness, we will inform the participant's GP and the participant will be
403	excluded from the study.
404	
405	Risk to research staff
406	Staff will follow local safety procedures when lone working. No other risks are anticipated.
407	
408	Safety considerations for infusion and monitoring of adverse reaction
409	Before infusion
410	Participants will be selected based on strict inclusion and exclusion criteria. Additionally, we
411	will carry out tests for TB, HIV, VZV antibody, and Hepatitis B and C because, though
412	unlikely after a single dose, tocilizumab could make these infections worse. Female
413	participants of childbearing age will be given a pregnancy test, which must be negative.
414	Participants who are sexually active will be asked to use at least one form of effective
415	contraception for six weeks post-infusion. Male participants will also be asked not to donate
416	sperm samples for six weeks post-infusion.
417	
418	During infusion

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
49 50
51
52
53
54
55
56
57
58
58 59
60

Infusions will be given under supervision of a designated study doctor. Participants will be
monitored for possible side effects, which will be managed in line with use of tocilizumab for
treating patients with RA.

422

1 2 3

423 After infusion

424 Participants will remain under observation for one-hour post-infusion. Participants will be 425 advised to seek help if they feel unwell after leaving the assessment centre and will be given 426 an information sheet containing a telephone number their health professionals can call. If 427 necessary, we will unblind the participant and inform their health professional whether they 428 received tocilizumab or normal saline. Adverse reactions will be recorded at each follow-up 429 visit. Additional, safety blood tests will be done at second follow-up (e.g., WBC count, liver 430 function, lipids).

431

³ 432 ETHICS AND DISSEMINATION

433 The study will be conducted in accordance with the REC, Health Research Authority (HRA),
434 and local Research and Development (R&D) department approvals and guidelines (REC
435 reference: 22/EE/0010). The study team will prepare protocol amendments as required and
436 ethics approval will be sought before implementing any changes to the approved protocol.
437 The ISRCTN Trial Registry and the Research Governance Office will be informed of any
438 amendments to the protocol.

440 **Consent**

439

4 441 Informed consent will be obtained prior to eligibility assessments for participation in the
442 study (Appendix I, II, and II). This will include consent to randomise, for contact with their
443 GP to inform them about participation, access GP/psychiatric records to verify medical

BMJ Open

2		
3 4	444	history to establish eligibility, and to inform the participant's GP any results/outcomes as
5 6	445	necessary. Consent for additional tests to establish safety for tocilizumab infusion and for
7 8 9	446	storing biological samples will also be obtained.
) 10 11	447	
12 13	448	Study management
14 15 16	449	The study is sponsored by the University of Bristol. The sponsor, the Chief Investigator
10 17 18	450	(GMK), and the co-Lead (RU) will have overall responsibility for the study. A named
19 20	451	principal investigator will take clinical responsibility for study activities at each site. The
21 22 23	452	study does not require the formal arrangement of a steering committee because, according to
23 24 25	453	the HRA, it is not a Clinical Trial of an Investigational Medicinal Product. However, to
26 27	454	enhance monitoring of the study, a study management group will be established, comprising
28 29 30	455	academic and clinical experts in psychiatry, rheumatology, neuroscience, and immunology.
30 31 32	456	
33 34	457	Data management and retention of samples
35 36	458	All potential participants will be assigned a unique study-specific participant ID number. All
37 38 39	459	data will be subject to good practice as laid down in the Data Protection Act. Each study
40 41	460	stage is tracked so that participant's (de-identified) status within the study is known, and
42 43	461	assessment and other appointment dates are forecasted. This information is held on a secure,
44 45	462	password-protected database. Anonymised data from assessments will be uploaded to a
46 47 48	463	secure, password-protected database using secure web-based data entry systems. Minimal
49 50	464	personal data (age, sex) will be indexed by each participant's unique ID number. Blood
51 52	465	samples collected in this study may be stored for up to 10 years after the completion for
53 54 55	466	additional research. Stored samples will be coded throughout the sample storage and analysis
56 57	467	process and will not be labelled with personal identifiers. Participants may withdraw their
58 59 60	468	consent for their samples to be stored for future research.

2.

1 2		
3 4	469	
5 6	470	Dissemination plan
7 8 9	471	Study results will be published in peer-review journals and will conform to the guidelines of
9 10 11	472	the International Committee of Medical Journal Editors. Findings will be disseminated at
12 13	473	conferences, departmental talks, and via social and traditional media.
14 15	474	
16 17 18	475	AUTHORS CONTRIBUTIONS
19 20	476	ÉMF wrote first draft of the PIMS trial protocol and of this manuscript. SLG, MK, GKM,
21 22	477	BD, DJ, JS, and NMB contributed to study design and protocol development and revised
23 24 25	478	manuscript drafts. RU contributed to study design and study protocol, and revised manuscript
23 26 27	479	drafts. GMK devised study design and trial protocol, and revised drafts. ÉMF and SLG
28 29	480	developed study materials and liaised with REC and HRA regarding approvals. AM, JR,
30 31 32	481	FCZ, HH, EW, and MW contributed to the revision of the manuscript and validation of
32 33 34	482	operating procedures and mechanistic protocols. RU and GMK co-lead the MRC grant that
35 36	483	funds the PIMS trial and provide overall supervision and oversight for the project.
37 38	484	
39 40 41	485	FUNDING STATEMENT
42 43	486	The PIMS trial is funded by a Medical Research Council (MRC) grant to RU and GMK;
44 45	487	Grant Ref: MR/S037675/1. ÉMF is supported by an MRC Integrative Epidemiology Unit
46 47 48	488	PhD Studentship. AM is supported by funding from the MRC for doctoral training
49 50	489	(MR/2434208). FCZ receives a PhD Fellowship from the São Paulo Research Foundation
51 52	490	(2019/13229-2 and 2021/07448-3). HH is supported by the PIMS Trial MRC grant
53 54 55	491	(MR/S037675/1). DJ is supported by the Cambridge Arthritis Research Endeavour and the
56 57	492	National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre
58 59	493	(BRC-1215-20014). NMB acknowledges funding support from the MRC (MR/R006008/1
60		

1	
-	
2	
3	
4	
5	
6	
6 7 8	
/	
8	
9	
10	
11	
12	
12	
15	
14	
15	
16	
17	
13 14 15 16 17 18	
19	
20	
21	
21 22	
23	
24	
25	
25	
26 27	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
00	

494	and MR/N019016/1), Ministry of Defence (702931454), Diabetes UK (20/0006296), NIHR
495	(14/WM/0093), and Innovate UK (84361). RU has grants from MRC, NIHR: Health
496	Technology Assessment, European Commission - Research: The Seventh Framework
497	Programme, and personal fees from Sunovion, outside the submitted work. GMK
498	acknowledges funding support from the Wellcome Trust (Grant No. 201486/Z/16/Z), the
499	Medical Research Council, UK (Grant No. MC_UU_00011/1; Grant No. MR/S037675/1; and
500	Grant No. MR/W014416/1), and the National Institute of Health Research Bristol Biomedical
501	Research Centre, UK (Grant No. NIHR203315). The funders had no role in the design of this
502	study.
503	
504	COMPETING INTERESTS STATEMENT
505	ÉMF, SLG, AM, JR, FCZ, HH, EW, MW, MK, GKM, BD, DJ, JS, RU, and GMK have no
506	conflicts of interest to report. NMB holds shares and is a Director of Celentyx Ltd.
507	
508	PIMS COLLABORATION
509	Members of the PIMS Collaboration include Golam Khandaker, Rachel Upthegrove, Alice
510	Egerton, Anthony David, Bill Deakin, Carmine Pariante, David Cotter, Ed Bullmore, Eva
511	Meisenzahl, Gary Donohoe, Georgios Gkoutos, Jack Rogers, James MacCabe, Joanna Neill,
512	John Suckling, Neil Harrison, Nicholas Barnes, Nikos Koutsouleris, Paola Dazzan, Peter
513	Jones, Stephen Burgess, Stephen Wood, Valeria Mondelli.
514	
515	REFERENCES
516 517 518	1 Khandaker GM, Cousins L, Deakin J, <i>et al.</i> Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. <i>Lancet Psychiatry</i> 2015; 2 :258–70. doi:10.1016/S2215-0366(14)00122-9

1			
2 3 4 5 6	519 520 521	2	Khandaker GM, Dantzer R. Is there a role for immune-to-brain communication in schizophrenia? <i>Psychopharmacology</i> 2016; 233 :1559–73. doi:10.1007/s00213-015-3975-1
7 8 9	522 523	3	Khandaker GM, Dantzer R, Jones PB. Immunopsychiatry: important facts. <i>Psychol Med</i> 2017; 47 :2229–37. doi:10.1017/S0033291717000745
10 11 12 13 14	524 525 526	4	Upthegrove R, Khandaker G. Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia. <i>Current topics in behavioral neurosciences</i> 2020; 44 :49– 66. doi:10.1007/7854_2018_88
15 16 17 18 19	527 528 529	5	Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. <i>Schizophr Res</i> 2014; 155 :101–8. doi:10.1016/j.schres.2014.03.005
20 21 22 23	530 531 532	6	Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. <i>Mol Psychiatry</i> 2016; 21 :1696–709. doi:10.1038/mp.2016.3
24 25 26 27	533 534 535	7	Miller BJ, Buckley P, Seabolt W, <i>et al.</i> Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. <i>Biological psychiatry</i> 2011; 70 :663–71. doi:10.1016/j.biopsych.2011.04.013
28 29 30 31 32	536 537 538	8	Potvin S, Stip E, Sepehry AA, <i>et al.</i> Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. <i>Biol Psychiatry</i> 2008; 63 :801–8. doi:10.1016/j.biopsych.2007.09.024
33 34 35 36 37	539 540 541 542	9	Wang AK, Miller BJ. Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression. <i>Schizophr Bull</i> 2018;44:75–83. doi:10.1093/schbul/sbx035
38 39 40 41 42	543 544 545	10	Khandaker GM, Zimbron J, Dalman C, <i>et al.</i> Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. <i>Schizophr Res</i> 2012; 139 :161–8. doi:10.1016/j.schres.2012.05.023
43 44 45 46 47	546 547 548	11	Khandaker GM, Zimbron J, Lewis G, <i>et al.</i> Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. <i>Psychol Med</i> 2013; 43 :239–57. doi:10.1017/S0033291712000736
48 49 50 51	549 550 551	12	Khandaker GM, Zammit S, Burgess S, <i>et al.</i> Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort. <i>Brain Behav Immun</i> 2018; 69 :264–72. doi:10.1016/j.bbi.2017.11.020
52 53 54 55 56	552 553 554 555	13	Perry BI, Upthegrove R, Kappelmann N, <i>et al.</i> Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study. <i>Brain, Behavior, and Immunity</i> 2021; 97 :176–85. doi:10.1016/j.bbi.2021.07.009
57 58 59 60	556 557 558	14	Williams JA, Burgess S, Suckling J, <i>et al.</i> Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders: A Mendelian Randomization Study. <i>JAMA Psychiatry</i> 2022; 79 :498. doi:10.1001/jamapsychiatry.2022.0407

2			
3 4 5 6	559 560 561	15	Kose M, Pariante CM, Dazzan P, <i>et al.</i> The Role of Peripheral Inflammation in Clinical Outcome and Brain Imaging Abnormalities in Psychosis: A Systematic Review. <i>Front Psychiatry</i> 2021; 12 :612471. doi:10.3389/fpsyt.2021.612471
7 8 9 10 11	562 563 564	16	Lesh TA, Careaga M, Rose DR, <i>et al.</i> Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms. <i>Journal of Neuroinflammation</i> 2018; 15 :165. doi:10.1186/s12974-018-1197-2
12 13 14 15	565 566 567	17	Trépanier MO, Hopperton KE, Mizrahi R, <i>et al.</i> Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. <i>Mol Psychiatry</i> 2016; 21 :1009–26. doi:10.1038/mp.2016.90
16 17 18 19 20	568 569 570	18	van Kesteren CFMG, Gremmels H, de Witte LD, <i>et al.</i> Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. <i>Transl Psychiatry</i> 2017;7:e1075–e1075. doi:10.1038/tp.2017.4
20 21 22 23 24	571 572 573	19	Marques TR, Ashok AH, Pillinger T, <i>et al.</i> Neuroinflammation in schizophrenia: meta- analysis of in vivo microglial imaging studies. <i>Psychological Medicine</i> 2019; 49 :2186–96. doi:10.1017/S0033291718003057
25 26 27 28 29 30	574 575 576 577	20	Murray AJ, Rogers JC, Katshu MZUH, <i>et al.</i> Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders. <i>Frontiers in Psychiatry</i> 2021; 12 .https://www.frontiersin.org/articles/10.3389/fpsyt.2021.703452 (accessed 9 Aug 2022).
31 32 33	578 579	21	Upthegrove R. The immune system and schizophrenia: An update for clinicians. <i>Advances in Psychiatric Treatment</i> 2014; 20 :83–91. doi:10.1192/apt.bp.113.011452
34 35 36 37 38	580 581 582 583	22	Conen S, Gregory CJ, Hinz R, <i>et al.</i> Neuroinflammation as measured by positron emission tomography in patients with recent onset and established schizophrenia: implications for immune pathogenesis. <i>Mol Psychiatry</i> 2021; 26 :5398–406. doi:10.1038/s41380-020-0829-y
39 40 41 42 43	584 585 586	23	van Mierlo HC, Schot A, Boks MPM, <i>et al.</i> The association between schizophrenia and the immune system: Review of the evidence from unbiased 'omic-studies.' <i>Schizophrenia Research</i> 2020; 217 :114–23. doi:10.1016/j.schres.2019.05.028
44 45 46 47 48	587 588 589 590	24	Plavén-Sigray P, Matheson GJ, Collste K, <i>et al.</i> Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta- analysis Using Individual Participant Data. <i>Biological Psychiatry</i> 2018; 84 :433–42. doi:10.1016/j.biopsych.2018.02.1171
49 50 51 52 53	591 592 593	25	Plavén-Sigray P, Matheson GJ, Coughlin JM, <i>et al.</i> Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences. <i>Biol Psychiatry</i> 2021; 89 :e5–8. doi:10.1016/j.biopsych.2020.05.028
54 55 56 57 58 59 60	594 595 596 597	26	Deakin B, Suckling J, Barnes TRE, <i>et al.</i> The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. <i>The Lancet Psychiatry</i> 2018; 5 :885–94. doi:10.1016/S2215-0366(18)30345-6

1 2 3	500	27	Waisse M. Lassi L. Develtain G. et al. The effect of mine section and section in
4 5 6	598 599 600	21	Weiser M, Levi L, Burshtein S, <i>et al.</i> The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. <i>Schizophrenia Research</i> 2019; 206 :325–32. doi:10.1016/j.schres.2018.10.023
7 8 9 10 11	601 602 603	28	Ramaker RC, Bowling KM, Lasseigne BN, <i>et al.</i> Post-mortem molecular profiling of three psychiatric disorders. <i>Genome Medicine</i> 2017; 9 :72. doi:10.1186/s13073-017-0458-5
12 13 14 15 16 17	604 605 606 607	29	González-Peñas J, Costas J, Villamayor MJG, <i>et al.</i> Enrichment of rare genetic variants in astrocyte gene enriched co-expression modules altered in postmortem brain samples of schizophrenia. <i>Neurobiology of Disease</i> 2019; 121 :305–14. doi:10.1016/j.nbd.2018.10.013
18 19 20 21	608 609 610	30	Gandal MJ, Zhang P, Hadjimichael E, <i>et al.</i> Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. <i>Science</i> 2018; 362 :eaat8127. doi:10.1126/science.aat8127
22 23 24 25	611 612 613	31	Gandal MJ, Haney JR, Parikshak NN, <i>et al.</i> Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. <i>Science</i> 2018; 359 :693–7. doi:10.1126/science.aad6469
26 27 28 29 30 31	614 615 616 617	32	Toker L, Mancarci BO, Tripathy S, <i>et al.</i> Transcriptomic Evidence for Alterations in Astrocytes and Parvalbumin Interneurons in Subjects With Bipolar Disorder and Schizophrenia. <i>Biological Psychiatry</i> 2018; 84 :787–96. doi:10.1016/j.biopsych.2018.07.010
32 33 34 35	618 619 620	33	Corsi-Zuelli F, Deakin B. Impaired regulatory T cell control of astroglial overdrive and microglial pruning in schizophrenia. <i>Neuroscience & Biobehavioral Reviews</i> 2021; 125 :637–53. doi:10.1016/j.neubiorev.2021.03.004
36 37 38 39 40	621 622 623	34	Corsi-Zuelli F, Deakin B, de Lima MHF, <i>et al.</i> T regulatory cells as a potential therapeutic target in psychosis? Current challenges and future perspectives. <i>Brain, Behavior, & Immunity - Health</i> 2021; 17 :100330. doi:10.1016/j.bbih.2021.100330
41 42 43 44 45	624 625 626 627	35	Jeppesen R, Christensen RHB, Pedersen EMJ, <i>et al.</i> Efficacy and safety of anti- inflammatory agents in treatment of psychotic disorders – A comprehensive systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> 2020; 90 :364–80. doi:10.1016/j.bbi.2020.08.028
46 47 48 49 50 51 52	628 629 630 631 632	36	Girgis RR, Ciarleglio A, Choo T, <i>et al.</i> A Randomized, Double-Blind, Placebo- Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia. <i>Neuropsychopharmacology : official publication</i> <i>of the American College of Neuropsychopharmacology</i> 2018; 43 :1317–23. doi:10.1038/npp.2017.258
53 54 55 56 57	633 634 635	37	Mondelli V, Ciufolini S, Belvederi Murri M, <i>et al.</i> Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis. <i>Schizophrenia bulletin</i> 2015; 41 :1162–70. doi:10.1093/schbul/sbv028
57 58 59 60	636 637 638	38	Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia: a review and meta-analysis. <i>Clinical schizophrenia & related psychoses</i> 2014;7:223–30. doi:10.3371/CSRP.MICU.020813

1 2			
2 3 4 5 6 7 8	639 640 641 642	39	Raison CL, Rutherford RE, Woolwine BJ, <i>et al.</i> A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. <i>JAMA Psychiatry</i> 2013; 70 :31–41. doi:10.1001/2013.jamapsychiatry.4
9 10 11 12 13	643 644 645 646	40	Dunleavy C, Elsworthy RJ, Upthegrove R, <i>et al.</i> Inflammation in first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> 2022; 146 :6–20. doi:10.1111/acps.13416
14 15 16 17 18 19	647 648 649 650	41	Khandaker GM, Stochl J, Zammit S, <i>et al.</i> Association between circulating levels of C-reactive protein and positive and negative symptoms of psychosis in adolescents in a general population birth cohort. <i>J Psychiatr Res</i> 2021; 143 :534–42. doi:10.1016/j.jpsychires.2020.11.028
20 21 22 23 24	651 652 653 654	42	Edwards CJ, Cella M, Tarrier N, <i>et al.</i> Investigating the empirical support for therapeutic targets proposed by the temporal experience of pleasure model in schizophrenia: A systematic review. <i>Schizophrenia research</i> 2015; 168 :120–44. doi:10.1016/j.schres.2015.08.013
25 26 27 28 29 30	655 656 657 658	43	Lalousis PA, Schmaal L, Wood SJ, <i>et al.</i> Neurobiologically Based Stratification of Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. <i>Biological Psychiatry</i> 2022;:S0006322322011568. doi:10.1016/j.biopsych.2022.03.021
31 32 33 34	659 660 661	44	Fioravanti M, Carlone O, Vitale B, <i>et al.</i> A Meta-Analysis of Cognitive Deficits in Adults with a Diagnosis of Schizophrenia. <i>Neuropsychol Rev</i> 2005; 15 :73–95. doi:10.1007/s11065-005-6254-9
35 36 37 38 39	662 663 664	45	Keefe RSE, Bilder RM, Davis SM, <i>et al.</i> Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> 2007; 64 :633–47. doi:10.1001/archpsyc.64.6.633
40 41 42	665 666	46	Chan A-W, Tetzlaff JM, Altman DG, <i>et al.</i> SPIRIT 2013 Statement: defining standard protocol items for clinical trials. <i>Rev Panam Salud Publica</i> 2015; 38 :506–14.
43 44 45	667 668	47	Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. <i>Nature reviews Rheumatology</i> 2014; 10 :720–7. doi:10.1038/nrrheum.2014.127
46 47 48 49 50 51	669 670 671 672	48	Choy EHS, Isenberg DA, Garrood T, <i>et al.</i> Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. <i>Arthritis and rheumatism</i> 2002; 46 :3143–50. doi:10.1002/art.10623
52 53 54 55 56 57 58 59 60	673 674 675 676 677	49	Woo P, Wilkinson N, Prieur A-M, <i>et al.</i> Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. <i>Arthritis research & therapy</i> 2005;7:R1281-8. doi:10.1186/ar1826

50 Gard DE, Gard MG, Kring AM, et al. Anticipatory and consummatory components of the

to peet terien only

2006;40:1086-102. doi:10.1016/j.jrp.2005.11.001


experience of pleasure: A scale development study. Journal of Research in Personality


2 3 4 5 6	678 679 680
7 8	681
9	
10 11	682
12 13	
14 15	
16 17	
18	
19 20	
21 22	
23 24	
25 26	
27 28	
29	
30 31	
32 33	
34 35	
36 37	
38 39	
40	
41 42	
43 44	
45 46	
47 48	
49 50	
51	
52 53	
54 55	
56 57	
58	

1

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2		
2 3 4 5 6	683	FIGURE LEGEND
5 6	684	Figure 1. Overview of study design
7 8		
9 10		
11 12		
13 14		
15 16		
10 17 18		
19		
20 21		
22 23		
24 25		
26 27		
28 29		
30 31		
32 33		
34 35		
36 37		
38 39		
40 41		
42 43		
44 45		
46 47		
48 49		
50 51		
52 53		
55 55		
55 56 57		
58		
59 60		





240x165mm (144 x 144 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Supplementary Material

Foley et al. Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: A randomised double-blind placebo-controlled trial of single dose tocilizumab in patients with psychosis.

Table of Contents

eTable1: SPIRIT 2013 Checklist - Recommended items to address in a clinical trial protocol and related documents*



Standard Protocol Items: Recommendations for Interventional Trials

Section/item	ltem No	Description	Addressed on page number
Administrative inf	ormatior		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
	2b	All items from the World Health Organization Trial Registration Data Set	4 (ISRCTN 23256704)
Protocol version	3	Date and version identifier	-
Funding	4	Sources and types of financial, material, and other support	24 - 25
Roles and	5a	Names, affiliations, and roles of protocol contributors	1, 24
responsibilities	5b	Name and contact information for the trial sponsor	23
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	23-25

BMJ Open

	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	23 - 25
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	6-9
	6b	Explanation for choice of comparators	6-9
Objectives	7	Specific objectives or hypotheses	9-10
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	9
Methods: Participa	ants, inte	erventions, and outcomes	
Study setting	9	Description of study settings (e.g., community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	9, 11
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	12, Table 1
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	11, 19, 21-22, Figure 1
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	22
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	-
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	12, Table 1
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	9-10, Figure 1, Table 2
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	18-19, Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	17
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	18
Methods: Assignme	nt of ir	nterventions (for controlled trials)	
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	17
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	17
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	17
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	17
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	22

Page 39 of 47

BMJ Open

Methods: Data colle	ection,	management, and analysis	
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	10-15, 18-19, Table 2
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	17-18
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	23-24
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	17-18
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	17-18
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	-
Methods: Monitorin	g		
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	23
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	-
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	20-22

Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	-
Ethics and dissemin	ation		
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	22
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	22
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	22-23
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	22-23
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	23-24
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	25
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	23
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	22
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	24
	31b	Authorship eligibility guidelines and any intended use of professional writers	24
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	-
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendix I, II and III
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	23-24

"It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Appendix I – Consent Form for Screening: All Participants

Informed Consent Form for Screening

REC No. 22/EE/0010, Date: 08.02.2022, Version: 1.2

Psychosis Immune Mechanism Stratified Medicine Trial: The PIMS Trial

PARTICIPANT ID: _____

Thank you for considering taking part in the PIMS Trial. The research team must explain the eligibility assessment of the study to you before you agree to take part. If you have any questions arising from the Participant Information Sheet or from the explanation already given to you, please ask a member of the research team before you decide to participate. You will be given a copy of this Informed Consent Form to keep for future reference.

Please read the statements below and insert your initial in the box next to each statement if you agree with them:

Statement	Initial	Here
1. I have read and understood the information sheet version XX,		
DD.MM.YYYY and have had the opportunity to ask questions.		
2. I understand that my participation is voluntary and I am free to withdraw at any time without giving a reason, without my current or future medical care or legal rights being affected.		
3. I agree to provide blood samples for eligibility screening. I understand my blood samples will be analysed to test for evidence of immune activation. The purposes and possible risks of donating these samples have been explained to me. I understand that donated samples will be considered a gift but I will have the right to withdraw permission for analysis.		
4. I agree that my GP can be told that I am participating in the eligibility assessment of the PIMS Trial, and can be informed if any unexpected results are found pertaining specifically to my health.		
5. I consent for my GP/Psychiatrist to share information from my medical record in order to confirm my eligibility to take part in this study. The study team may access my GP/Psychiatrist records if necessary.		
Optional (Not agreeing to these will not exclude you from this study). Please tick Yes / No (as appropriate)	Yes	No
6. I agree that the samples can be stored after completion of the screening analysis, for use in future, ethically approved, non-genetic studies, even if I am deemed non-eligible to partake in the PIMS study.		
7. I agree that data and samples can be stored after completion of the PIMS Trial for use in future, ethically approved, genetic studies. This includes the main stocks of any genetic material collected, such as DNA and RNA.		

If you want to participate in the screening session of the PIMS Trial, please sign your name below:

Participant Signature

Participant Full Name _____

1 2	
3	
4	
5	Date//
6	
7 8	
9	
10	
11	
12	The researcher who has explained this study to you also needs to sign this form:
13	
14	
15	Staff Signature
16	
17	Staff Full Name
18 19	Staff Full Name
20	Date//
20	
22	Date//
23	
24	Thank you for your help.
25	Thank you for your help.
26	By completing and returning this form, you are giving us your consent that the personal
27	information you provide will be treated as strictly confidential and handled in accordance with
28	the provisions of the UK Data Protection Act 2018.
29	
30 31	*When completed: 1 for participant; and 1 for researcher site file.
32	
33	
34	
35	
36	
37	
38	
39	
40 41	
41 42	
43	
44	
45	
46	
47	
48	
49	
50 51	
52	
52	
54	
55	
56	
57	
58	
59	
60	

Appendix II – Informed Consent Form for Study Participation: Patients

Informed Consent Form for Study Participation

REC No. 22/EE/0010, Date: 24.08.2022, Version: 1.5

Psychosis Immune Mechanism Stratified Medicine Trial: The PIMS Trial

PARTICIPANT ID: _____

Thank you for taking part in the PIMS Trial eligibility assessment. Based on this assessment, you are eligible to take part in the PIMS Trial. Before you agree to take part, the research team must explain the study to you. If you have any questions arising from the Participant Information Sheet or from the explanation already given to you, please ask a member of the research team before you decide to participate. You will be given a copy of this Informed Consent Form to keep for future reference.

Please read the statements below and insert your initial in the box next to each statement if you agree with them:

Statement	Initial Here
1. I have read and understood the information sheet version XX	
dated DD.MM.YYYY and have had the opportunity to ask questions.	
2. I agree to take part in the PIMS Trial. I understand that my participation is	
voluntary and I am free to withdraw at any time without giving a reason,	
without my current or future medical care or legal rights being affected.	
3. I understand that confidentiality and anonymity will be maintained and it will	
not be possible to identify me in any publications.	
4. I agree to partake in interviews, complete questionnaires, and cognitive	
tests as part of this study. I understand what will happen during the study	
assessments.	
5. I agree to provide blood samples. The purposes and possible risks of	
donating these samples have been explained to me. I understand that	
donated samples will be considered a gift but I will have the right to withdraw	
permission for analysis.	
6. I understand that blood samples collected from me will be used to measure	
non-genetic factors such as biochemical changes in the blood.	
7. I agree that the samples and information I provide can be stored, used and	
shared between PIMS Trial sites and with collaborators/contractors for the	
purpose of the study.	
8. I understand that blood samples collected will be stored at PIMS Trial	
centres.	
9. I understand that any of my samples (labelled with an anonymous ID only),	
or any information obtained from them, including the sequence of my genetic	
material, may be sent to specialist research laboratories in the UK and abroad	
for analyses and the results returned to PIMS Trial centres. Researchers at	
these laboratories have no access to personal information about study	
participants.	
10. I agree, if necessary, to provide blood/urine samples to test for pregnancy,	
COVID-19 immunity, Hepatitis B, Hepatitis C, HIV, VZV and Tuberculosis, and	
to undergo a chest X ray.	
11. I agree to being randomised into the tocilizumab or placebo group if	
deemed eligible to take part.	

1	
2	
2	
ر م	
4	
5	
6	
7	
, 0	
0	
9	
10	
11	
12	
12	
15	
14	
15	
16	
17	
18	
10	
19	
20	
21	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 4 35 36 37 8 9 10 11 12 13 14 15 16 17 18 19 20 21 23 24 25 26 27 28 29 30 31 31 4 35 26 27 28 29 30 31 31 32 26 27 28 29 30 31 32 26 27 28 29 30 31 32 26 27 28 29 30 31 32 33 34 35 36 37 37 37 37 37 37 37 37 37 37	
22	
23	
24	
25	
26	
27	
28	
20	
29	
30	
31	
32	
33	
24	
54	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
59 60	
60	

13. I agree that my GP can be told that I am participating in this study, and about any findings that require further attention.		
14. I understand that information related to my participation in this study may be accessed by responsible individuals from the sponsors of this study for quality control purposes. I give permission for these individuals to have access to this data.		
15. I understand that relevant sections of my medical notes and data collected during the study, may be looked at by individuals from research team, from regulatory authorities or from the NHS Trust, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records.		
Optional (Not agreeing to these will not exclude you from this study). Please tick Yes / No (as appropriate)	Yes	Nc
16. I agree to undergo brain scans as part of the PIMS Trial.		
17. I agree to be contacted in future by researchers to participate in follow up studies to this project, or in future studies of a similar nature.		
18. I understand that researchers may use the blood samples for genetic analysis.		
19. I agree that the samples can be stored after completion of the PIMS Trial for use in future, ethically approved, non-genetic studies.		
20. I agree that the information I give can be stored after completion of the PIMS Trial for use in future, ethically approved, non-genetic studies.		
21. I agree that data and samples can be stored after completion of the PIMS		

If you want to participate in the PIMS Trial, plea ur name below: 07

Participant Signature	
-----------------------	--

Participant Full Name _____

Date ___/ ___/

Research staff who has explained this study to you also needs to sign this form:

Staff Signature	
-----------------	--

Staff Full Name	

Date ___/ ___/

Thank you for your help.

By completing and returning this form, you are giving us your consent that the personal information you provide will be treated as strictly confidential and handled in accordance with the provisions of the UK Data Protection Act 2018.

*When completed: 1 for participant; and 1 for researcher site file.

tor oeer terien only

Appendix III – Informed Consent Form for Study Participation: Healthy Controls

Healthy Controls Informed Consent Form for Study Participation REC No. 22/EE/0010, Date: 17.02.2022, Version: 1

Psychosis Immune Mechanism Stratified Medicine Trial: The PIMS Trial

PARTICIPANT ID: _____

Thank you for taking part in the PIMS Trial eligibility assessment. Based on this assessment, you are eligible to take part in the PIMS Trial. Before you agree to take part, the research team must explain the study to you. If you have any questions arising from the Participant Information Sheet or from the explanation already given to you, please ask a member of the research team before you decide to participate. You will be given a copy of this Informed Consent Form to keep for future reference.

Please read the statements below and insert your initial in the box next to each statement if you agree with them:

Statement	Initial	Here
1. I have read and understood the information sheet version XX		
dated DD.MM.YYYY and have had the opportunity to ask questions.		
2. I agree to take part in the PIMS Trial. I understand that my participation is		
voluntary, and I am free to withdraw at any time without giving a reason,		
without my current or future medical care or legal rights being affected.		
3. I understand that confidentiality and anonymity will be maintained, and it wil	I	
not be possible to identify me in any publications.		
4. I agree to partake in interviews, complete questionnaires, and cognitive		
tests as part of this study. I understand what will happen during the study		
assessments.		
5. I agree to provide blood samples. The purposes and possible risks of		
donating these samples have been explained to me. I understand that		
donated samples will be considered a gift, but I will have the right to withdraw		
permission for analysis.		
6. I understand that my blood samples collected will be stored at PIMS Trial		
centres.		
I understand that blood samples collected from me will be used to measure		
non-genetic factors such as biochemical changes in the blood.		
8. I understand that any of my samples (labelled with an anonymous ID only),		
or any information obtained from them, including the sequence of my genetic		
material, may be sent to specialist research laboratories in the UK and abroad	1	
for analyses and the results returned to PIMS Trial centres. Researchers at		
these laboratories have no access to personal information about study		
participants.		
9. I agree that the samples and information I provide can be stored, used and		
shared between PIMS Trial sites and with collaborators/contractors for the		
purpose of the study.	<u> </u>	
10. I understand that information related to my participation in this study may		
be accessed by responsible individuals from the sponsors of this study for		
quality control purposes. I give permission for these individuals to have access	5	
to this data.		
Optional (Not agreeing to these will not exclude you from this study).	Yes	No
Please tick Yes / No (as appropriate)		

12. I agree to be contacted in future by researchers to participate in follow up studies to this project, or in future studies of a similar nature.	
13. I understand that researchers may use the blood samples for genetic analysis.	
14. I agree that the samples can be stored after completion of the PIMS Trial for use in future, ethically approved, non-genetic studies.	
15. I agree that the information I give can be stored after completion of the PIMS Trial for use in future, ethically approved, non-genetic studies.	
16. I agree that data and samples can be stored after completion of the PIMS Trial for use in future, ethically approved, genetic studies. This includes the main stocks of any genetic material collected, such as DNA and RNA.	
f you want to participate in the PIMS Trial, please sign your name below	:

Participant Full Name

Date ___/ ___/ ____/

Research staff who has explained this study to you also needs to sign this form:

Staff Signature _____

Staff Full Name

Date ___/ ___/ ____

Thank you for your help.

By completing and returning this form, you are giving us your consent that the personal information you provide will be treated as strictly confidential and handled in accordance with the provisions of the UK Data Protection Act 2018.

*When completed: 1 for participant; and 1 for researcher site file.